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ABSTRACT 
 
 
Andrographis paniculata (AP) is a traditional herbal medicine which is widely used 
for the treatment of many diseases in Asia. Recently, various biological activities of 
AP extract or andrographolide (AND), such as immunostimulatory activity, anti-
inflammatory effect, cytokine induction or deduction, a potential cancer therapeutic 
agent and T cell activation suppression, have been reported. However the potential of 
AP extract or AND to stimulate the specific or adaptive immune response using 
microbial vaccines has not been determined. In this project, AND has been purified 
from AP and its identity confirmed by the melting point, colour test,  TLC, UV 
absorption spectrum, ESI-MS and1 H-NMR. An aqueous and two ethanolic extracts of 
Andrographis paniculata and AND, an active principle of Andrographis paniculata, 
were investigated for their antimicrobial activity against nine bacterial species in vitro 
using the disc diffusion method. It was discovered that neither the aqueous extract nor 
AND were bacteriostatic or bactericidal against S. typhimurium, E. coli, S. sonnei, S. 
aureus, P. aeruginosa, S. pneumoniae, S. pyogenes, L. pneumophila or B. pertussis 
but the two ethanolic extracts of AP were bacteriostatic against L. pneumophila  and 
B. pertussis. It was also observed that the ethanol extract of AP and AND stimulated 
both antibody and cell-mediated immunity (CMI) responses to a killed S. typhimurium 
vaccine. Mice were vaccinated with either one dose or two doses of killed S. 
typhimurium vaccine. They were fed two different quantities of an ethanol extract of 
AP or AND for 14 days in mice immunised with one dose of the vaccine, and for 28 
days in mice immunised with two doses of vaccine, respectively. Both the extract and 
AND significantly increased the IgG antibody titres against S. typhimurium, with the 
increase in antibody titres being statistically significant in the two dose vaccine group. 
Although not statistically significant, there was also a substantial increase in the IgG 
antibody titres in the one dose vaccine group. Splenocyte cultures from mice from 
both the immunisation groups treated with the extract or AND stimulated with the S. 
typhimurium lysate showed a significant increase in the production of IFN-γ in both 
14 and 28 day AP extract or AND treatment groups. The increase indicates the 
induction of a cell-mediated immune response. To confirm the immunomodulatory 
potential of AP extract and determine the immunomodulatory potential of AND, 
experiments were conducted using mouse salmonellosis as a model system.  Mice 
were vaccinated with two doses of killed S. typhimurium vaccine by intraperitoneal 
(i/p) route and orally dosed with AP extract at 25 mg/kg bodyweight or AND at 4 
mg/kg bodyweight for total 28 days, followed by oral challenge with virulent S. 
typhimurium. Both AP extract and AND substantially increased the survival rate by 
50% after mice were challenged with 10 fold of a sublethal dose (1.5x10 6  cfu)  of 
virulent S. typhimurium. They also promoted clearance of S. typhimurium from 
challenged mice by days 8 or 12 post-challenge with 1.5x10 5 cfu virulent S. 
typhimurium respectively. Sera IgG, IgA antibody titres against S. typhimurium and 
ii    
IFN-γ or IL-2 were detected after the mice were challenged by the oral route with a 
sublethal dose (1.5x10 5 cfu) of virulent S. typhimurium for 12 days. It was thus 
concluded that both Andrographis paniculata and AND not only elicited both 
humoral and cell-mediated immune responses in the mouse model, but also increased 
the protective efficacy against salmonellosis on mice vaccinated with inactivated S. 
typhimurium. Therefore the ability of Andrographis paniculata and AND to promote 
acquired immunity, particularly in inducing CMI may be important in protection 
against intracellular pathogen infection.  
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Chapter 1 Literature Review 
 
This Chapter provides the background literature underpinning the research embodied 
in this doctoral dissertation. It includes the immunological concepts relevant to the 
exploration of the immunobiological properties of Andrographis paniculata (AP) and 
one of its bioactive pharmaceuticals, andrographolide (AND). Also reviewed are the 
strategies used in the development of vaccines against infections caused by the 
intracellular pathogen, Salmonella typhimurium, the model used in this study to 
investigate the immunomodulatory properties of AP and AND.  
  
1.1 The Immune system 
 
There are two aims of the immune response that are involved in protection against 
foreign invaders including infectious agents. Host defences against foreign invaders 
can be innate and adaptive or acquired immunity. Innate immunity is constituted by 
intrinsic defence mechanisms that are always present ready to recognize infectious 
agents by recognition of structures (pathogen-associated molecular patterns, PAMPs). 
These structures are shared by different types macrobes (bacteria, viruses or fungi), 
but are not present on the host cells. The recognition of PAMPs is affected by pattern 
recognition receptors or PRRs on the host cells compusing the immune system. The 
latter are encoded in the germ line and not by somatic recombination of genes (Abbas 
et al., 2007). Because the results of this investigation embodied in this dissertation 
examined the immune-response modifying effect of AP extract and AND on adaptive 
or specific immunity, no discussion of the mechanisms of innate immunity in 
protection against foreign invaders has been presented in this review. However, 
excellent reviews on innate immunity have been published elsewhere (Beutler, 2003; 
Beutler and Rietschel, 2003; Janeway and Medzhitov, 2002; Medzhitov and Janeway, 
2002; Medzhitov and Janeway, 2000). Adaptive immunity, in contrast to innate 
immunity, is the ability of the host to induce an acquired immune response specific to 
a given infectious antigen (Levine et al., 2004; Black, 2002; Janeway, 2001). Aspects 
relevant to research embodied in this thesis are presented below.  
 
1.1.1 Adaptive or acquired immunity 
 
In most instances, the innate immune system is unable to completely eliminate a 
foreign invader and requires the assistance of antigen-specific acquired immune 
effector mechanisms such as humoral and / or cell-mediated immunity (the two arms 
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of acquired immunity). Acquired immunity occurs after exposure to an antigen and is 
effective at preventing infection by activating antigen-specific arms of the immune 
response that results in improved response after repeated exposure and immunological 
memory (Playfair and Bancroft, 2006; McNeela and Mills, 2001). Acquired immunity 
is more specialized than innate immunity in that another cell type, lymphocyte, is 
brought into play and supplements the protection provided by innate immunity. And 
acquired immunity, that came into play relatively late in evolution, is present only in 
vertebrate species. Although the two arms of acquired immunity have different sets of 
participants and different sets of purposes, their aim is the same, which is to eliminate 
the antigen. Of these two arms of the acquired immune response, humoral immunity 
is mediated mainly by circulating antibodies that are produced by epitope-specific B 
cells, with or without interaction with CD4 T cells depending upon the thymus-
dependence or –independence of stimulating epitope or antigen, following 
differentiation into plasma cells, not withstanding the participation of B cells as 
antigen-presenting cells (APCs), Whereas cellular or cell-mediated immunity, on the 
other hand, is mediated by T cells (Playfair and Bancroft, 2006).  
 
1.1.2 Cell populations involved in acquired immunity 
 
Apart from the antigen-presenting cells, the two types of lymphocyte populations 
required for the induction of acquired immunity are B and T cells. Both these types of 
cells are involved in the presentation of thymus-dependent antigens following 
phagocytosis. B cells are derived from bone marrow after fetal life (liver, in the fetal 
life), produce antibodies after differentiation to plasma cells and are mainly effective 
against extracellular infection. Two distinct populations of T-cells are recognized by 
the presence of two different types of co-receptor surface proteins (CD antigens), 
CD4 and CD8 lymphocytes (Gao et al., 2002; Konig, 2002; Nemazee, 2000). 
Cytotoxic T cells (CTLs) and Th1 cells produce cytokines leading to the activation of 
macrophages and proliferation of CTLs, are mainly effective against intracellular 
pathogens (Schluns and Lefrancois, 2003; Kaech, Wherry and Ahmed, 2002; Seder 
and Hill, 2000). 
 
After binding of antigen/epitopes displayed by the major histocompatiblity complex 
molecules by the lymphocyte receptors, the cells are stimulated into a cell cycle, 
producing large numbers of identical cells. This clonal expansion or clonal 
proliferation is the fundamental basis of acquired immunity providing large numbers 
of effector cells (e.g. plasma cells producing antibodies or Th1 T-lymphocytes for 
activating macrophages or CD8 CTLs depending on the pathway of antigen 
presentation) to cope with infectious agents and also producing memory cells for 
subsequent encounters with the same antigen (Levine et al., 2004).  
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The effector T-cells fall into functional categories based on their interaction with 
peptide antigens derived from different pathogens processed via endogenous or 
exogenous pathways (Janeway et al., 2001). Peptides from the intracellular pathogens, 
which are processed via the endogenous pathway because they multiply in the 
cytoplasm, are carried to the cell surface by the MHC class I molecules and presented 
to CD8 T cells. These CD8 T cells differentiate into cytotoxic T cells that kill the 
infected cells (Jankovic et al., 2001; Harty et al., 2000; Abbas et al. 1996). On the 
other hand, peptides derived from ingested extracellular bacteria or soluble proteins, 
which are processed via the exogenous pathway, are carried to the cell surface via 
MHC class II molecules and presented to CD4 T cells (Levine et al., 2004). These 
helper T cells can formerly differentiate into two types of effector T cells, Th1 and 
Th2. Intracellular pathways, which are capable of surviving in large numbers within 
the macrophages and dendritic cells, tend to stimulate the differentiation of Th1 cells. 
In contrast, the extracellular pathways tend to stimulate the production of Th2 cells. 
Th1 cells are involved in the activation of microbiocidal properties of macrophages 
and differentiation of B cells for production of highly opsonic IgG isotype antibodies 
e.g. IgG 2a in the mouse (Goffman, 2006; Constant and Bottomly, 1997). Th2 cells on 
the other hand, initiate the humoral immune response by activating naive antigen-
specific B-cells to produce IgM which undergo antibody class switching upon booster 
vaccination to produce IgG, IgA or IgE antibody classes (Goffman, 2006; Janeway et 
al., 2001). Regardless of the antigen presented to the antigen-presenting cells, 
cytokines play a crucial role in determining the type of effector T cell stimulated and 
also the regulation of the Th1 and Th2 subset responses (McGuirk and Mills, 2002; 
Jankovic et al., 2001; Constant and Bottomly, 1997; Abbas et al., 1996). More 
recently, Th17 cells have been described as differentiating from Th1 or Th2 cells as 
the third types of effector T cells. These cells may be effective protection against 
certain extracellular pathogens, but also play a role in the amplification of 
autoimmune disorders (Leceta et al., 2007). Cytokines also play an important role in 
determining and regulating this type of effector T cells (Bettelli et al., 2007; 
Steinman, 2007; Romagnani, 2006; Harrington et al., 2005).  
 
1.1.2.1 Production of effector T cells 
 
In order to be activated, a naive T cell must recognize and interact with foreign 
peptides bound in the MHC class I and class II pocket of the APCs (dendritic cells, 
macrophages and B cells) and bind with high affinity to each through cell to cell 
interaction mediated by cell-adhesion molecules particularly LFA-1, CD2 and ICAM-
3 on the T cell and ICAM-1, ICAM-2, IFA-3 and DC-SIGN (c-type pectin which 
binds to ICAM-3 with high affinity) (Gao et al., 2002; Konig, 2002; Tybulewicz, 
2002; Butcher et al., 1999; Petty and Todd, 1996), and the simultaneous delivery of a 
co-stimulatory signal via the B7 molecules, expression of which is enhanced by 
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interaction of CD40 ligand (T cell)-CD 40L (APC) and CD28 (CTLA-4)-B7 
interactions (Coico et al., 2003; Janeway et al., 2001). 
 
1.1.2.2 Activation of CD4 T cells and their functions--biological 
perspectives 
 
As described above, two signals are required for activation of naive CD4 T cells in 
addition to cell-cell interactions via the adhesion molecules. One signal is the 
recognition of antigen bound to MHC class II on the APC (including B cells) by the 
TCR on the CD4 T cell surface whereas the other is the ligation for B7 co-stimulatory 
molecules on the APC to the molecules on the CD4 T cell (Dubey et al., 1995). Once 
CD4 T cells have been activated, they then progress to Th differentiation. The 
differentiation process is influenced by a number of factors including the type of 
APC, the concentration of antigen, the ligation of select co-stimulatory molecules and 
the local cytokine environment (Szabo et al., 2003). The APC can be dendritic cells, 
tissue macrophages, and/or B cells. Dendritic cells (found in almost all tissues) have 
potent antigen-processing capabilities and express abundant MHC class II molecules. 
Recent studies have suggested that dendritic cells may be the major or exclusive APC 
in the primary responses of CD4 T cells by acquiring the antigen at the site where it 
enters the body (Jenkins et al., 2001; Moser and Murphy, 2000; Pulendran et al., 
1999; Rissoan et al., 1999). On the other hand, B cells act as the major APC in the 
responses of primed (memory) CD4 T cells; however, dendritic cells have been 
shown to present only a limited number of epitopes, whereas B cells can present a 
broader range of peptides (Gapin et al., 1998). 
 
Another important factor that is considered to influence Th polarization is the nature 
and abundance of an antigen (Constant and Bottomly, 1997; Tao et al., 1997), 
although the evidence presented is conflicting. Several studies have demonstrated that 
small quantities or low affinity of antigen favors Th differentiation to Th2, while high 
affinity and abundance of antigen favors Th1 response (Chaturvedi et al., 1996; Guery 
et al., 1996; Hayglass et al., 1986; Pfeiffer et al., 1995). In contrast, other studies 
demonstrated the opposite dichotomy in response, in which high doses of antigen lead 
to Th2 response and low doses lead to Th1 response (Balamuth et al., 2001; Sarzotti 
et al., 1996; Bancroft et al., 1994). A key difference among these studies may be due 
to the type of antigen used. The studies in which low doses of antigen favored Th1 
response used parasites as antigens, whereas those that showed low doses of antigen 
inducing Th2 used soluble proteins. This could indicate that the antigen itself 
influences Th differentiation. 
The most important determinant of Th differentiation is considered to be cytokines. 
The cytokine IL-12 was initially characterized as a dominant cytokine promoting the 
induction of Th1 response; however, newly emerged evidence suggests that other 
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cytokines, such as IFN-γ and TNF-β play a significant role in Th1 development 
(Szabo et al., 2003; Jankovic et al., 2001; Abbas et al., 1996). IFN-γ has now been 
demonstrated to be the most important in this respect. IFN-γ is not only secreted by 
NK, CD8 and CD4 Th1 cells, but also by a number of other cells including 
macrophages, dendritic cells, naive CD4 cells and B cells (Grogan et al., 2001; Fukao 
et al., 2000; Ohteki et al., 1999; Yoshimoto et al., 1998). IFN-γ plays an important 
role in both the innate and acquired immune system. It has an essential role in the 
elimination of intracellular pathogens, via activation of macrophages, resulting in an 
increased phagocytosis, MHC class I and II expression, and the induction of IL-12, 
nitric oxide, and superoxide production (Boehm et al., 1997). Studies on in vivo Th 
differentiation have shown that the absence of IFN-γ (either IFN-γ deficient or by 
administrating anti-IFN-γ antibodies) inhibit Th1 development and promote the Th2 
response (Reiner and Locksley, 1995; Wang et al., 1994; Scott, 1991). Other studies 
have shown that IFN-γ alone, independently of IL-12, was capable of inducing Th1 
development (Bradley et al., 1996; Lu et al., 1998; Smeltz et al., 2002). Additional 
studies have shown that IL-12 may not be demanded to initiate Th1 response 
(Brombacher et al., 1999; Kaplan et al., 1998; Mullen et al., 2001). IL-12 may be 
more critical in the late stages of infections to induce optimal IFN-γ secretion by T 
cells (Park et al., 2000; Yap et al., 2000). IL-12 is secreted by activated APC such as 
dendritic cells, monocytes, and macrophages (Kato et al., 1996; Koch et al., 1996; Ma 
et al., 1996). IL-12 and IFN-γ together form a Th1-promoting loop: IL-12 induces 
production of IFN-γ by T cells, which in turn stimulates the production of IL-12. As 
for Th2 development, IL-4 was demonstrated to have the greatest influence in driving 
Th differentiation to Th2 (Le Gros et al., 1990; Swain et al., 1990). Basophils (Seder 
et al., 1991), Th2 cells or mast cells (Singh and Agrewala, 2006; Plaut et al., 1989) are 
the main sources of IL-4. Another cytokine IL-10 has also been reported to promote 
Th2 development; however, its major role may be more to do with suppressing Th1 
development by suppressing IL-12 activity and thus IFN-γ production (Hsieh et al., 
1993). Similarly, IL-12-induced IFN-γ also suppresses IL-4, thus promoting Th1 
response by down regulating Th2 cytokines (Grogan et al., 2001). TGF-β1, IL-6, IL-
1β, TNF-α and IL-23 were recently demonstrated to promote Th17 response (Liang et 
al., 2006; Harrington et al., 2005; Hofstetter et al., 2005; Park et al., 2005), the latter 
being considered to be responsible fordestructive tissue damage in autoimmune 
disorders and delayed-type hypersensitivity reactions . Th1 and Th2 cytokines, such 
as IFN-γ and IL-4 were reported to potently suppress naive precursor cells to Th17 
cell development, whereas committed Th17 cells were resistant to suppression by Th1 
or Th2 cytokines (Hofstetter et al., 2005). 
 
Based on their patterns of cytokine production and their functional responses, the 
primed CD4 T cells are traditionally divided into two major subsets, Th1 and Th2 
cells (London et al., 1998; Carter and Dutton, 1996; Mosmann and Sad, 1996). Th1 
cells secrete IL-2, IFN-γ and tumor necrosis factor beta (TNF-β), which are mainly 
involved in the induction of cell-mediated immunity (CMI) and activation of CD8 T 
6   Chapter 1 Literature review 
cells, NK cells and macrophages. Th2 cells produce IL-4, IL-5, IL-10 and IL-13, 
which are essential for the induction of humoral immunity such as in the activation of 
B cells to produce antibodies and their class switching (Szabo et al., 2003). Prior to 
Th polarization towards a Th1 or Th2 phenotype, a subset called Th0 cells has been 
identified and is thought to be the precursor of Th1 and Th2 cells. Th0 cells produce 
IL-2, IFN-γ and IL-4 (Paliard et al., 1988; Firestein et al., 1989), but do not express 
receptors for IL-12 until activated (Igarashi et al., 1998). Finally after the course of 
response to antigen, the majority of the activated T cells die off by apoptotic 
mechanisms, and only a small portion of T cells become the long-lived antigen-
specific CD4 T memory cells (Jenkins et al., 2001). Th17 cells have recently been 
identified as a third independent T cell subset that is distinct from Th1 and Th2. Th17 
cells produce IL-17 and IL-22, which are CD4 T cell-derived cytokines and 
associated with autoimmune disorders and T cell-mediated tissue damage (Steinman, 
2007; Liang et al., 2006; Harrington et al., 2005; Park etal., 2005). It is worth noting 
that though our understanding of Th cell biology over the past several years has 
increased substantially, the molecular mechanisms regulating the initiation of a Th1 or 
Th2 or Th17 response and their down-regulatory pathways are still not completely 
understood. 
 
1.1.2.3 Activation of CD8 cells and their functions--biological 
perspectives 
 
CD8 T cells, a major component of cell-mediated immunity, are normally referred to 
as CTL. CTL cells kill cells that have been infected by pathogens such as bacteria, 
viruses and protozoa, as well as tumor cells and transplanted foreign cells during graft 
rejection (Coico et al., 2003). Upon binding to antigen-MHC class I complex, and in 
the presence of cytokines by Th1 cells, CD8 cells are activated to proliferate and 
differentiate into cytotoxic T cells. As almost every cell in the body, except the 
immunologically privileged sites such as gametes, neurons, lens of the eye and 
trophoblast cells (Delves and Roitt, 2000a and 2000b), expresses MHC class I, CD8 
cells are capable of killing off almost any cell in the body that is infected with a 
pathogen. MHC class I molecules are generally only associated with peptides that are 
generated in the cytosol by proteasome-mediated protein degradation. However, 
evidence has shown that CD8 cells can be induced by MHC class I molecules 
presenting exogenous antigens either in soluble (Staerz et al., 1987; Wraith et al., 
1987) or particulate forms (Falo et al., 1995; Harding and Song, 1994), or by tumor 
cell-derived heat shock proteins (Udono and Srivastava, 1993). How these antigens, 
which are taken up by phagocytosis or macropinocytosis gain access to the cytosol is 
not yet known. This unusual pathway is found to be particularly prominent in 
macrophages and dendritic cells (Bevan, 1987). CD8 cells also attack cells harboring 
vacuolar pathogens such as Mycobacteria and Salmonella species (Kerksiek and 
Pamer, 1999). CD8 cells also secrete cytokines such as tumour necrosis factor (TNF) 
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and IFN-γ, which play important roles in target cell killing (Sad et al., 1995). In 
addition, pathogen-specific CD8 cells produce chemokines that act in concert with 
inflammatory mediators to attract inflammatory cells such as neutrophils, monocytes, 
and lymphocytes to sites of infection (Fahy et al., 2001). 
 
1.1.2.4 Activation of B cells and antibody responses--biological 
perspectives 
 
In the presence of cytokines produced by Th2 cells, specific recognition of foreign 
antigen by cell surface Ig induces B cells to proliferate and differentiate into antibody-
producing plasma cells, as well as undergo antibody class switching (Born et al., 
1999). The pattern of cytokines produced by activated T cells directs the antibody 
class switching. For example, if the T cell produces IL-4, then B cells will switch to 
making IgE and IgG1, whereas IFN-γ directs B cells to switch to making IgG2a 
(Constant and Bottomly, 1997). However, some antigens such as bacterial 
lipopolysaccharides and polysaccharides that have numerous repeating epitopes are 
capable of activating B cells to produce an antibody without T cell help (known as 
thymus-independent antigen), however, these B cells only make IgM and do not 
undergo class switching (Mond et al., 1995). 
 
An antibody response usually occurs in two phases: the primary and secondary 
responses. When exposed to an immunogen for the first time (such as primary 
immunization), there is a lag of usually 10-12 days before the first antibody IgM 
becomes detectable in the serum (Figure 1-1). This lag phase in the primary response 
is necessary for T and B cells to interact with the antigen, to proliferate, and to 
differentiate. Then some of the B cells enter exponential production phase by 
differentiating into plasma cells and secrete IgM, while other B cells continue to 
proliferate and then undergo class switch to IgG. Some of these B cells then 
synthesize IgG exponentially while others become memory cells. After a few weeks, 
the antibody level declines. In some instances, IgM may be the only antibody made in 
the primary response (Benjamini et al., 2000). If at a later date the same antigen is 
encountered, there is a far more rapid immune response (secondary response) and IgG 
production is much greater and may remain detectable for months or years. On the 
other hand, IgM is produced at the similar level as it was in the primary response 
(because there are no memory cells for IgM) and IgM may disappear altogether after a 
short time. IgA and IgE may also appear in the secondary response (Benjamini et al., 
2000). 
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Figure 1-1 Kinetics of serum antibody responses (This Figure is adapted from Figure 
4.11 of Benjamini et al., 2000) 
 
 
The primary response is slow onset, low magnitude, short-lived and production of 
IgM and/or IgG. The secondary response is rapid onset, high magnitude, long-lived 
and greater production of IgG that may not be followed by production of other 
isotypes depending on a number of factors including the route of immunization 
(Coico et al., 2003)  
 
1.1.3 Mucosal immunity 
 
Skin and mucosa provide physical and chemical barriers to prevent entry of 
pathogens. Pathogens adjust to infect mucosae and express virulence factors. These 
factors allow them to adhere, colonize or invade the epithelium. Therefore, mucosal 
immunity is critical in prevention of mucosally acquired infectious diseases (Neutra et 
al., 1996b; Neutra, 1998). The major mucosal portals of entry for pathogens include 
the gastrointestinal tract, respiratory tract, and urogenital tract. Because of extensive 
exposure to the outside world, the majority of the body’s lymphoid tissue is 
distributed along mucous membranes forming the MALT (Mucosa-associated 
lymphoid tissue) system (Neutra et al., 1996b). The MALT is found in the 
submucosal areas of the gastrointestinal, respiratory and urogenital tracts, in the 
lamina propria of the intestinal wall, and aggregates of densely packed lymphoid cells 
organized into Peyer’s patches in the lower ileum (Hobson at al., 2003; Neutra et al., 
1996b). Major mucosal inductive sites, where mucosal immune responses are 
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initiated, are found in both the intestinal and upper respiratory tract including Peyer’s 
patches, nasal-associated lymphoid tissue in the oropharyngeal cavity, the tonsils, and 
adenoids (Frederik et al., 2000; Neutra et al., 1996b). Common features of these 
inductive sites are specialized epithelial cells termed M (Membraneous) cells, 
macrophages, dendritic cells, CD4 and CD8 cells and secretory IgA (S-IgA) 
producing B cells (Neutra et al., 1996a). M cells are thought to uptake, transport, 
process and possibly present antigens to subepithelial lymphocytes initiating immune 
responses (Allan et al., 1993; Neutra et al., 1996b; Neutra and Kraehenbuhl, 1993). 
Under the influence of local cytokines and accessory cell populations, B cells are 
activated and switched to IgA isotype (Weinstein et al., 1991; Defrance et al., 1992; 
Fujihashi et al., 1997). The activated lymphocytes then migrate via the regional lymph 
nodes and thoracic duct into the blood stream. These cells then selectively enter the 
spleen for clonal expansion before they enter via the blood into the mucosal effector 
sites such as lamina propria and probably other mucosal sites in the body (Russell et 
al., 1996). Hence both peripheral and mucosal immunity can be induced far from the 
site of original antigen stimulation. In addition, this broad immunity is both humoral 
and cellular. S-IgA secreted into the lumen is the principle antibody in mucosal 
immunity (Mazanec et al., 1993; Mestecky and Jackson, 1994). The major role of S-
IgA is to prevent absorption of pathogens such as viruses, bacteria and toxins. This is 
achieved by blocking the adhesion of the pathogens while they are still on the external 
side of the epithelial barrier. Thus the pathogen can be washed out in the flow of 
secreted fluids and mucous which washes over the epithelial membranes. IgA has also 
been shown to be important in the intraepithelial neutralization of viruses. As IgA 
traverses the epithelial cell, it may encounter pathogen(s) intracellularly, where it has 
the potential to neutralize the pathogen (Mazanec et al., 1992; Neutra et al., 1996b).  
 
Cellular immunity may also play an important role in combating mucosally infectious 
pathogens. These mucosally committed T cells may function either to prevent 
mucosal surface from injury by infectious pathogens or by exhibiting cellular 
cytotoxicity directed against intracellular pathogens (Musey et al., 1997; Wong and 
Pamer, 2003). 
 
1.2 Potential role of Immunomodulators  
 
The development of the immune system is to eliminate foreign (non-self) invaders to 
prevent the establishment of infectious disease. However in certain infectious or non-
infectious insults, immune responses to self-antigens leads to the manifestation of 
autoimmune conditions (Coico et al., 2003). One reason for the development of type 1 
diabetes, for example, is the formation of auto-antibodies against pancreatic beta-
cells. Another example is rheumatic fever, a heart disease, which may occur following 
infection with Streptococcus pyogenes due to the formation of antibodies to bacterial 
antigens which share antigenic determinants with the heart muscle (Veasy and Hill, 
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1997). There also are autoimmune conditions in which cell-mediating effector arm of 
the immune response is involved in the pathological process, for example, rheumatoid 
arthritis in which the chronically inflamed synovium becomes densely crowded with 
lymphocytes resulting in the destruction of cartilage and bones (Joosten et al., 1999). 
Then there are secondary immunodeficiency disorders such as AIDS and conditions 
requiring chemo- or radiation therapy in which cells of the immune system suffer 
great damage and destruction (Plettenberg et al., 1997). Resolution of such conditions 
would be greatly assisted if immunomodulating compounds capable of either 
suppressing or stimulating the induction of cellular or humoral immune responses 
respectively were available. 
 
Cellular and humoral immune responses are regulated by cytokines promoting the 
induction of distinct Th1 or Th2 subtypes of T cells (described in Sections 1.1.2.2 and 
1.1.2.4). The discovery of immunomodulators with the potential of promoting the 
selective induction of these distinct populations of T cells could greatly improve 
immune responses thus adding value to immunotherapy (Dumont, 2002).  
 
A diterpene lactone, andrographolide (AND), isolated from Andrographis paniculata 
(AP) has been reported to be immunostimulatory or immunosuppressive particularly 
in promotion or down-regulation of innate non-specific immunity as assessed by 
cytokine production and anti-carcinogenic activity (Burgos et al., 2005; Kumar et al., 
2004; Rajagopal et al., 2003; Panossian et al., 2002; Shen et al., 2002; Madav et al., 
1996). It has also been reported to either stimulate (Puri et al., 1993) or suppress 
adaptive immunity depending on the administration of AND (Iruretagoyena et al, 
2006; 2005). However, essentially no information on the modulation of the cell-
mediated effector arm in adaptive immunity against infectious disease agents by this 
medicinal plant is available, the theme underpinning the research embodied in this 
thesis. 
Although AP is widely used in infections and infestations in traditional Chinese 
medicine, it has been suggested that its main clinical benefit could be due to a 
possible immune-enhancing effect (Mills and Bone, 2000). The immunomodulatory 
property of AP and the diterpene lactone AND will be reviewed in Section 1.3.5.6. 
Adjuvants are substances that can be used in combination with specific antigens to 
produce immunity better than the antigens used alone (Schmidt et al., 2007). There 
are a number of adjuvants which have been proven to stimulate the production of 
antibodies and many are used in vaccines currently in the marketplace (Edelman, 
2002; Hunter, 2002) and yet aluminum-based adjuvants such as aluminum hydroxide 
or phosphate are the only adjuvants licensed for use in humans (Schmidt et al., 2007) 
e.g., in acellular pertussis vaccine (Guy, 2007; HogenEsch, 2002). However, there are 
no universally accepted immunostimulants, which promote the induction of cell-
mediated immunity. Whilst a wide variety of immunosuppressants are being used in 
certain conditions such as in cancer patients undergoing chemo- or radiotherapy, most 
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of them suppress both Th1 and Th2 responses rendering the patient susceptible to 
infections yielding with undesirable outcomes (Garay et al., 2007; Caras et al., 2004; 
Roila et al., 1998).  
 
1.3 Andrographis paniculata 
1.3.1 General description of Andrographis paniculata 
 
Andrographis paniculata (Burm.f.) Nees, a member of the family of Acanthaceae and 
commonly known as Kalmegh, is an herb used in traditional medicine in China, India 
and Southeast Asia. It is known as king of bitters in English and Chuan Xin Lian in 
Chinese, but is more commonly referred to simply as andrographis. AP is an up to 1 
meter tall annual shrub with lanceolate leaves and small white to pink, hairy flowers. 
It grows in moist deciduous forests and is also cultivated. The leaf is the main 
medicinal part, but the whole plant including the root has been used (WHO, 2002). 
 
 
 
  
Figure 1-2  Andrographis paniculata (Burm.f.) Nees plant 
 
(This Figure is adopted from Wu, 2005) 
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1.3.2 Chemical composition of AP 
 
Boorsma first isolated AND from AP in 1896 and Corter identified AND as a lactone 
in 1911. It is a colourless or light yellow crystal compound with a very bitter taste 
(Tang and Eisenbrand, 1992; SCHRI, 1973). 
 
Deng et al (1982) reported there are four lactones in Andrographis paniculata. They 
are (1) 14-deoxyandrographolide, which was also identified by Sangalungkarn et al 
(1990) and Garcia et al (1980), (2) AND, (3) neoandrographolide (a non-bitter, C 3 O-
glucoside derivative of the major constituent andrographolide) and (4) 14-deoxy-
11,12-didehydroandrographolide which were also identified by Dhamma-upakorn et 
al (1992). AND and total lactone are the common names used in clinics for the active 
ingredients (Deng et al., 1982). The other medicinal chemical principles are 
diterpenoids viz. 14-deoxyandrographolide, -19β-D-glucoside which has been isolated 
from the leaves (Techadamrongsin et al., 1999; Chem and Liang, 1982). Du et al 
(2003) separated AND and neoandrographolide from the leaves of AP using high-
speed counter-current chromatography. 
 
The content of the major component, AND depends on both growing region and the 
collection time. AP grows best in the tropical and subtropical areas of China and 
Southeast Asia. The leaves contain more than 2% andrographolide before the plant 
blooms and less than 0.5% afterwards. The stem contains 0.1-0.4% of 
andrographolide (Zhu et al., 1984). The best harvesting time is early autumn (Sharma 
et al., 1992). AP is sold commercially as a medicine in China, India, Thailand and 
Malaysia. Thin-layer chromatography, ultraviolet spectrophotometry, liquid 
chromatography and volumetric and colorimetric techniques are used in a variety of 
laboratory methodologies to ensure a standardized level of andrographolides (PPRC, 
1997; Sharma et al., 1992). 
 
The other active chemical constituents of AP which have been identified so far 
include diterpene dimers (Matsuda et al., 1994) and flavonoids (Zhu and Liu., 1984; 
Koteswara et al., 2004).  
 
1.3.3 General characterization of Andrographolide 
 
Andrographolide’s chemical name is 3α, 14, 15, 18-tetrahydroxy-5β, 9βH, 10α-
labda-8(20), 12-dien-16-oic acid γ-lactone. Its molecular formula and weight are 
C 20 H 30 O 5 and 350.4 (C 68.54%, H 8.63%, O 22.83%) respectively. A colourless 
plate from ethanol or methanol with a melting range from 205-235.3°C has been 
reported (Fujita et al., 1984; Rajani et al., 2000; Du et al., 2003). It is also reported 
that its UV absorption maxima in methanol or ethanol is 222-224 nm (Fujita et al., 
Y Xu  13 
1984; Rajani et al., 2000; Du et al., 2003). Its structure was analysed by X-ray, 1 H, 
13 C-NMR and ESI-MS (Fujita et al., 1984; Medforth et al., 1990; Rajani et al., 2000; 
Du et al., 2003; Cui et al., 2005). It does not mix well with water, but is soluble in 
acetone, chloroform, ether and hot ethanol. Crystalline AND was reported to be 
highly stable even at 70°C (75% relative humidity) over a period of 3 months 
(Lomlim et al., 2003). 
 
Rajani et al. (2000) reported a simple and rapid method for isolation of AND from the 
leaf of AP. They extracted it from the leaf powder using 1:1 mixture of 
dichloromethane and methanol in cold condition and then isolated andrographolide 
directly from the extract by recrystallisation. They confirmed the compound through 
IR, UV, MS, melting point and co-chromatography with a reference standard on TLC. 
The purity of the compound was also checked by TLC, UV absorption spectrum, 
HPLC, LCMS and differential scanning calorimetry (DSC), the DSC gave the melting 
point of andrographolide as 235.3°C. 
                              
HO
CH2OH
O
OHO
 
 
Figure 1-3 Structure of andrographolide (Tang and Eisenbrand, 1992) 
 
 
1.3.4 Traditional uses of AP 
 
AP, as a traditional medicinal plant, has been used for centuries to successfully treat 
respiratory, skin infections, fever, sore throat, herpes, dysentery, lower urinary tract 
infections and to reduce inflammation and stop diarrhoea (Techadamrongsin et al., 
1999). Clinically, the use of this herb is reported in contemporary and ancient Chinese 
writings (WHO, 1978). In Traditional Chinese Medicine, AP is a bitter and ‘cold 
property’ herb. It is used in the treatment of ‘hot’ conditions such as acute infections 
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and fever, including throat infection, pneumonia, tonsillitis, dysentery, gastroenteritis 
and pyelonephritis (Mills and Bone, 2000; Bensky and Gamble., 1993; Deng et al., 
1982). It is also prescribed for snakebite (Chang and But, 1986; Duke and Ayensu, 
1985). It is used in Malaysian folk medicine for diabetes and hypertension (Ahmad 
and Asmawi, 1993; Zhang and Tan, 1996; Zhang and Tan, 2000). Yeung et al. (1987) 
reported that AP had pharmacological properties which include antibacterial, 
immunological, antivenomous and antithrombotic properties. More recently, AP has 
been used in the treatment of chronic bronchitis, administered via aquapuncture, i.e. 
the injection of an infusion into acupuncture points (Duke and Ayensu, 1985). In 
Ayurvedic medicine, it is used as a bitter tonic and stomachic, for diabetes, debility, 
hepatitis and as an anthelmintic (Mills and Bone, 2000).  
 
AP extract has been used in different forms, such as tablet or injection. In China, in 
tablets form it has different names: “Kan Jang” tablets, “Chuanxinlian” tablets, 
“Xiaoyan Lidan” tablets and “Chuanxinlian antiphologistic” Pills (Zhao et al., 2002). 
The injection forms are “Yamdepieng” and “Chuanxinlian Ruangas” injection 
(Maunwongyathi, 1994). In Indian pharmacopoeia, at least 26 Ayurvedic formulas are 
widely used (Kumar et al., 2004). 
 
The knowledge of the benefits of AP for human health has also led to its use in 
livestock production in Thailand. AP or mixtures of AP and other plants have been 
used to treat poultry in broiler production instead of antibiotics on several farms. 
Farmers believe that AP or the plant mixture containing AP reduce mortality 
especially that caused by digestive tract and respiratory tract diseases 
(Chaiwongkeart, 1997), but little systematic research has been reported. 
 
1.3.5 Physiological and pharmacological properties of AP and 
AND 
 
Andrographis paniculata has been widely studied in the last 50 years. Previous 
studies have focused on Andrographis paniculata’s pharmacological composition, 
efficacy, safety and mechanisms of action (Panossian et al., 2002; WHO, 2002; Mills 
and Bone, 2000). 
 
1.3.5.1 Anti-diarrhoeal and intestinal effects 
 
Diarrhoea diseases are one of the top ten causes of death worldwide, especially for 
children under the age of five in developing countries (Lopez et al., 2006). An 
inflammation of the intestinal tract can cause acute diarrhoea. The inflammation can 
be caused by pathogenic bacteria overgrowth or a viral or parasitic infections and 
irritations. Medications and certain foods are the sources of pathogenic growth. 
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Campylobacter, Salmonella, Shigella and Escherichia coli are common bacteria that 
cause diarrhoea. Although antibiotics are effective in treating bacterial infections, 
antibiotic-resistant strains of bacteria can be produced by the over use of antibiotics. 
Many drugs, such as kaolin-pectin, loperamide, bismuth, etc, are used to relieve the 
symptoms of diarrhoea, but they may cause undesirable side effects (Sindermsuk, 
1993). An inexpensive and easily obtainable herbal remedy would benefit many 
people, especially those in developing countries. Experiments in animals demonstrate 
that AP can prevent diarrhoea. Extracts of AP have effectually been shown against the 
diarrhoea connected with E. coli infections (Duke and Ayensu, 1985). The AP 
components, AND and neoandrographolide showed comparable activity to 
loperamide (Imodium), the most common anti-diarrhoea drug. Gupta et al (1990) 
reported that the active ingredients against diarrhoea are AND and 
deoxyandrographolide. 
 
In Thailand, an extract made by boiling AP stem with methanol was reported to be 
effective against Proteus vulgaris and AP stem and leaves blended powder can be 
effective against the Shigella bacteria but is not effective against cholera (Thanangkul 
and Chaichantipyuth, 1985). Patients, who were orally administrated 1 g blended 
powder every 12 hours for 2 days, were more effective than those given a dose of 500 
mg every 6 hours for 2 days (Thanangkul and Chaichantipyuth, 1985). In China, this 
regimen was combined with rehydration (Yin and Guo, 1993). There were 66 cures of 
80 treated patients (82.5% cure rate). Seven patients (8.8%) responded favourably to 
the treatment. This was indicated by reduced nausea and vomiting. Only seven 
patients (8.8%) did not respond to the treatment. Laboratory tests of stool samples 
confirmed the effectiveness of the treatment (Yin and Guo, 1993). A comparison 
experiment was conducted in a pharmacological research institute in Shanghai, China 
in 1973. 165 patients were given AP tablets equal to the amount of 15.6 g crude 
powder per day. Twenty-eight patients were given Fluroxone, a common drug used to 
treat dysentery. The result showed the effective rate of AP was 75.2% and the 
effective rate of Fluroxone was 71.4% (SCHRI, 1973). 
 
AP was believed to be effective against bacterial dysentery and diarrhoea because it 
has antibacterial activities. Pleumjai and Sithisomwonges (1990) found in vitro that 
AP extracts with 70% and 80% ethanol could kill bacteria that cause diarrhoea such as 
E. coli and V. cholera, but Sindermsuk (1993) could not confirm this effect. The 
antibacterial activity of aqueous, ethanol or methanol extracts of Andrographis 
paniculata has been tested in vitro against Escherichia coli, Staphylococcus aureus, 
Proteus vulgaris, Salmonella typhi, Shigella species and Pseudomonas aeruginosa 
(George & Pandalai, 1949; Nakanishi et al., 1965; Bunyapraphatsara, 2000; Prajjal et 
al., 2003). However, no antibacterial activity was observed with the aqueous extract 
tested against E. coli, S. aureus, S. typhi or Shigella species (Leelarasamee et al., 
1990). So it is necessary to extend these investigations using a broader spectrum of 
microbial pathogens of relevance to human health.  
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In one study on mice it was found that 50% and 85% alcohol extracts of AP leaf 
powder were effective in reducing intestinal tract movements (Choudhury & Poddar, 
1985).  The researchers compared the effect of AND and AP extract on intestinal 
brush-border membrane-bound hydrolases. They suggested that both andrographolide 
and AP extract activated intestinal disaccharidases; the latter accelerated intestinal 
digestion and absorption of carbohydrate. 
 
1.3.5.2 Effect on upper respiratory infections 
 
One of the most common causes of childhood illness and adult discomfort is upper 
respiratory infection. Upper respiratory infection includes any infection in the nose, 
throat, sinuses, and ears. The common cold is the most common upper respiratory 
infection. Viruses and bacteria in the surrounding environment may cause upper 
respiratory infection (Ozkan and Dweik, 2004; Black, 2002). Crude aqueous or 
alcohol extractions of AP and one principle of AP, AND have been reported to be 
effective in the treatment of upper respiratory infections (Hancke et al., 1995; 
Caceres, 1997; Melchior et al., 1997; SCHRI, 1973; Thamlikitkul et al.,1991; 
Subjareun, 1996). Sixtyone adult patients were used to measure the effectiveness of 
AP extract compared to a placebo, to reduce the symptoms associated with the 
common cold. The effects of AP were measured on days 0, 2 and 4 of treatment. On 
day 2, the group taking AP extract displayed alleviation of several of the associated 
symptoms. On day 4, the group receiving 1200 mg extract daily showed a significant 
reduction (p<0.0001) in clinical symptoms such as sore throat, tiredness, muscular 
ache and malaise, as compared with the placebo group (Hancke et al., 1995).  
 
One clinical trial has investigated the efficacy of a standardized AP extract to prevent 
the common cold by Caceres (1997). 107 healthy students in a rural school had daily 
taken either placebo or a dose of 200 mg (minimum 5.8% AND) of Kan Jang (a 
formulation of AP provided by the Swedish Herbal Institute) for three months. The 
number of colds occurring over a three month period was observed. After 1 month no 
significant difference was found. However, the difference was statistically significant 
in the second and third month. The placebo group was 2.1 times more likely to catch a 
cold than the Kan Jang group. The incidence of the common cold was 30% in the AP 
group, whereas the incidence was 62% in the placebo group. 
 
In a study conducted by Melchior et al (1997), fifty adult patients received either 1020 
mg extract or a placebo daily for 5 days to evaluate the efficacy of AP extract on the 
initial symptoms of the common cold and uncomplicated sinusitis. The results 
demonstrated that the AP group took fewer sick leave days than the placebo group. 
Furthermore, 68% of treated patients felt totally recovered, but only 36% of the 
placebo group recovered. 
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In China, clinical studies of bacterial and viral respiratory infections demonstrated 
favourable effects after patients were orally taken AP or andrographolides. 
Investigations from the Sichuan Traditional Medicine Research Institution found that 
AP reduced body temperature in the treatment of infectious diseases associated with 
cold symptoms: 70 out of 84 treated patients achieved normal body temperature 
within 48 hours (Melchior et al., 1997). In 1972, researchers from the Chinese Herb 
Research Institute used deoxyandrographolide and neoandrographolide to treat 24 
cases of upper respiratory tract infection, acute tonsillitis and bronchitis. The average 
recovery time was about 4 to 7 days compare to the placebo which was 14 days 
(SCHRI, 1973). The antibiotic rifampin is usually used to treat tuberculosis. 10 % of 
patients still die when rifampin is used alone (Aquinas and Sanatorium (1977). In a 
study, an injectable solution of 2.5% andrographolide (50-80 mg/kg body weight per 
day) was used for two months. The therapeutic results were improved in seventy cases 
of tubercular meningitis. 30% of patients were cured with a fatality rate of 8.6%. The 
combination of AND plus rifampin resulted in a 2.6 fold decrease in fatality rates 
(DIDPHSP, 1977). 
 
AP was used to treat cough and sore throat by Thamlikitkul et al (1991). They 
compared AP leaf powder with Paracetamol and found that 6 g AP powder per day 
after 3 days reduced fever and sore throat better than Paracetamol. However, after 7 
days there was no difference between them. In 1996, AP was compared with 
penicillin in its capacity to heal sore throat. The results showed that there was no 
significant difference in recovery rate between the two groups of patients. More than 
75% of patients were cured with an additional 15% showing improvement (Subjareun, 
1996). 
 
More recently, AP extracts in fixed combination with Kan-jang, A. senticosus, 
Eleutherococcus senticosus Maxim, Schizandra chinensis Bail and Glycyrrhiza 
glabra L. extracts were also found to show significant improvement in the verum 
group as compared with the placebo in the treatment of uncomplicated upper-
respiratory tract infection (Melchior et al., 2000; Poolsup et al., 2004; Coon and Ernst, 
2004; Amaryan et al., 2003; Gabrielian et al., 2002; Spasov et al., 2004). 
 
1.3.5.3 Effect on inflammation and fever 
 
AP is used as a folk medicine for reducing inflammation. Three ingredients: 
deoxyandrographolide, AND and neoandrographolide are effective in reducing 
inflammation (Dutta & Sukul., 1982). In other studies it was found that AP extracted 
with alcohol (Sawasdimongkol et al., 1990; Chantasutra & Limpapanichkul, 1989), 
AP extracted with water (Sawasdimongkol et al., 1990) and AP extracted with 
chloroform (Chantasutra & Limpapanichkul, 1989) reduced inflammation. Madav et 
al (1996) found that AND significantly inhibited carrageenin-, kaolin-and nystatin-
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induced paw oedema (different models of inflammation) in rats after oral 
administration at doses of 30, 100 and 300 mg/kg bodyweight.  In China, it has been 
reported that AND has some beneficial effects as an anti-inflammatory agent (Chiou 
et al., 2000; Shen et al., 2000), whereas Deng et al (1982), who studied rats and mice 
concluded that four lactones from AP have anti-inflammatory and anti-pyretic effects. 
Deng et al (1982) also suggested AP might exert its anti-inflammatory effect through 
stimulation of the adrenal gland since the herb showed no effect when the adrenal 
gland of the animals were totally removed. Habtemariam (1998) suggested that AND 
inhibited tumour necrosis factor-α to induce endothelial monocyte adhesion, which is 
part of the inflammatory process. Other possible mechanisms involved in AND anti-
inflammatory effects were also reported (Amroyan et al., 1999; Shen et al., 2002; Xia 
et al., 2004; Hidalgo et al., 2005). Shen et al. (2002) reported that the possible 
mechanism involved in its anti-inflammatory effect might be due to AND preventing 
oxygen radical production by human neutrophils. Xia et al. (2004) and Hidalgo et al. 
(2005) suggested its anti-inflammatory effect involved AND inhibiting a nuclear 
factor kappa B (NF-kappaB) binding to DNA in endothelial cells or HL-60-derived 
neutrophilic cells, and thus reducing the expression of proinflammatory proteins. In a 
study from Thailand, rats were given injections with carrageenan (an agent for 
stimulating inflammation) to study the anti-inflammatory effect of AP water extract 
ranging from 500, 1250, 2500 mg / body weight. The result showed that water extract 
of AP effectively reduced the paw volume in rats treated with AP whereas the control 
group did not (DMPRD, 1990). 
  
The ability of AP to lower fever has been demonstrated in several laboratories 
(Huang, 1993; Madav et al., 1995; DMPRD, 1990). Rat studies have shown that fever 
produced by different fever-inducing agents, such as Pneumococcus spp., hemolytic 
Streptococcus, P. multocida and the chemical 2, 4-dinitrophenol can be lowered by 
AND, neoandrographolide and dehydroandrographolide in China (Huang, 1993). 
Indian researchers (Madav et al., 1995) tested AP to determine whether it could 
reduce fever in rats. They found that there was a reduction in rectal body temperature 
for 30, 100 and 300 mg of AND /kg bodyweight. The antipyretic activity of 300 mg 
of AND / kg bodyweight was comparable to that of 300 mg aspirin. In Thailand, 
studies on rabbits showed that the antipyretic effect of 2.5 g 85% ethanol extract of 
AP / kg bodyweight was as effective as 300 mg/kg of aspirin (DMPRD, 1990). 
 
1.3.5.4 Cardiovascular activity 
 
Amroyan et al (1999) found that AND from AP did not affect the biosythesis of 
eicosanoids, but inhibited the platelet-activating factor (PAF)-induced human blood 
platelet aggregation (eicosanoids and PAF are two of the most important 
inflammatory mediators. Inhibition of the biosythesis of eicosanoids is characteristic 
for non-steroidal anti-inflammatory drugs, while PAF antagonists are used as 
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potential agents in inflammation). They indicated that the mechanism of action may 
differ from that of non-steroidal anti-inflammatory drugs. This mechanism is most 
likely combined with the cardiovascular and antithrombotic activity of AP. Zhang and 
Tan (1996) found a hypotensive activity of aqueous extract of AP in rats and they 
suggested that the aqueous extract of AP lowers the systolic blood pressure of 
spontaneously hypertensive rats possibly by reducing circulating angiotensin-
converting enzyme in the plasma as well as by reducing free radical levels in the 
kidneys. A hypotensive activity of AND in rats was also reported by Yu et al (2003). 
In further studies by Zhang & Tan (1997, 1998) on cardiovascular activity of 14-
deoxyandrographolide (DA) and 14-deoxy-11, 12-didehydroandrographolide (DDA) 
in rats, they reported that DA and DDA significantly decreased the mean arterial 
pressure and heart rate of anaesthetized rats. Both DA and DDA activated nitric oxide 
production in endothelial cells; the latter caused relaxation of the isolated rat thoracic 
aortae. Chiou et al. (1998) reported that andrographolide inhibits nitrite synthesis by 
suppressing expression of inducible nitric oxide synthase (iNOS) protein in vitro, and 
the inhibition of iNOS synthesis may be good at haemodynamic effects of AND in 
endotoxic shock. Zhao and Fang (1991) demonstrated that AP decreased the damage 
that occurred to the heart muscle when given to dogs that had one hour myocardial 
infection. Such damage occurs after the blood supply is restored to the muscle. A 
sudden influx of oxygen (which produces free radicals that damage tissue) and 
abnormally high amounts of calcium cause the damage. In the same article, abnormal 
changes in heart were prevented by pretreatment with AP through 
electrocardiography. Clumping of platelets was also inhibited and clotting that could 
cause infarction was not induced (Zhao and Fang, 1991). The effect of AP was that it 
activated fibrionolysis, which dissolves clots in the body (Huang, 1993). Hsu et al. 
(2004) reported that AND increased the radioactive glucose uptake in cultured 
myoblast C2C12 cells and the uptake may reduce glucose in blood flow. 
 
1.3.5.5 Hepatoprotective and choleretic activity 
 
AP has also shown to protect liver. In Ayurvedic medicine, there are 26 different 
formulations containing AP used to treat liver disorders. AP is hepatoprotective in 
mice treated with carbon tetrachloride or tert-butylhydroperoxide (Kapil et al., 1993). 
These chemicals are highly toxic compounds which damage the liver by causing lipid 
peroxidation (Choudhury and Poddar, 1984). They produced free radicals and the 
later destroyed cellular membranes around liver cells. Significant liver protection 
occurred when the AP compounds were given to animals three days earlier than when 
the toxic chemicals were given. This protection was assigned to the antioxidant ability 
of the AP compounds and the hepatoprotective effect could compare with the known 
hepatoprotective agent silymarin by biochemical parameter (Rana and Avadhoot, 
1991). Handa and Sharma (1990a) reported that AND was the major active 
antihepatotoxic principle of AP against carbontetrachloride. AP was also reported to 
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be better than silymarin in protecting the liver against paracetamol toxicity (Visen et 
al., 1993) and against paracetamol and galactosamine (Handa and Sharma, 1990b). 
Hepatoprotective effect of AND was studied in rats. An acute hepatitis was induced 
by a single dose of galactosamine (800 mg/kg, ip) and paracetamol (3 g/kg, po) in 
rats. The livers of experimental rats were used to monitor hepatoprotective activity by 
determining the serum transaminases (GOT and GPT), alkaline phosphatase and 
bilirubin in serum, hepatic triglycerides and histopathological changes (Choudhury et 
al., 1987). The in vivo hepatoprotective effect of AND against galactosamine or 
paracetamol-induced hepatotoxicity in rats was confirmed by the results (Visen et al., 
1993; Handa & Sharma, 1990b). 
 
Infective hepatitis is an acute liver inflammation (Zender et al., 2003). In India, 
twenty patients of infective hepatitis (hepatitis A) were treated with 200 mg of AP 
extract twice times per day for over twenty-four days. The conjunctiva of the eyes and 
the urine changed colour from yellow to normal. It was reported that 80% of the 
patients were cured and 20% improved based on symptoms changes and biochemical 
tests. 90% of patients had regained appetites and 83% were relieved from general 
depression (Chturvedi et al., 1983). In another similar mode study in China, 83% of 
112 cases of hepatitis were recovered (Deng, 1978). 
 
Andrographolide showed choleretic activity in rat and guinea pig increasing bile 
volume as well as the amount of bile salts and bile acids (Shukla et al., 1992). The 
bile flow of the animals pretreated with AND was increased when paracetamol, which 
usually decreases bile production, was given to the animals.  In this case, AND was 
more powerful as compared to silymarin. Andrographolide also increases the amount 
of bile that acetaminophen toxicity decreases (Holt & Comac, 1998). 
 
1.3.5.6 Immunomodulatory activity  
Intra-gastric administration of ethanol extracts of the stems and leaves (25 mg/kg 
bodyweight) or purified andrographolides (1 mg/kg bodyweight) to mice was reported 
to stimulate antibody production and the delayed-type hypersensitivity response to 
sheep red blood cells (Puri et al., 1993). The extract and purified andrographolide was 
also reported to stimulate an innate immune response in mice, measured by 
macrophage migration index, phagocytosis of [ 14 C] leucine-labelled E.coli, and 
proliferation of splenic lymphocytes stimulated with Andrographis paniculata extract 
(Puri et al., 1993). However, the mechanism of the immunostimulation of 
andrographolide was not investigated.  
Andrographolide has been reported to have both immuno-stimulant and suppressant 
activities. The immunomodulatory property of a diterpene lactone andrographolide 
was reported to be associated with enhancement of proliferation of human peripheral 
blood lymphocytes as well as the production of key cytokines and the expression of 
Y Xu  21 
immune activation markers (such as INF-γ, neopterin and β-2-microglobulin) in 
whole blood cells in culture in vitro (Panossian et al., 2002). Rajagopal et al (2003) 
and Kumar et al. (2004) reported the immunostimulatory activity of andrographolide 
in vitro in PHA stimulated HPBLs (human peripheral blood lymphocytes) by 
increased proliferation of lymphocytes and production of IL-2. However, 
Iruretagoyena et al. (2005) reported that andrographolide could interrupt T cell 
activation both in vitro and in vivo. In vitro, this molecule could interrupt T cell 
proliferation and cytokine release in response to allogenic stimulation. T cell 
activation by antigen-pulsed dendritic cells (dendritic cells (DCs), one of antigen-
presenting cells) was suppressed by andrographolide in B3Z/0T4H T cell hybridomas 
(DCs-T cell co-culture). The authors suggested that andrographolide could interrupt 
maturation of DCs and their ability to present antigens to T cells. In vivo immune 
responses such as antibody response to a thymus-dependent antigen (NP17-BSA) and 
delayed-type hypersensitivity were extremely lessened in mice treated with 
andrographolide. In addition, Iruretagoyena et al. (2006) reported that 
andrographolide enhanced the tolergenic properties of immature DCs in Experimental 
Autoimmune Encephalomyelitis (EAE) by inhibiting NF-kappaB activation in murine 
DCs. Andrographolide was also reported to reduce IFN-γ and IL-2 production in 
murine T-cells stimulated with concanavaline A (Con A) in vitro (Burgos et al., 
2005). Moreover, Qin et al. (2006) reported that andrographolide inhibited the 
production of TNF-α and IL-12 in macrophages stimulated by lipopolysaccharide. 
Hence, the molecular and cellular mechanisms responsible for the immunomodulatory 
properties of andrographolide are still unclear. 
 
1.3.5.7 Other activities of AP 
 
AP was demonstrated to have anti-cancer activity. Matsuda et al. (1994) found that 
methanol extract of AP had potent cell differentiation-inducing activity on mouse 
leukaemia (M1) cells in vitro. Trivedi and Rawal (1998) also reported that an aqueous 
extract of AP had prolonged effects in inhibiting the tumorous condition of mouse 
liver, induced by hexachloro cyclohexane (hexachloro cyclohexane is an agent used 
for inducing liver damage to an extent of tumorous condition). A methanol extract of 
AP has also reported by Kumar (2004) to inhibit the proliferation of HT-29 (human 
colon cancer). Andrographolide has shown cytotoxic activity against KB (human 
epidermoid carcinoma), P388 (lymphocytic leukaemia), PC-3 (prostate cancer) and 
myeloid leukemic HL-60 cells (Kim et al., 2005; Cheung et al., 2005; Siripong et al., 
1992). Furthermore, Indian researchers reported that andrographolide not only 
inhibited the in vitro proliferation of different tumor cell lines, representing various 
types of cancers (Satyanarayana et al., 2004; Kumar et al., 2004; Nanduri et al., 2004; 
Rajagopal et al., 2003), but it also exerts direct anticancer activity on cancer cells by 
cell-cycle arrest at G0/G1 phase through induction of cell-cycle inhibitory protein p27 
and decreased expression of cyclin-dependent kinase 4(CDK4) (Rajagopal et al., 
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2003). Other suggestions of andrographolide-induced cell death were also reported 
either through the apoptotic pathway, via action of the caspase cascade (Kim et al., 
2005) or regulation of expression of pre-apototic markers (Zhou et al., 2006; Cheung 
et al., 2005). 
 
AP was also reported to show anti-virus activity. Aqueous extracts of AP leaves were 
reported to inhibit human immunodeficiency virus (HIV)-1 replication in the 
lymphoid cell line MOLT-4 (Yao et al., 1992). A hot aqueous extract of the aerial 
parts reduced (greater than 3 times of standard deviation below the mean) in the 
percentage of HIV antigen-positive H9 cells (Chang & Yeung, 1988). Syncytia 
formation in co-cultures of uninfected and HIV-1 infected MOLT cells was 
suppressed by a methanol extract of leaves at 70µg/ml (Otake et al., 1995). 
Dehydroandrographolide not only inhibited HIV-1 (UCD123) infection of H9 cells at 
1.6µg/ml and 50µg/ml, respectively, but also inhibited HIV-1 infection of human 
lymphocytes at 50µg/ml (Chang et al., 1991). Andrographolide was reported to inhibit 
HIV-1 by increasing plasma CD4 lymphocyte level in HIV-1 infected patients 
(Calabrese et al., 2000). Andrographolide, neoandrographolide and 14-deoxy-11, 12-
didehydroandrographolide showed anti-HSV-1 (herpes simplex virus 1) activity in 
human foreshin fibroblast and green ape kidney cell lines at tested concentrations 
(Wiart et al., 2005).  
 
1.3.6 Pharmacokinetics and safety of AP 
 
AND is highly bioavailable in human and animals. Panossian et al (2000) used 
validated analytical methods (HPLC, capillary electrophoresis and GC-MS) to 
determine the amount of AND in the blood plasma of rats and human volunteers 
orally administrated of AP extract. They found that AND was quickly and almost 
entirely absorbed into the blood. AND reached a peak plasma value in 1.5-2 hours and 
had a mean plasma residence time of 10 hours when the rats were orally 
administration of AP extract at a dose of 20 mg/kg bodyweight. The C max , AUC in rat 
at 2 hours were 1.3 μg/ml, 7.1 μg h/ml after oral administration of 20 mg/kg APE. 
They were 3.0 μg/ml, 15.1 μg h/ml after oral administration of 200 mg/kg. After 
radiolabelled AND was given oral dose to mice, AND accumulated in organs 
throughout the viscera. In one study, after 28 hours, 20.9% of labelled AND was 
accumulated in the brain; 14.9% in the spleen; 11.1% in the heart; 10.9% in the lung; 
8.6% in the rectum; 7.9% in the kidney; 5.6% in the liver; 5.1% in the uterus; 5.1% in 
the ovary and 3.2% in the intestine (Zheng et al., 1982). Absorption and excretion is 
fast. The kidney (urine) and the gastrointestinal tract remove almost 80% AND within 
8 hours. Ninety percent is taken away within 48 hours. 
 
Human studies have not found that AP associates with any side effects, although 
animal studies raise concerns about its effects on fertility such as male reproductive 
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system toxicity. However, according to Hancke et al. (2006), no toxicity was observed 
when humans had been treated in adose of 1200 mg daily for 4 days. 
 
Burgos et al. (1997) used male rats to evaluate the possible testicular toxicity of AP 
dried extract for 60 days. No toxicity was found after the rats were treated with 20, 
200 and 1000 mg/kg bodyweight for 60 days by evaluation of reproductive organ 
weight, testicular histology, ultrastructural analysis of Leydig cells and testosterone 
level. They suggested that AP extract had no subchronic testicular toxicity effect in 
male rats. Another subchronic toxicity of AP was given at doses of 0, 0.12, 1.2 and 
2.4 g/kg bodyweight / day with doses equal to 1, 10 and 20 times used for human 
doses (6g/day/person), to 24 rats for 6 months. Rat growth rate and body weight were 
normal. Also no abnormalities were found in blood serum, inner organs, testis and 
ovary (DMPRD, 1990).  
 
None of the mice died when mice received oral extract of AP (10 g/kg bodyweight) 
per day for seven days (Huang, 1978). This high amount did decrease activity and 
caused general lethargy, but the mouse heart, kidney, liver and spleen were found to 
be normal. Also extract of 20 g leaves with 600 ml water administered at the rate of 
10 ml/kg bodyweight did not produce abnormalities in rats and rabbits (Chantasutra & 
Limpapanichkul, 1989). No abnormal cardiovascular responses were found when 
rabbits were given intravenous andrographolide (10 mg/kg bodyweight). Liver 
enzyme tests and heart, liver, kidney and spleen were normal in these animals (Guo et 
al., 1988). In another study for toxicity, rats or rabbits received 1 g/kg bodyweight of 
andrographolide or neoandrographolide orally for 7 days; there was no effect on their 
body weight, blood counts, liver or kidney function (Yin and Guo., 1993). 
 
AP has been reported to have anti-fertility effects in experimental animals. Akbarsha 
et al. (2000; 1990) found that AP leaves at a dose of 20 mg per day for 60 days had an 
antispermatogenic effect in male rats, but Panossian et al (1999) found that a high 
therapeutic dose of AP extract (at 2g/kg bw) could not induce progesterone-mediated 
termination of pregnancy in pregnant rats. Male rats were also reported becoming 
infertile at intakes of 20 mg/ day or at high doses (Akbarsha et al., 1990; Zoha et al., 
1989). Other side effects are that high doses may cause gastric discomfort, anorexia 
and emesis but few side effects and no toxicity have found (Chang and But, 1986). 
However, in general, evidence to date indicates that AP is a natural product with low 
toxicity when used appropriately. 
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1.4 Mouse salmonellosis as a model system 
1.4.1 Salmonellosis 
 
Salmonellosis is a serious infectious disease of both animals and humans. Over 2000 
Salmonella serovars have been identified, most of which can colonize virtually all 
animals including food-producing animals (Mandell et al., 2005). Salmonellosis may 
manifest, depending on the serovar, as: 
(1) Enteric fever, also called typhoid fever, caused by S. typhi or paratyphoid 
fever caused by S. paratyphi. 
(2) Entertitis, characterized by fever, nausea, vomiting and bloody or nonbloody 
diarrhoea generally with abdominal cramps, which in immunocompletent 
human is generally a self-limiting disease. 
(3) Bacteraemia commonly encountered with infection caused by S. typhi, S. 
paratyphi, S choleraesuis and S. enteritidis. 
 
While enteric fever and bacteraemia warrant immediate treatment with an effective 
antibiotic, selected by in vitro susceptibility tests, which may include 
fluoroquinolones, trimethoprim/sulfamethoxazole or a broad-spectrum cephalothin, 
antitriches are not recommended for treatment of enteritis, the latter being self-
limiting. Both these clinical manifestations that involve S. typhi as the etiological 
agent are best handled using a prevention or prophylactie strategy involving 
vaccination. 
 
1.4.2 Salmonella vaccines and mechanisms of protection 
 
Traditionally, vaccines have been prepared in two ways, either live vaccines 
comprising live weakened or attenuated pathogens that have reduced pathogenicity 
but retained immunogenicity, or dead (non-living) vaccines such as killed or 
inactivated whole pathogens, and soluble pathogen proteins or protein subunits (Lee 
and Bishop, 1997). Live attenuated Salmonella vaccines may have come very close to 
meeting the criteria for an ideal vaccine that replicate similarly to the natural 
microorganism in vivo, and elicit both humoral and cellular immunity similar to that 
elicited by the natural infection (Viret et al., 1999; Harrison et al., 1997; Mastroeni et 
al., 1993; Mukkur et al., 1991a, 1991b; Mukkur et al., 1987). However, they may pose 
some risk such as reversion to virulence, and may also be dangerous to 
immunocompromised hosts including the state of pregnancy (Black, 2002; Lee & 
Bishop, 1997). On the other hand, killed or nonviable vaccines may be safer than live 
vaccines, but they generally cannot efficiently enter the MHC class I pathway, and 
thus are unable to elicit cell-mediated immunity, a pre-requisite for protection against 
intracellular pathogens including Salmonella speices. In adoptive transfer experiments 
carried out by Mastroeni et al., (1993) in Salmonella typhimurium-susceptible mice, 
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they suggested that protection against an oral challenge of virulent Salmonella 
typhimurium required both immune T cells and sera. Killed vaccines generally 
produce a less broad immune response than live, attenuated vaccines (Babu et al., 
2004; Babu et al., 2003; Harrison et al., 1997; Thatte et al., 1993). They are more 
likely to elicit an antibody response other than cell-mediated immunity although there 
are some reports that killed Salmonella enteritidis vaccine also induced cell-mediated 
response in chickens in an age-dependent manner (Okamura et al., 2004; 2003).  
 
The efficacy of live vaccines in the mouse model is because of their ability in not only 
to elicit an antibody response but also induce in cell-mediated immunity, which killed 
vaccines fail to do (Harrison et al., 1997; Mastroeni et al., 1993; Mukkur et al., 1991a, 
1991b; Mukkur et al., 1987). Orally ingested bacteria reach the spleen and liver to 
cause systemic infection by penetrating the intestinal mucosa and travelling via the 
lymph nodes (Finaly et al., 1997; Jones et al., 1996). During bacterial infection, 
macrophages serve as professional phagocytes and key effectors of the immune 
responses. However, Salmonella typhimurium uses the macrophage’s phagocytic 
nature to its advantage, as it resides intracellularly within macrophages. This enables 
it to replicate in the macrophage’s specialised vacuoles (Richter-Dahlfors et al., 1997; 
Leung and Finlay, 1991), protected from its host’s killings when this occurs. The 
antimicrobial actions of infected macrophages are vital in determining the outcome of 
disease (Kaufman, 1993). IFN-γ (an indicator of CMI) is reported as an effective 
stimulator of macrophage gene expression and is therefore necessary when 
Salmonella typhimurium or other intracellular bacteria need to be cleared 
(Rosenberger et al., 2000; VanCott et al., 1998; Nauciel et al., 1992; Muotiala et al., 
1990). In the in vivo mouse model of human typhoid fever, IFN-γ is released by NK 
and T cells 2-3 days following Salmonella typhimurium infection (Rosenberger et al., 
2000). 
 
Salmonelloses in food-producing animals and humans are continuing problem that 
warrants application of prophylactic strategies. The initial strategy used evaluating the 
protective efficancy of killed vaccines in the mouse model. Initial studies in mice, 
using killed Salmonella vaccines claimed those vaccines to be protective (Angerman 
and Eisenstein, 1980), but were later reported to be due to the innate resistance of 
some mouse strains to salmonellosis (Kaufmann et al., 2001). The most direct 
demonstration of the lack of relevance of anti-Salmonella antibodies to protection 
against salmonellosis was reported by Mukkur et al. (1991a) when mice immunized 
with the formalin-killed S. bovis-morbificans vaccine. High antibody titres did not 
protect mice against experimental challenge infection, whereas mice vaccinated with 
live attenuated S. bovis-morbificans were significally protection. The high level of 
protective efficacy recorded for the live attenuated S.  typhimurium (aroA) vaccines in 
sheep and cattle (Villarreal-Ramos et al., 1998; Begg et al., 1990; Mukkur et al., 
1987) clearly valuates the use of such vaccines against salmonellosis in food 
producing animals. Another attenuated S.  typhimurium vaccine strain in which the 
catabohte receptor protein (crp) and adenylate cyclare (cya) genes were inactivated 
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(∆crp, ∆cya) has also been reported to impart protection in mice, chickens and 
humans (Levine et al., 2001; Hassan et al., 1993; Curtiss and Kelly, 1987). It is 
beyond the scope of this review of literature to provide the history leading to the 
development of aromatic-dependent (aroA/ aroD) and ∆crp, ∆cya S.  typhi vaccines. 
However, an excellent review on this aspect is available elsewhere of Levine et al. 
(2004). 
  
Two new typhoid vaccines have been licensed and widely used in humans during the 
past 15 years. One is the Vi polysaccharide from S. typhi for parenteral (subcutaneous 
or intramuscular) and the other is a live attenuated strain of S. typhi Ty21a for oral 
application. The S. typhi Ty21a strain, which is derived by chemical mutagenesis, 
becomes completely deficient of the activities of the gal E gene product. Not only its 
ability to produce complete lipopolysaccharide is restricted, but Ty21a also has 
several nutritional auxotropies, approximately half the growth rate of the parent strain 
Ty2, does not produce H 2 S, and lacks the Vi antigen (capsular acidic polysaccharide 
which is present on almost all virulent S. typhi strains). It takes galactose to facilitate 
production of lipopolysaacharide (which leads to immunogenicity) when Ty21a is 
grown in the low concentrations of galactose. However, an oversupply of galactose in 
growing Ty21a has been supposed to cause an accumulation of toxic metabolites 
within the bacterial cells, which leads to bacterial lysis. The attenuation and safety of 
the Ty21a strain has always been attributed to the combination of two factors, the gal 
E mutation and the lack of Vi antigen. This view has been shown to be at least 
partially incorrect by the observation that a similar mutant (Vi negative, galE deletion 
mutant) of S. typhi, constructed by recombinant DNA techniques, is virulent. 
Futhermore, galactose induced lysis of Ty21a is subdued in vitro in the prescence of 
glucose. Consequently, neither the safety of Ty21a nor the failure to recover vaccine 
organisms from people ingesting the usual dose could be completely explained by the 
combination of galE and Vi mutations. Hence, the mechanism of Ty21a attenuation is 
not completely understood. 
 
These two vaccines have widely replaced the old heat-phenol inactivated whole-cell 
vaccine in many countries. Another acetone-killed whole-cell human typhoid vaccine 
given subcutaneously (s.c.) has also been in use for many years 
(http://www.who.int/vaccines/en/typhoid.shtml). Inactivation with acetone was 
originally designed to retain the protective Vi capsular antigen of S. typhi, thereby 
making the vaccine more immunogenic and protective than the older heat-phenol-
killed vaccine that lacked the Vi antigen. However, it was discovered to elicit poor 
cell-mediated immunity, the latter considered to be important confering significant 
albeit limited protection (Tacket et al., 2000; Harrison et al., 1997; Mastroeni et al., 
1993). The current formulations at least of the Vi- and Ty21a vaccines are only 50%-
70% efficient in children of fewer than five years and young adults. Furthermore, 
neither the Vi-based polysaccharide vaccine nor the Ty21a vaccine is permitted to 
give children under two years old (WHO, 2003).  
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1.5 Immune response modifiers/adjuvants 
 
Immune response modifiers or adjuvants are compounds or molecules that enhance or 
suppress one or both the effector arms of immune response (Akdis et al., Singh and 
Srivastava, 2003). This definition is based on the assumption that adjuvants enhance 
the delivery of the antigen to the lymph node followed by incompletely understood 
different mechanisms (O’Hagan, 2004). Description and discussion of different type 
of adjuvants or delivery systems used so far, some of which may also induce and 
enhance CMI, are beyond the scope of this literarure review. However, it is clear that 
the potential mechanism of action of andrographolide may have to involve 
consideration of the action of metabolites generated in vivo after oral administration 
of this immuno-stimulatery compound, an area of a research apportunity for the 
future. 
 
1.6 Goals and objectives 
 
There are many ways to protect ourselves against infectious diseases. For example: 
antibiotics and other antimicrobial agents may directly inhibit or kill the pathogens; 
vaccines activate the immune system to respond to an infectious agent by inducing 
antibodies or CMI. An adjuvant (such as alumium hydroxide, calcium phosphate gel) 
used in combination with specific antigen that produces more immunity than the 
antigen alone, has been reported (Edelman, 2002; HogenEsch, 2002; Hunter, 2002; 
Kenney et al., 2002; O’Hagan, 2000). It is worth to think other adjuvants to select for 
modulating humoral or CMI. Plants and plant derived substances have become new 
sources in the investigation of antimicrobials. The use of herbal extracts either as an 
alternative or complimentary medicine to the conventional chemotherapy for 
treatment of diseases has a long history or is well documented in China and India 
(Hoareau et al., 1999). Therefore, they have been perceived as sources for new 
antimicrobial research. It would be ideal if an immunodulating compound, capable 
inducing CMI in the target species (mice in this study), when administered at the 
same time as the non-CMI inducing vaccine such as the killed vaccine, was 
discovered as vaccines against salmonellosis capable of inducing both antibodies and 
CMI are protective both in humans and animals. 
 
AP, as a traditional Ayurvedic/Chinese herbal medicine has been claimed to possess 
many therapeutic properties including immunostimulation. Clinically, AP extract has 
been used to treat patients with the common cold, urinary infections, dysentery and 
infectious hepatitis. More recently, various biological activities of AP extract or AND 
have been reported such as immunostimulatory activity (Puri et al., 1993), anti-
inflammatory effect (Chiou et al., 2000; Shen et al., 2000; Madav  et al., 1996; 
Sawasdimongkol et al., 1990; Chantasutra & Limpapanichkul, 1989; Dutta & Sukul., 
1982), anti-human immunodeficiency virus (HIV) activity (Otake et al., 1995; Yao et 
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al., 1992; Chang and Yeung, 1988), cytokine induction (Kumar et al., 2004; 
Rajagopal et al., 2003; Panossian et al., 2002), cytokine deduction (Qin et al., 2006; 
Burgos et al., 2005), a potential cancer therapeutic agent (Zhou et al., 2006; Kumar et 
al., 2004; Rajagopal et al., 2003) and T cell activation suppression when given 
systemically (Iruretagoyena et al., 2006; 2005). These studies, taken together, 
suggested that one of the pharmacological effects of AP might be mediated via its 
immunomodulatory property (ies) (Mills & Bone, 2000). As a major chemical 
constituent of AP along with the above activities, AND might be the active principle. 
However the potential of AP extract or AND to modulate the specific or adaptive 
immune response, particularly to the infectious diseases caused by intracellular 
pathogens (such as Salmonella typhimurium) has not been determined. The purposes 
of this project were to determine the immunomodulatory and protective potentials of 
the ethanol extract of AP and one active principle of AP, AND, with the aim of 
assessing their cell-mediated immunity (CMI)-inducing and their protective potential 
particularly against infectious diseases caused by intracellular pathogen, Salmonella 
typhimurium. As described above, cytokine production involved in the induction of 
CMI or humoral immunity. In this project, IL-4, in addition to the measurement of 
antibody response was used as an indicator of humoral immunity, whereas induction 
of IL-2 and specially, interferon-γ were used as indicators of CMI.   
 
The goals of the research embodied in this thesis were to (1) test the direct anti-
microbical potential of AP in vitro using a broader spectrum of microbial pathogens 
of relevance to human health (2) to determine the immunomodulatory of AP using 
mouse salmonellosis caused by Salmonella typhimurium in mice as a model system 
(3) and to immunologically characterize the bioactive principle, andrographolide 
thought to be responsible for immunomodulatory activities. 
 
These aims were achieved by: 
1. Purification and chemically characterisation of purifed AND from AP. 
2. Evaluation, in vitro, of the antibacterial activity of AND or AP extracts with 
different solvents, using the disk agar diffusion method--antibacterial 
susceptibility test. 
3. Evaluation of the immune response-modifying potential of ethanol extract of 
AP (APE) and purified AND against intracellular microbial infections in mice 
immunized with killed Salmonella typhimurium vaccine, the latter stimulating 
only the humoral arm of immunity. 
4. Determination of the protection status of mice, treated with APE and AND, 
following oral challenge with virulent Salmonella typhimurium. 
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Chapter 2  Purification and identification 
of andrographolide from Andrographis 
paniculata  
  
2.1 Introduction 
 
Andrographis paniculata, as a traditional Ayurvedic/Chinese herbal medicine has 
been claimed to possess many therapeutic properties (mentioned in Sections 1.3.4 
and 1.3.5). One of the ways of administration of this medicine is via herbal extract 
prepared using aqueous or alcoholic solvents. Such extracts contain a mixture of 
bioactive and inactive chemical ingredients. In addition, the chemical composition 
varies depending on growing region and the collection time. Hence, it is desirable 
to identify the bioactive chemical ingredient (s) from the traditionally-claimed 
therapeutic herbs with the aim of (1) standardising the herbal extract or (2) 
evaluating the therapeutic potential of the purified bioactive principles for use in 
the treatment of the traditionally-claimed disease conditions. The objective of this 
study was to purify one of these major components (andrographolide) from 
Andrographis paniculata and to analyse its quality. 
 
2.2 Materials and methods 
 
2.2.1 Plant materials 
 
AP whole plant coarse powder was purchased from Woods plus Woods Co. Ltd. 
(Sydney, Australia). The whole dried plants had been crushed and ground into 
powder prior to purchase. Preliminary tests and confirmatory tests were conducted 
to confirm the presence of AND in the purchased AP. Commercial AND 
(purchased from Sigma-Aldrich, 98%, St Louis, MO, ) was used as standard.  
 
2.2.2 Preliminary test (colour test) 
 
1 g of AP powder with 20 ml of ethanol was boiled in a water bath for 5 mins. 300 
mg of activated charcoal was added, stirred and then filtered. The filtrate was used 
for the following two tests. The first test involved 2 drops of a 2% w/v solution of 
3,5-dinitrobenzoic acid in ethanol and 2 drops of a 5.7% w/v solution of 
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potassium hydroxide in ethanol being added to 0.5 ml of filtrate. A colour change 
to a purplish red indicated that the sample had active compounds (MPRI, 1999). 
The second test involved 3-5 drops of the 5.7% w/v solution of potassium 
hydroxide in ethanol being added to 0.5 ml of filtrate until a red colour appeared. 
The filtrate was set aside for 10 to 15 mins. The red colour changed to yellow. 
These two tests indicate that the sample contained diterpene lactones as active 
constituents (MPRI, 1999). 
 
2.2.3 Confirmatory test 
 
Thin layer chromatography (TLC) analysis was carried out following the colour 
test to confirm that AND is contained in AP powder. The filtrate was obtained as 
above (Section 2.2.2). The filtrate was evaporated under reduced pressure until 
fully dried. The filtrate powder and 1 mg of standard andrographolide were 
dissolved in 0.5 ml of warm ethanol separately. A precoated plate of silica gel 
60F254 (Merck, Kilsyth, VIC) and mobile phase (chloroform: methanol: ethyl 
acetate 8: 1.5: 1) were used. 5 microliters was used for each spot. TLC of the 
isolated samples was firstly detected by UV radiation (Electronic UV 
Transilluminator, Quantum Scientific) and then confirmed by spraying with 2% 
w/v solution of 3,5-dinitrobenzoic acid in ethanol and an excess of 5.7% w/v of 
potassium hydroxide in ethanol.  
 
2.2.4 Purification of AND 
 
After confirmation that AP contained AND, a modification of the method reported 
by Rajani et al. (2000) was used to isolate AND from AP. Briefly, 200g whole 
dried crushed AP was extracted twice with a 1:1 mixture of dichloromethane and 
methanol by cold maceration (one with 1 liter and then 0.2 liter of the maceration 
mixture) (1×1 liter and 1×0.2 liter). Each extraction was conducted for 6 hours 
with constant stirring. The extract was filtered and the filtrate was concentrated in 
vacuo at a temperature below 70°C to produce a green mass (4.3g). The green 
mass was washed with toluene several times until most of coloured matter was 
removed from the residue. The toluene was completely removed from the residue 
by evaporation. The residue was dissolved in 60-70°C hot ethanol and filtered 
while hot. The filtrate was cooled in a refrigerator for crystallisation. This process 
was repeated several times until small yellow plates of constant melting point, 
range of 220-228°C (2.5g) were obtained (a melting range from 224-230°C is 
used in China in laboratories of government offices to test and control the quality 
of AND, http://www.plantpharm.net/new_page_25.htm). The isolation of AND 
was confirmed by UV absorption spectrum, TLC, ESI-MS and 1 H-NMR (see 
following Section). 
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2.2.5 Identification of purified AND 
2.2.5.1 Melting point  
 
Melting point was determined using a melting point apparatus (FSE, England). 
 
2.2.5.2 Colour test  
 
The colour test was performed by the following two methods 
(http://www.plantpharm.net/new_page_25.htm). The first method involved adding 
1ml 1% w/v solution of 3,5-dinitrobenzoic acid in ethanol and 2 drops of 5.7% 
w/v of potassium hydroxide in ethanol to 1mg AND in 3ml ethanol. A colour 
change to purple indicated that the sample had active compounds such as AND 
present. The second method involved adding 2-3 drops of 5.7% w/v of potassium 
hydroxide in ethanol to 1 ml 0.1 mg/ml purified AND in ethanol until the solution 
showed a red colour. After sitting for 10-15 minutes, a colour change to yellow 
indicated that the sample had active compounds such as AND present. 
 
2.2.5.3 UV maximum absorption spectrum (UV: λ max nm)  
 
UV spectrophotometry was used to determine the maximum absorption spectra 
within the range from 200 to 270 nm (CE2021, 2000 SERIES; Cecil, UK) 
(http://www.plantpharm.net/new_page_25.htm). The concentration of purified 
AND and commercial AND (purchased from Sigma-Aldrich, 98%) was 25 µg/ml 
in ethanol.  
 
2.2.5.4 Thin layer chromatography (TLC) 
 
1 mg of commercial AND and purified AND was dissolved in 0.5 ml of warm 
ethanol (2mg/ml) separately. A precoated plate of silica gel 60F254 (Merck, 
Kilsyth, VIC) and mobile phase (chloroform: methanol: ethyl acetate 8: 1.5: 1) 
were used. 5 microliters were used for each spot. TLC of the isolated samples was 
firstly detected by UV radiation (Electronic UV Transilluminator, Quantum 
Scientific) and then by spraying with 2% w/v solution of 3,5-dinitrobenzoic acid 
in ethanol and excess 5.7% w/v potassium hydroxide in ethanol. 
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2.2.5.5 1 H-NMR ( 1 H- nuclear magnetic resonance spectroscopy) 
 
1 H-NMR was determined by Dr. Russell Barrow from the Australian National 
University (ANU). 1 H-NMR spectra were recorded at 298 K on a Varian Gemini 
300 instrument with 300 MHz and referenced to the central peak from residual 
methanol at 3.30 ppm.  
 
2.2.5.6 ESI-MS (electrospray ionization mass spectrometry)  
ESI-MS was determined by Dr. Russell Barrow from the ANU. ESI-MS was 
recorded on a Bruker Apex 3 (Karlsruhe, Germany).  
 
2.3 Results  
2.3.1 Preliminary test 
 
The result of preliminary test was that the colour of AP filtrate changed to 
purplish red after ethanolic 3,5-dinitrobenzoic acid and potassium hydroxide 
being added in the first test. The filtrate first appeared red in colour after ethanolic 
potassium hydroxide was added, and then the red colour changed to yellow 10 
mins later in the second test. 
  
2.3.2 Confirmatory test 
 
The result of the TLC is shown in Figure 2-1. For the AP sample, six spots 
appeared (Figure 2-1B) and the Rf value of each spot is 0.05, 0.14, 0.24, 0.39, 
0.62 and 0.79 respectively. A large spot with Rf value equal to 0.62 (Figure 2-1 A 
& B) shows the same Rf value as the standard AND (0.62) in the same precoated 
plate of silica gel 60F254 after development. 
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A: Photo of UV radiation   B: Photo of spraying with reagents  
 
Figure 2-1 Thin layer chromatography of AP extract and standard AND after 
development, lane 1: AP solvent sample, lanes 2, 3 and 4: standard AND 
 
 
2.3.3 Purification of AND 
 
2.5 g of pale yellow crystalline plates was obtained by the modification of the 
method reported by Rajani et al. (2000, Figure 2-2).    
 
 
 
Figure 2-2 Andrographolide crystalline plates in bottles 
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2.3.4 Identification of purified AND 
2.3.4.1 Melting point 
 
The melting point of the purified sample was 220-228°C and the commercial 
sample (purchased from Sigma-Aldrich, 98%) was 222-228°C. 
 
2.3.4.2 Colour test 
 
In the colour test, the purified AND solution changed to purplish red after 
chemical solvents were added according to method 1. The solution first changed 
to red after the chemical was added by method 2, 10-15 minutes later it changed 
to yellow. 
 
2.3.4.3 UV (EtOH): λmax nm 
 
UV λmax = 224 nm in ethanol was obtained (Figure 2-3).  
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Figure 2-3 Absorption spectra of AND isolated (square) and reference standard 
(ST, diamond), in the UV ranges from 210 to 270 nm. 
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2.3.4.4 Thin layer chromatography (TLC) 
 
The result of TLC is that only one purple/red spot appeared for each sample after 
development with the colour reaction reagents (Figure 2-4A) and one spot was 
detected by UV radiation (Figure 2-4B). 
Rf (lane 1) =0.48; Rf (lane 3) =0.48; 
Rf (lane 2) =0.48; Rf (lane 4) =0.48. 
 
     
       
       1        2        3         4                              1      2        3        4 
 
     A           B 
 
A: Photo after spraying with reagents B: Photo of UV radiation 
  
 
Figure 2-4 Thin layer chromatography of purified AND and standard AND after 
development, lanes 1 & 3: the standard AND, lanes 2 & 4: the purified AND. 
 
2.3.4.5 1 H-NMR 
 
1 H-NMR was carried out by Dr. Russell Barrow of ANU (Figure 2-6 and Table 2-
1). 1 H-NMR spectra were recorded at 298 K on a Varian Gemini 300 instrument 
with 300 MHz and referenced to the central peak from residual methanol at 3.30 
ppm. 1H-NMR spectroscopy (300MHz, CD3OD) was entirely consistent with 
published data for AND and revealed the sample to be pure to the limits of 
detection (Medforth et al., 1990; Cui et al., 2005). δ at which signals are shown 
for purified AND and reference data is given in the below table (Table 2-1).  
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Figure 2-5 The structure of andrographolide 
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(a) 
 
 
 
 
 
(b) 
 
 
 
Figure 2-6 1H-NMR of purified AND (a) and standard AND (b) 
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Table 2-1 Proton chemical shift assignments of AND 
  
(ppm measured in CD 3 OD and 300 MHz) relative to residual methanol (MeOH) 
at 3.30 ppm 
 
Proton δ of purified 
AND (ppm) 
δ of reference data (ppm) 
(Medforth et al., 1990) 
δ of reference data (ppm) 
(Cui et al., 2005) 
H(1)ax 1.28 1.30 1.28 
H(1)eq 1.80 1.80 1.83 
H(2)ax 1.80 1.80 1.79 
H(2)eq 1.78 1.80 1.76 
H(3) ax 3.41 3.41 3.40 
H(3)eq - - - 
H(5)ax 1.32 1.32 1.32 
H(6)ax 1.38 1.38 1.36 
H(6)eq 1.85 1.86 1.87 
H(7)ax 2.03 2.04 2.03 
H(7)eq 2.43 2.43 2.41 
H(9)ax 1.91 1.92 1.91 
H(11a) 2.61 2.63 2.60 
H(11b) 2.59 2.58 2.60 
H(12a) 6.85 6.85 6.84 
H(12b) - - - 
H(14) 5.01 5.01 5.00 
H(15a) 4.45 4.45 4.45 
H(15b) 4.16 4.16 4.14 
Me(16) 0.75 0.76 0.74 
H(17a) 4.89 4.89 4.87 
H(17b) 4.66 4.67 4.65 
Me(18) 1.20 1.22 1.20 
H(19a) 4.09 4.12 4.10 
H(19b) 3.37 3.37 3.36 
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2.3.4.6 ESI-MS  
ESI-MS was determined by Dr. Russell Barrow (ANU). ESI-MS was recorded on 
a Bruker Apex 3 (Karlsruhe, Germany). The data are given as follows (from 
Figure 2-7). ESI-MS (+ve) m/z: (1) purified AND: 373.0 [M+ Na]
+
, 723.2 [2M+ 
Na]
+
 ; (2) standard AND: 373.1 [M+ Na]
+
, 723.0 [2M+ Na]
+
. Hence, the 
molecular weight of purified AND is 350. 
 
 
(a) 
 
 
(b) 
 
  
 
 
Figure 2-7 ESI-MS of purified AND (a) and standard AND (b) 
 
(80% MeOH, ESI +ve, CV=60) 
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2.4 Discussion 
 
The preliminary colour test used here is the official test used in the Thai 
laboratories to test and control the quality of medicinal plants (MPRI, 1999). This 
test is easy, inexpensive and quick. However, as Tipakorn (2002) mentioned, this 
is a primary test which only indicates the presence of compounds which react 
chemically like the active compounds of AP. Further identity tests in the 
laboratory are needed to confirm the presence of AND. 
 
The confirmatory test showed that the AP plant sample appeared as a large spot 
and the spot had the same Rf value (0.62) as the AND standard which was used 
for comparison in this test (Figure 2-1). For the AP solvent sample, there were 
some additional spots between photos A and B. This is because some compounds 
which can be detected by UV are not shown by colour test and vice versa. 
   
AND was purified from AP using a slightly modified method reported by Rajani 
et al. (2000). AND is a white or pale yellow plate crystal which does not mix well 
with water, but is soluble in chloroform, acetone, ether, methanol and hot ethanol. 
A 1:1 mixture of dichloromethane and methanol was added to the AP powder to 
extract AND from AP. After removing most of the colour from the extract mass, 
hot ethanol was used to dissolve AND and then allowed to crystallize in a 
refrigerator. Hot ethanol was substituted for methanol in the original literature 
method (Rajani. et al., 2000) because methanol remaining in AND may be 
injurious when the AND is dosed to mice.  
 
The purified AND was identified by melting point, colour test, UV λmax, TLC, 
ESI-MS and 1 H-NMR and compared with commercial AND and the data from 
references (http://www.plantpharm.net/new_page_25.htm; Medforth et al., 1990; 
Cui et al., 2005). The melting point (224-230°C), colour tests (purple, red and 
yellow), UV λmax (224 nm in ethanol), TLC (single spot) are normally used in 
China in laboratories of government offices to test and control the quality of AND 
(http://www.plantpharm.net/new_page_25.htm). The data obtained here concur 
with these. The melting point of purified AND is slightly lower than the 235.3°C 
reported by Rajani et al. (2000). This may be due to the author using DSC, not a 
normal melting point apparatus to record melting point. The isolation of AND was 
further confirmed by mass spectrometry and 1H-NMR spectroscopy.  Electrospray 
ionisation mass spectrometry (ESI-MS) showed an intense pseudomolecular ion at 
m/z 373, consistent with a sodiated molecular ion (M+Na) for AND.  High 
resolution mass measurement under electrospray conditions confirmed a 
molecular formula for the ion at m/z 373 as C20H30NaO5. From ESI-MS data, the 
molecular weight of purified AND is 350 which is the same as the AND standard 
(Sigma-Aldrich, 98%). 1H-NMR spectroscopy (300MHz, CD3OD) was entirely 
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consistent with published data for AND and revealed the sample to be pure to the 
limits of detection (Medforth et al., 1990; Cui et al., 2005). 
 
In order to further assure quality of the purified AND, it was necessary to have 
methods which are selective and sensitive for detection. TLC is the simplest and 
cheapest method of detecting plant constituents because the method is easy to run, 
reproducible and requires little equipment. HPLC coupled to mass spectrometry 
(LC/MS) is a newer technique. Mass spectrometry is one of the most sensitive 
methods of molecular analysis and yields information on the molecular weight as 
well as on the structure of the sample. Electrospray, one of three LC/MS 
interfaces, covers the ionization ion (ESI-MS) and has been used to identify the 
purified AND molecular weight as well as analysing its structure. NMR 
spectroscopy is by far the most powerful spectroscopic technique for obtaining 
structural information about organic compounds in solution (Hostettmann, 1999).  
The purified AND was completely confirmed by TLC, ESI-MS and 1H-NMR. 
 
2.5 Conclusions 
 
Confirmatory tests indicated that the whole plant material contained the active 
compound of AP: andrographolide. All data from melting point, TLC, UV λmax, 
ESI-MS and 1H-NMR indicate that AND was successfully purified from AP.  
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Chapter 3 An investigation on the 
antimicrobial activity of Andrographis 
paniculata extracts and andrographolide 
in vitro 
 
3.1 Introduction 
 
The development of bacterial resistance to currently available antibiotics has 
made it necessary to search for new antibacterial agents. New sources, especially 
natural products from plants, are being investigated because medicinal plants have 
been widely used for treatment of many types of acute and chronic diseases in 
Asia, and many plants with antimicrobial activity have been reported (Cowan, 
1999; Al-Howiriny, 2002; Dulger and Gonuz, 2004). Crude aqueous or alcohol 
extractions of AP and one principle of AP viz., AND have been reported to be 
effective in the treatment of dysentery, diarrhoea and upper respiratory tract 
infection (Duke and Ayensu, 1985; Thanangkul and Chaichantipyuth, 1985; 
Gupta et al., 1990; Yin & Guo, 1993; Chturvedi et al., 1983; Chang and But., 
1986; Hancke et al., 1995; Caceres, 1997; Melchior et al., 1997; Thamlikitkui et 
al., 1991; Subjareun, 1996; Melchior et al., 2000; Poolsup et al., 2004 and Coon & 
Ernst, 2004; Amaryan et al., 2003; Gabrielian et al., 2002; Spasov et al., 2004). 
The antibacterial activity of aqueous, ethanol or methanol extracts of 
Andrographis paniculata has been tested in vitro against Escherichia coli, 
Staphylococcus aureus, Proteus vulgaris, Salmonella typhi, Shigella species and 
Pseudomonas aeruginosa in vitro (George & Pandalai, 1949; Nakanishi et al., 
1965; Pleumjai and Sithisomwonges, 1990; Sindermsuk, 1993; Bunyapraphatsara, 
2000; Prajjal et al., 2003) with no antibacterial activity observed with the aqueous 
extract tested against E. coli, S. aureus, S. typhi or Shigella species (Leelarasamee 
et al., 1990). Therefore, it is desirable to extend these investigations using a 
broader spectrum of microbial pathogens of relevance to human health. The 
objective of this chapter was to evaluate in vitro the antibacterial activity of 
andrographolide or Andrographis paniculata extracts with different solvents. 
 
 
 
3.2 Materials and methods 
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3.2.1 Plant materials 
 
AP whole plant coarse powder was purchased from Woods plus Woods Co. Ltd. 
(Sydney, Australia). The major active compound, AND was purified and 
identified as outlined in Chapter 2. 
 
3.2.2 Preparation of extracts 
 
Based on the methods used for chemical analysis described by Cowan (1999), AP 
powder was extracted in a series of three different solvents: distilled water, 80% 
and 100% food grade ethanol (recorded as water extract, 80%APE, 100%APE 
respectively).  
 
AP powder (100g) was weighed and placed in flasks, and then soaked and stirred 
in distilled water, 80% or concentrated ethanol (1:10 w/v) overnight (o/n). After 
filtration through cotton wool, the filtrates were centrifuged at 10,000×g for 20 
mins (Beckman Avanti J251 centrifuge, Beckman Instruments, Palo Alto, CA) at 
room temperature (Cowan, 1999; Puri et al., 1993). The extract solutions were 
evaporated in a rotary evaporator (Labrota 4001, Heidolph) at 60°C until dry. 
Dried extracts were weighed and stored in labelled sterile screw capped bottles at 
-20°C. 
 
3.2.3 Microorganisms 
 
The bacteria used included: Salmonella typhimurium (bovine, 12313), Salmonella 
typhimurium (aroA SL3261), Salmonella bovis-morbificans, Escherichia coli 
(ATCC 25922), Escherichia coli (Q 358), Shigella sonnei, Staphylococcus aureus 
(ATCC 49476), Pseudomonas aeruginosa (ATCC 27853), Streptococcus 
pneumoniae, Streptococcus pyogenes, Legionella pneumophila, and Bordetella 
pertussis (Tohama I), (obtained from stocks in the Department of Biological and 
Physical Sciences, University of Southern Queensland). 
 
3.2.4 Analysis of the AP extracts by TLC 
 
Thin layer chromatography analysis was used to authenticate the AP extracts as 
judged by the detection of AND.  The AP extracts were dissolved as per their 
preparation details above (Section 3.2.2) and 5 micro liters (µl) were used for each 
spot. The AND was dissolved in hot ethanol (5 mg/ml) and 5 µl were used for 
each spot. A precoated plate of silica gel 60F254 (Merck, Kilsyth, VIC) and 
mobile phase (chloroform: methanol: ethyl acetate 8: 1.5: 1) were used. The 
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extracts fractionated by TLC were detected by UV radiation (Electronic UV 
Transilluminator, Quantun-Scientific). The Rf (retardation factor) of AND was 
0.58.  
 
3.2.5 Screening for antimicrobial activity 
3.2.5.1 Preparation of discs with AP extracts or AND 
 
The dry extracts prepared as described in Section 3.2.2, were dissolved as per 
their preparation details above (Section 3.2.4) and diluted with distilled water to 
obtain concentrations at 100 mg/ml, 10 mg/ml or 1 mg/ml (w/v) to determine 
which of these concentrations had an inhibitory effect on bacterial growth. AND 
was firstly dissolved with ethanol and then diluted with distilled water to obtain 
concentrations of 10 mg/ml, 1 mg/ml or 0.1 mg/ml (w/v). Fifty µl of each 
prepared dilution was added to each 6 mm diameter sterilized disc (Whatman, 
England). After adding the dilutions, the discs that had the equivalent to 5 mg, 0.5 
mg or 50 µg of extracts, and 0.5 mg, 50µg or 5 µg of AND per disc, were placed 
in an oven and dried at 55°C overnight. The discs with 50 µl of 80% ethanol were 
also prepared in the same way as a control to account for any inhibition caused by 
any residual ethanol remaining after drying of the disc overnight.  
 
3.2.5.2 Preparation of bacterial culture media 
3.2.5.2.1 Culture media for E. coli, S. typhimurium, S. bovis-
morbificans, S. sonnei, S. aureus and P. aeruginosa 
 
E. coli, S. typhimurium, S. bovis-morbificans, S. sonnei, S. aureus and P. 
aeruginosa were grown on LB agar and broth. LB broth and agar were prepared 
according to the manufacturer’s instructions (Difco, Detroit, MI). 
3.2.5.2.2 Culture media for S. pneumoniae and S. pyogenes 
 
S. pneumoniae, S. pyogenes were grown on horse blood agar. 100ml of LB agar 
was prepared according to the manufacturers’ instruction (Difco, Detroit, MI). 
After sterilization at 121°C for 15 mins, the molten agar was allowed to cool to 
50°C in a water-bath. 10 ml of sterile defibrinated horse blood was then added and 
mixed gently to avoid bubbles, and the agar mix was then poured into petri dishes. 
 
3.2.5.2.3 Culture media for L. pneumophila 
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L. pneumophila was grown on Legionella CYE agar with BCYE growth 
supplement (Oxoid, Adelaide, SA). 2.5 g Legionella CYE agar base in 90 ml of 
distilled water was sterilized at 121°C for 15 mins.  The sterile agar base was 
allowed to cool to 55°C and the contents of one vial (in 10 ml sterile distilled 
water) of Legionella BCYE growth supplement was added aseptically. The agar 
base and the supplement were gently mixed and then poured into sterile petri 
dishes. 
 
3.2.5.2.4 Culture media for B. pertussis  
 
B. pertussis was grown on charcoal agar. The charcoal agar was prepared 
according to the manufacturer’s instruction (Difco, Detroit, MI). Briefly, 6.25 g 
charcoal agar base in 100 ml of distilled water was mixed thoroughly and boiled, 
with frequent agitation, for 1 min to completely dissolve the powder. After 
sterilizing at 121°C for 15 mins, the sterile agar base was mixed thoroughly and 
then poured into sterile petri dishes.  
 
3.2.5.3 Preparation of bacteria 
 
The bacteria were grown in petri dishes with appropriate agar.  S. pneumoniae and 
S. pyogenes were grown on blood agar plates (see Section 3.2.5.2.2). L. 
pneumophilia was grown on legionella cye agar with BCYE supplement (see 
Section 3.2.5.2.3). B. pertussis was grown on charcoal agar (see Section 
3.2.5.2.4). All other micro-organisms were grown on LB agar (see Section 
3.2.5.2.1). The inoculum suspensions were prepared in 0.9% saline to an 
equivalent 1 McFarland Standard. Alternatively the suspensions were adjusted to 
an absorbance of 0.26 using a spectrophotometer set at wavelength of 640 nm 
(OD 640 = 0.26). 0.1 ml of bacterial suspension was spread over the entire agar 
surface using a sterile swab. The plate was allowed to dry for 5 mins before 
placing the tested discs on the surface.  
 
3.2.5.4 Determination of antimicrobial activity 
 
The antibacterial activity of AND and each AP solvent extract was analyzed by 
disc diffusion susceptibility methods as described elsewhere by Navarro et al. 
(1996) or Dulger and Gonus (2004). The discs with extracts or AND were placed 
on the agar plates on which the bacteria were spread, followed by incubation at 
37°C for 18 hours (the plates of L. pneumophilia, and B. pertussis were incubated 
for 3 days in a humid atmosphere). The results were interpreted using zone 
diameter of inhibition for susceptible strains. The diameters of inhibition zones 
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(clear zones) around the disc were measured in mm. Select reference antibiotic 
discs were used as positive controls, depending on the test micro-organisms. 80% 
ethanol soaked and dried discs were also used as a control. 
  The results were measured for medicinal plants as described by Dulger and 
Gonus (2004). 
 Resistant:     =< 10 mm  (-) 
 Moderately susceptible:  10-13 mm  (+) 
 Susceptible:    > 14 mm  (++) 
 
3.3 Results 
3.3.1 The recoveries of AP extract 
 
The following AP extracts recoveries were obtained (Table 3-1).  
Table 3-1 AP extracts and their recoveries  
 
Extract Recovery  
Absolute ethanol AP extract (100% 
APE) 
9.8 % 
80% ethanol extract (80% APE) 6.0 % 
Water extract (WE) 5.7 % 
 
3.3.2 Detection of the AP extracts constituents 
 
The thin layer chromatographs of the AP ethanol and aqueous extracts are shown 
in Figure 3-1. The water extract showed two major spots in a lane whereas all the 
ethanol extracts showed more than 3 spots in a lane. The spot representing AND 
(Rf =0.58) was present in all the three AP extracts. The colour associated with the 
APE extracts was removed by absorption with activated charcoal (Sigma, St 
Louis, MO). 
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Lane    1    2   3   4   5   6                     1   2   3   4   5   6 
   A    B 
Figure 3-1 Thin layer chromatography of AP extracts 
 
From left to right, A: lanes 1 & 2: 80% APE; lanes 3 & 4: 100% APE; lanes 5 & 
6: AND. B: lanes 1 & 2: water extract; lanes 3 & 4: APE; lanes 5 & 6: AND 
 
3.3.3 Antibacterial susceptibility profiles 
 
None of the concentrations at 5 mg/disc, 0.5 mg/disc or 50µg/disc of AP extracts 
showed any antibacterial activity against S. typhimurium (bovine, 12313), E. coli 
(ATCC 25922), E. coli (Q 358), S. typhimurium (area SL3261), S. bovis-
morbificans (sheep, liver), S. sonnei, S. aureus, P. aeruginosa, S. pneumoniae or 
S. pyogenes. However, the concentrations of 5 mg/disc, 0.5 mg/disc and 50µg/disc 
of 80% APE and 100% APE showed antibacterial activity against both L. 
pneumophila and B. pertussis (Table 3-2). The tested concentrations of AND 
showed no antibacterial activity towards any of the pathogens mentioned above. 
Antimicrobial activities of select antibiotics used as positive controls are shown in 
Table 3-3.   
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Table 3-2 Antimicrobial activity of AND or different AP extracts  
 
(inhibition zone: mm diameter) 
  
Micro-organisms AND 
 
Aqueous extract  80% ethanol extract 100% ethanol 
extract  
Overnight dry of 80% 
ethanol 
1. S. typhimurium (aroA, SL3261) - - - - - 
2. S. typhimurium (bovine,12313) - - - - -  
3. E. coli (ATCC 25922) - - - - - 
4. E. coli (Q 358) - - - - - 
5. S. bovis-morbificans  - - - - -  
6. Shigella sonnei - - - - -  
7. S. aureus - - - - -  
8. P. aeruginosa - - - - -  
9. S .pneumoniae - - - - - 
10. S. pyogenes - - - - - 
11. L. pneumophila - - ++22 (5mg/disc) 
++22(0.5mg/disc) 
++22(50µg/disc) 
++16 (5mg/disc) 
++16(0.5mg/disc) 
++16(50µg/disc) 
- 
12. B. pertussis - - ++18(5 mg/disc) 
+14(0.5mg/disc) 
+12(50µg/disc) 
++12(5 mg/disc) 
+12(0.5mg/disc) 
-10(50µg/disc) 
- 
 
Note: For medicinal plants, Resistant = < 10 mm diameter zone of inhibition. 
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Table 3-3 Antimicrobial activity of select antibiotics against common intestinal 
and respiratory tract pathogens 
  
Micro-organisms ST P10 VA30 E15 FOX30 SXT AM10 GM10 
1. S. typhimurium 
(aroA SL3261) 
- 13 - - 14 18 19 17 
2. S. typhimurium 
(bovine,12313) 
18 15 - - 19  22 20 15 
3. E. coli (ATCC 
25922) 
20 - - - 21 24 18 17 
4. E. coli (Q 358) - - - 9 24 29 25 16 
5. S. bovis-
morbificans  
16 14 - - 19  21 19 17 
6. Shigella sonnei 10 - - - -  20 - 15 
7. S. aureus 10 28 9 18 14  - 22 9 
8. P. aeruginosa 7 - - - -  - - 16 
9. S. pneumoniae  34 18  16 15 22  
10. S. pyogenes  24 13 18 15 -   
11.L.pneumophilia    40 31 27 12 20 
12. B. pertussis    30 22  26 22 
 
Note: ST: Streptomycin (100µg), P10: Penicillin G (10IU), VA30: Vancomycin 
(30µg), E15: Erythromycin (15µg), FOX30: Cefoxitin (30µg), SXT: 
sulfamethoxazole/trimethoprim (23.75:1.25µg), AM10: Ampicillin (10µg), 
GM10: Gentamicin (10µg) 
 
3.4 Discussion 
 
Resistant bacteria are emerging world wide as a threat to the outcome of common 
infections in community and hospital settings. Resistance of Salmonella sp to 
streptomycin, tetracycline, ampicillin, chloramphenicol, sulfamethoxazole, 
ceftiofur, gentamicin, nalidixic acid, penicillin and cephalosporin have been 
reported (Zhao et al., 2005; White et al., 2003; Chaudhary and Aggarwal, 2004). 
Resistance to penicillin, macrolide and cephalosporin is also detected among the 
leading bacterial pathogens that cause respiratory tract infections, such as S. 
pneumoniae, H. influenzae (Dunbar, 2003; Lorenz, 2002). In the antibiotic control 
test, S. typhimurium (aroA SL3261), S. typhimurium (bovine, 12313) and S. bovis-
morbificans were observed to resist to 5 tested antibiotics (ST, P10, VA30, E15 
and GM10) as judged by the diameter zone of inhibition less than 18 mm. 
Resistance to 2 tested antibiotics (FOX30 and SXT) was also observed in strain S. 
pneumoniae. P. aeruginosa was shown to resist almost all 8 tested antibiotics. 
Bacteria become drug resistant in several different ways. Pathogens often become 
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resistant simply by preventing entrance of the drug (Prescott et al., 2002). Many 
gram-negative bacteria are unaffected by penicillin G because it can not penetrate 
the envelope’s outer membrane (Prescott et al., 2002). Some pathogens, such E. 
coli, P. aeruginosa and S. aureus, have plasma membrane translocases that pump 
the drug out of the cells after it has entered (Prescott et al., 2002). Many 
pathogens produce β-lactamase to hydrolyse the β-lactam ring of many types of 
penicillin (Jain et al., 2003; Chaudhary and Aggarwal, 2004). β-lactamase has 
been found in a variety of Enterobacteriaceae species, including Klebsiella spp., 
Escherichia coli, Enterobacter spp., Salmonella spp., Pseudomonas aeruginosa 
and Proteus mirabilis etc. (Nathisuwan et al., 2001; Chaudhary and Aggarwal, 
2004).  
 
In the experiment, the direct antibacterial activities of AP extracts and one of its 
active compounds, andrographolide were determined using the disc diffusion test. 
The advantages of the disc diffusion are cost effectiveness and flexibility. It is the 
least expensive method and is very flexible because the selection of the tested 
discs is done by the user. Another benefit is that the method is quick to determine 
anti-microbial properties. In the disc diffusion susceptibility test, discs containing 
known amount of an antimicrobial agent are placed on the surface of an agar plate 
which has been inoculated with a standardized suspension of a strain of bacteria. 
The agent diffuses from paper into the agar, thereby preventing the growth of the 
organism in a zone around the disc. The zone diameter gives an indication of the 
sensitivity of the organism to the agent being tested (Prescott et al., 2002). 
However, this method has also a few sources of error. An important source of 
error in susceptibility testing is that certain bacterial species may not grow well in 
a particular culture medium. Therefore, the appropriate culture media were used 
for bacterial growth instead of using Muller-Hinton Agar. Another commonly 
used screen to determine antimicrobial susceptibility is the broth dilution assay 
(Hess et al., 1995). This method is difficult because the compound be tested must 
be diluted several times for each sample, so it is time-consuming and is more 
expensive than the disc diffusion test. Therefore, the disc diffusion test was 
chosen in the antibacterial activity test. 
 
 
AP is an herbal medicine that has been used for therapy of respiratory tract 
infection as well as acute diarrhoea with a reported efficacy of 75-100% in 
Thailand (Leelarasamee et al., 1990). To investigate whether anti-bacterial 
activity was responsible for the reported therapeutic successes of AP, direct anti-
bacterial activity of AP extracts and AND was determined using disc diffusion 
tests. Direct anti-bacterial activity of two ethanolic Andrographis paniculata 
extracts against Legionella pneumophila, and Bordetella pertussis was observed. 
However, no direct anti-microbial activity of the aqueous extract of AP and AND 
against the other microorganisms was observed, including S. typhimurium, E. coli, 
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S. sonnei, S. aureus, P. aeruginosa, S .pneumoniae, S. pyogenes, L. pneumophila, 
and B. pertussis.   
 
The results obtained with the aqueous extract of AP did not support the findings 
reported by Prajjal et al. (2003) with respect to S. aureus, E. coli or P. aeruginosa. 
Although it is possible that the lack of antimicrobial activity of the aqueous 
extract in our study may be attributable to a lesser concentration of the aqueous 
extract used per disc than that used by Prajjal et al. (2003) viz., 5mg/disc instead 
of 10mg/disc, this is unlikely because (a) no zone of inhibition against the 
pathogens tested was observed in this study and (b) Leelarasamee et al. (1990) 
also did not observe any antimicrobial activity of the aqueous extract either in 
vitro against Salmonella, E. coli, Shigella, S. aureus even at concentrations as 
high as 25 grams/litre of AP powder suspended in water. 
 
Although APE or AND did not show any direct antibacterial activity against 
intestinal pathogens tested in this study, extracts of AP have been claimed to have 
significant effects against the diarrhoea associated with E. coli infections using 
rabbit as the model system (Gupta et al., 1990). Yin & Guo (1993) found that a 
dose of 500 mg per day for six days of AND was effective in controlling or 
treating acute bacterial diarrhoea in human patients. In another study, AP was 
used to treat 1611 cases of bacterial dysentery and 955 cases of diarrhoea with 
overall effectiveness of 91.3% (Chaturvedi et al., 1983). However, we discovered 
that AP had no direct bacteriostatic or potential bactericidal reaction against S. 
typhimurium (bovine, 12313), E. coli (ATCC 25922), E. coli (Q 358), S. 
typhimurium (aroA SL3261), S. bovis-morbificans or S. sonnei.  
 
Andrographis paniculata has also been used clinically for symptomatic treatment 
of the common cold and uncomplicated sinusitis, pharyngotonsillitis, pneumonia 
and bronchitis (Chang and But, 1986; Hancke et al., 1995; Caceres, 1997; 
Melchior et al., 1997; Thamlikitkui et al., 1991; Melchior et al., 2000; Poolsup et 
al., 2004; Amaryan et al., 2003; Gabrielian et al., 2002; Spasov et al., 2004 and 
Coon & Ernst, 2004). Chinese clinical studies involving oral administration of AP 
or AND to patients suffering from bacterial and viral respiratory infections 
reported positive effects. Details were described in Section 1.3.5.2. We found that 
ethanoic AP extracts, but not AND, were inhibitory in vitro only for those 
respiratory pathogens that were associated with bronchitis or pneumonia viz., L 
pneumophila and B. pertussis respectively. It is thus clear that a 
component/principle other than AND may be responsible for the previously 
reported antimicrobial activity. Research aimed at identifying the component(s) 
responsible for antimicrobial activity against a common intestinal pathogen tested 
in this investigation is reported in the following two chapters. The hypothesis is 
that the antimicrobial activity claimed in the use of AP against microbial 
infections in vivo may be due to the immunomodulatory effects of an AP extract 
and one of its active compounds including AND. As it has been suggested that the 
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main clinical benefit of AP could be due to a possible immune-enhancing effect 
(Mills & Bone, 2000). 
 
The constituents of AP extracts were detected using TLC with UV radiation. 
From figure 3-1, AND is contained in all tested extracts of AP, no matter whether 
water or ethanol was used as extract solvents. TLC is the simplest and cheapest 
method of detecting plant constituents because the method is easy to run, 
reproducible and requires little equipment. Although two spots from the water 
extract and more than 3 spots from other extracts of AP were detected in TLC, 
there may be other constituents which could not be detected under UV radiation in 
the extracts. 
 
3.5 Conclusions 
 
Neither the aqueous extract nor AND were bacteriostatic or bactericidal against 
Salmonella typhimurium, E. coli, Shigella sonnei, S. aureus, P. aeruginosa, S. 
pneumoniae, S. pyogenes, L. pneumophila or B. pertussis, but the two ethanolic 
extracts of AP were bacteriostatic against L. pneumophila  and B. pertussis. 
Although active constituents in AP have the capability to reduce the symptoms of 
upper respiratory tract infection as well as acute diarrhoea in human (Chapter 1, 
Sections 1.3.5.1 and 1.3.5.2), the effects seem to be more then a direct 
antibacterial effect. It has been suggested that the main clinical benefit of AP 
could be due to a possible immune-enhancing effect (see Chapter 1, Section 
1.3.5.6). In the next two chapters, investigations of the immunomodulatory effects 
of an AP extract and one of its active compounds, AND using an immunized 
mouse model are reported. 
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Chapter 4 Evaluations of 
immunomodulatory properties of ethanol 
extract of Andrographis paniculata or 
andrographolide 
 
4.1 Introduction 
 
Traditional herbal medicines have been widely used for the treatment of many 
kinds of acute and chronic diseases in Asia. Mills and Bone (2000) suggested that 
the clinical efficacy of many herbal traditional medicines could be partially 
attributable to their immunoregulatory properties. In recent years, more and more 
researchers have become interested in discoveries of potent immunostimulant or 
immunosuppressive compounds isolated from herbal medicines. Most of these 
investigations have focussed on herbal products stimulating or suppressing innate 
immunity as assessed by cytokine induction by naïve lymphocytes in vitro (Tega 
et al., 2005; Ko et al., 2004a; Ko et al., 2004b; Nakada et al., 2002; Huang et al., 
2001; Chen et al., 2005; Kang et al., 2005; Kang et al., 2004; Huang et al., 2004). 
Extracts of whole plants of Andrographis paniculata have been reported to have 
anti-cancer, anti-inflammatory, anti-allergic, immunostimulatory, antithrombotic, 
hypoglycaemic and hepatoprotective activities (Gupta et al., 1998; Habtemariam 
S, 1998; Handa & Sharma, 1990; Matsuda et al., 1994; Puri et al., 1993; Trivedi 
& Rawal, 1998; Zhao & Fang, 1991; Zhang & Tan, 1996 & 2000). 
Andrographolide has been reported to be anti-inflammatory, to stimulate or 
suppress innate immunity as assessed by cytokine induction or deduction and anti-
carcinogenic activity (Kumar et al., 2004; Madav et al., 1996; Panossian et al., 
2002; Burgos et al., 2005; Rajagopal et al., 2003; Shen et al., 2002). It has also 
been reported to either stimulate (Puri et al., 1993) or suppress adaptive immunity 
(Iruretagoyena et al, 2005; 2006). This experiment was designed to investigate the 
effects of APE and AND on both humoral and cell mediated immunity in mice 
vaccinated with inactivated Salmonella typhimurium. Mice immunised with an 
inactivated Salmonella typhimurium vaccine have been previously reported to 
induce only humoral (antibody) response but little or no cell-mediated immune 
response or immunity (CMI) in the mouse model (Mukkur et al., 1987; 1991a; 
1991b; Harrison et al., 1997), although in chickens, a killed Salmonella enteritidis 
vaccine was reported to induce splenocyte lymphocyte proliferation following 
stimulation with ConA (a T–cell mitogen) apparently in an age-dependent manner 
(Okamura et al., 2004; 2003). The mouse model was chosen for this investigation 
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because of the demonstrated inability of the killed salmonella vaccines to induce 
CMI in this model. 
 
 
4.2 Materials and Methods 
 
4.2.1 Preparation of an ethanol extract of Andrographis 
paniculata  
200g of whole dried plant coarse powder (purchased from Woods plus Woods Co. 
Ltd., Sydney, Australia) was percolated with 100% food grade ethanol twice 
(1×700ml and 1x200 ml) and each time soaked and stirred for 6 hours at room 
temperature. After filtration through cotton wool, the filtrates were centrifuged at 
10000×g for 20 mins at room temperature (Beckman Avanti J251 centrifuge, 
Beckman Instruments, Palo Alto, CA). The extract was evaporated in a rotary 
evaporator (Labrota 4001, Heidolph) at 60°C until dry. A stock solution for the 
AP extract (APE) was prepared by suspending APE in food grade ethanol at 50 
mg/ml, which was then serially diluted in PBS immediately prior to experiments.  
 
4.2.2 Isolation of andrographolide 
 
A modification of the method reported by Rajani et al. (2000) was used to isolate 
AND from AP (as described in Chapter 2, Section 2.2.4). The isolation of AND 
was further confirmed by UV absorption spectrum, TLC, LC-MS and 1 H-NMR 
(as described in Chapter 2, Section 2.3.4). 
 
4.2.3 Animals 
 
All experiments with laboratory animals were carried out to comply with the 
Animal Care and Protection Act 2001 and approved by the Animal Ethics 
Committee of the University of Southern Queensland (approved number: 
04STU235). Six week old female Balb/c mice were purchased from the Animal 
Resource Centre, (Perth, Australia). A one-week acclimatization period was 
allowed for all mice prior to any experimentation. The animals were maintained in 
specific pathogen free conditions in the PC2 Animal House at the University of 
Southern Queensland and housed with 12 hours of light and 12 hours of darkness 
in a controlled temperature (23±1°C). Two mice groups were used. One group 
was administered one dose of vaccine and treated with APE or AND for 14 days. 
Another group was given two doses of vaccines and treated with APE or AND for 
28 days (as described in Sections 4.2.4 and 4.2.10 below).  
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4.2.4 APE and AND treatment 
 
The treatment started 1 week before the (primary) immunization and continued 
through all the experiment (for treatment periods see Section 4.2.3). Mice were 
orally given a daily dose equal to 25 mg/kg bodyweight (bw) and 50 mg/kg bw of 
APE in 250 µl PBS or 1 mg/kg bw and 4 mg/kg bw of AND in PBS using a 
flexible plastic gavage (plastic sheath of 24 G3/4, Insyte TM Catheter, BD). The 
first day of APE or AND treatment was recorded as day 1. At the doses used, APE 
and AND were well tolerated by mice, and no apparent evidence of toxicity was 
observed. As controls, age-matched female mice were immunized with killed S. 
typhimurium alone or were provided with PBS alone. Therefore, for each mouse 
group, there were the following six sub-groups (each sub-group containing 5 
mice): 
 
(1) PBS group: Mice in this group were provided with PBS alone. 
(2) Vaccine group: Mice were immunized with 1 or 2 dose(s) of whole-cell killed 
S. typhimurium alone on day 7 or days 7 and 21. 
(3) 25APE + Vaccine group: Mice were treated with 25 mg/kg bw of APE and 
immunized with 1 or 2 dose(s) of whole-cell killed S. typhimurium. 
(4) 50APE + Vaccine group: Mice were treated with 50 mg/kg bw of APE and 
immunized with 1 or 2 dose(s) of whole-cell killed S. typhimurium. 
(5) 1AND + Vaccine group: Mice were treated with 1 mg/kg bw of AND and 
immunized with 1 or 2 dose(s) of whole-cell killed S. typhimurium. 
(6) 4AND + Vaccine group: Mice were treated with 4 mg/kg bw of AND and 
immunized with 1 or 2 dose(s) of whole-cell killed S. typhimurium.   
 
4.2.5 Reagents and culture media 
 
A stock solution for AND was prepared by dissolving AND in food grade ethanol 
at 5 mg/ml, which was then serially diluted in PBS immediately prior to 
experiments. Goat anti-mouse IgA (α-) HRP conjugate, goat anti-mouse IgG (Fc) 
HRP conjugate, o-phenylenediamine dihydrochloride (OPD) peroxidase substrate 
and concanavalin A (ConA) were purchased from Sigma (St Louis, MO). 
Defibrinated horse blood was sourced from Progen Pty Ltd (Brisbane). LB (Luria-
Bertani) Miller and LB agar Miller were purchased from Difco Pty Ltd (Detroit, 
MI). Dulbecco’s Modified Eagle Medium (DMEM), penicillin-streptomycin, fetal 
bovine serum and HEPES buffer solution (1M) were purchased from Gibco 
(Invitrogen Corporation, Auckland, NZ). Polymyxin B was from Sigma (St Louis, 
MO) and 2-mercaptoethanol was from BDH (Merck Pty Ltd, Kilsyth, VIC). 
Details regarding the sourcing of chemicals are provided in appendix K. Enzyme-
linked immunosorbent assay (ELISA) kits were used for IL-4, IL-2 and IFN-γ (R 
& D Systems, USA) determination (as described in Section 4.2.15). 
58                     Chapter 4 Evaluations of immunmodulatory properties of APE or AND 
4.2.6 Bacteria  
 
The avirulent S. typhimurium (aroA SL3261) (obtained from stock in the 
Department of Biological and Physical Sciences, University of Southern 
Queensland) was used in these experiments. 
 
4.2.7 Preparation of SL3261 (whole-cell killed) vaccine for 
immunization 
Avirulent S. typhimurium aroA strain SL3261 was used to prepare the inactivated 
whole-cell vaccine. A single colony was picked up from an LB agar plate grown 
with S. typhimurium and inoculated in 10 ml LB broth, then incubated with 
agitation overnight (o/n) at 37°C at 200rpm (Bioline Shaker Incubator, Edwards 
Instrument Co, Australia).1 ml o/n culture was transferred to 200ml LB broth and 
incubated with agitation at 37°C at 200rpm until an optical density at 600 nm 
reached 1.2 (OD 600 =1.2). 
 
A series of dilutions was prepared in LB broth, and dilutions 10 4− to 10 8−  were 
plated out on LB agars for o/n incubation at 37°C to count the number of colony 
forming units (cfu) per ml. Formalin (37%) to a final concentration of 1% was 
added to the culture broth, which was re-incubated with agitation for 4 hours at 
37°C at 200rpm. 100 µl of the broth culture was then plated out on LB agar to 
check for sterility. The remaining broth was centrifuge at 8500xg for 15 mins at 
room temperature (Biofuge Primo-R, Heraeus, supplied by Radiometer Pacific) 
and the pellets were washed three times with sterile phosphate buffered saline 
(PBS, pH 7.2). The final pellets were resuspended in 50ml sterile PBS equivalent 
to a bacterial count of 1.0 × 1010  cfu/ml, and stored at -20°C and prior to use 
diluted in PBS. 
 
4.2.8 Preparation of Salmonella antigen for ELISA 
 
Avirulent S. typhimurium aroA strain SL3261 was used to prepare the antigen for 
ELISA. S. typhimurium strain SL3261 was grown and processed as mentioned in 
Section 4.2.7 above. After washing three times with sterile PBS, the final pellet 
was resuspended in 10 ml of sterile borate saline coating buffer (see Appendix D 
for preparation) instead of in 50 ml sterile PBS and then sonicated on ice six times 
and each time had 20 second bursts at 60 duty-cycle, output 7 with 20 second 
pauses (Branson Sonifier 450, Branson Ultrasonics Corporation, Danbury, CT). 
The cell lysate was further diluted with sterile borate saline coating buffer 
(120mM NaCl, 50mM H 3 BO 4 & 24 mM NaOH, pH 9.0) to OD 600 =0.4, and 
stored at 4°C until used. 
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4.2.9 Preparation of SL3261 lysate for splenocyte 
stimulation 
 Avirulent S. typhimurium aroA strain SL3261 was used to prepare lysate for 
splenocyte stimulation. Formalin (37%) to a final concentration of 1% was added 
to an o/n, stationary 200 ml LB culture of SL3261, which was re-incubated with 
agitation for 4 hours at 37°C at 200rpm (Bioline Shaker Incubator, Edwards 
Instrument Co, Australia). 100 µl of the broth culture, was then plated out on LB 
agar to check for sterility. The remaining broth culture was pelleted at 8500×g for 
15 mins (Biofuge Primo-R, Heraeus, supplied by Radiometer Pacific). The pellet 
was washed once in 40ml PBS containing 5 mM EDTA (ethylene diamine 
tetraacetic acid) and twice with PBS separately. The pellets were resuspended in 
10 ml PBS and sonicated on ice six times and each time had 20 second bursts at 
60 duty-cycle, output 7 with 20 second pauses (Branson Sonifier 450, Branson 
Ultrasonics Corporation, Danbury, CT). Cell disruption was checked by gram 
stain. The cell lysate was further diluted to one-third volume sterile PBS. The 
dilution was stored in a sterile tube at -20°C until used. 
 
The protein concentration was determined using Coomassie® Plus TM  Protein 
Assay reagent kit (Pierce, Rockford, USA, See Appendix B, Determination of 
protein concentration). 
 
4.2.10 Immunization  
 
One dose (1x10 7 cfu) of whole-cell killed S. typhimurium was administered on 
day 7, whereas, two doses (1x10 7 cfu and 5x10 7 cfu) of whole-cell killed S. 
typhimurium were administered on days 7 and 21 (vaccine preparation see Section 
4.2.7 above). Animals received bacteria in 250 µl PBS by the intraperitoneal [i/p] 
route. 
 
4.2.11 Sampling of mice 
 
Mice were anaesthetized intraperitoneally with a mixture of 40μl ketamine 
(100mg/ml, Troy Laboratories P/L, Smithfield, NSW) and 40μl xylazine 
(20mg/ml, Troy Laboratories P/L, Smithfield, NSW). A cardiac puncture (23G ¾ 
needle, Becton-Dickinson, Eight Mile Plains, QLD) was then performed to obtain 
the blood sample, followed by cervical cordotomy to ensure rapid and painless 
euthanasia before collection of the organs. 
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4.2.11.1 Serum collection 
Blood was collected from anaesthetized mice via cardiac puncture in a 23G3/4 
needle attached to 1 ml syringe (Becton-Dickinson, Eight Mile Plains, QLD). 
These were then added to serum collection tubes (Sarstedt, Australian Pty Ltd, 
Ingle Farm, SA) and clotted on ice for at least 30 mins. The blood was centrifuged 
at 6100g for 2 mins at room temperature (Mikro 12-24, Hettich Zentrifugen, 
Tuttlingen). Serum was transferred to a microfuge tube and stored at -20°C. 
 
4.2.11.2 Collection of spleens 
 
After cardiac puncture and cervical cordotomy, the spleen was aseptically 
removed by cutting through the peritoneal membrane to expose the lower 
abdominal organs (livers, intestines and spleen). The spleen was removed and 
placed into a 50ml tube with 5 ml of Dulbecco’s Modified Eagle Medium 
(DMEM) without Fetal Bovine Serum (FBS) (See Appendix C (a)). The tube was 
left on ice for further preparation. The spleens from each group were placed in the 
same tube. 
 
4.2.11.3 Collection of small intestines  
 
Small intestine was aseptically removed, finely cut and put into a tube containing 
3 ml of PBS with 1mM PMSF and 50mM EDTA solution on ice for preparation 
of small intestinal washes (see Section 4.2.12).  
 
4.2.12 Preparation of small intestinal washes for 
determination of anti-S. typhimurium IgG and IgA by ELISA 
 
Small intestinal washes were prepared as described by Mukkur et al (1995). 
Briefly, the finely cut small intestine was put into a tube containing 3 ml of PBS 
with 1mM PMSF and 50mM EDTA solution on ice. After being vortexed for 2 
minutes, the solution with small intestine was centrifuged at 4500g for 10 mins at 
4°C (Biofuge Primo-R, Heraeus, supplied by Radiometer Pacific). The 
supernatant was collected and stored at -20°C until ELISA for IgG and IgA 
(described in Section 4.2.13). 
 
4.2.13 Measurement of antibody responses by ELISA 
 
The measurement of antibody responses in serum and small intestinal washes by 
ELISA was mentioned as the following. 100 µl of killed and sonicated S. 
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typhimurium (OD 600 =0.4) was used to coat wells of a 96-well microtiter plate 
(Sarstedt, Australian Pty Ltd, Ingle Farm, SA). The plates were incubated o/n at 
4°C and washed with PBS-T (PBS containing 0.05% Tween 20) three times. 200 
µl PBS-T containing 2.5% skim milk powder block buffer was added and the 
plates blocked for 1 hour at RT and then they were washed with PBS-T three 
times. A series of twofold dilutions of mouse sera or small intestinal washes in 
PBS-T containing 2.5% skim milk powder were added, in 50 µl. A positive 
control anti- S. typhimurium high-titre serum was included on each plate as an 
internal standard. Plates were incubated for 1 hour at 37°C and washed 4 times 
with PBST. Antibody isotypes were detected using 50 µl /well diluted horseradish 
peroxidase (HRP)-conjugated goat anti-mouse antibody, diluted 1/1000 for Ig A 
and 1/2000 for Ig G in PBS-T containing 2.5% skim milk powder. The plates 
were incubated for 1 hr at 37°C and washed. The plates were developed with 
100µl 0.4 mg/ml OPD substrate in the dark at room temperature for 30 mins. 
Plates were read at 450 nm on the BIO-Rad 550 microplate reader (Hercules, 
CA). Antigen-specific titres were calculated as follows. A curve extrapolated by 
plotting absorbance due to specific binding (raw absorbance minus absorbance of 
antigen control) against dilution factor. The antibody titre was extrapolated by 
bisecting the curve with a cut-off point, determined by the maximum absorbance 
for the non-immunized and non-treated mouse serum. The point at which the 
curve bisected the cut-off line was extended to the x-axis to obtain a dilution 
factor titre, the reciprocal of which was considered to be the antibody titre of the 
serum sample. Titres were then normalized to the internal standard positive 
control serum titre included in each assay to control for plate-to-plate variations as 
described elsewhere (Mukkur et al., 1995). 
 
4.2.14 T-cell assay 
 
Spleens were removed in aseptic conditions, placed into 5 ml DMEM without 
FBS media (See Appendix C (a)) and mashed through a sieve with a syringe 
plunger. After rinsing thoroughly through a sieve 3 times using 1ml DMEM 
(without FBS) media each time, the spleen extract was centrifuged at 1000rpm for 
10 mins at room temperature (Biofuge Primo-R, Heraeus, supplied by Radiometer 
Pacific). Supernatants were discarded and the cell pellets were washed once again 
in 10 ml DMEM without FBS, and resuspended to 1×10 7 cells/ml in DMEM with 
10% FBS (see Appendix C (b)). The method for white cell counting was 
described in Appendix A. 1 ml of cells was then added to each well of a 24 well 
plate containing 1 ml of culture medium (DMEM media with 10% FBS, see 
Appendix C (b)). Cells were plated in duplicate (5×10 6  cells/well) and then were 
incubated with the relevant concentration of antigen [2 µg/ml killed and sonicated 
S. typhimurium; 2 µg /ml ConA (Sigma)] in 5% CO 2 , 37°C (Sanyo MCO-20AIC, 
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Japan). The supernatants were harvested at 72 hours and stored at -20°C prior to 
use. 
 
4.2.15 Measurement of cytokine production 
 
Interleukin-2 (IL-2), IL-4 or interferon-γ (IFN-γ) were measured by Quantikine R  
Mouse IL-2, IL-4 and  IFN-γ Immunoassay kits (R & D Systems Inc, USA) 
following the manufacturer’s manuals. Briefly, standards were prepared using a 
series of dilutions of mouse IFN-γ, or IL-2 or IL-4 as per instructions. All 
samples, standards and controls were aliquoted into the pre-coated plate as per 
instructions. The plate was allowed to incubate for 2 hours at room temperature, 
followed by 5 washes using the wash buffer provided by the manufacturer. Mouse 
IFN- γ, or IL-2 or IL-4 conjugate provided was added to the appropriate plate and 
then the plate was incubated for 2 hours at room temperature, followed by 5 
washes using the wash buffer provided. The plate was then incubated with 
substrate solution provided by the manufacturer for 30 mins in the dark. The stop 
solution was added and the plate was read at 450 nm on the BIORad 550 
microplate reader (Hercules, CA). A standard curve was plotted from the standard 
data, and the concentration for samples and standards extrapolated. Each sample 
was analyzed in duplicate. 
 
4.3 Statistical Analysis 
 
All statistical analysis was conducted using SPSS 12.0 for Windows™. The data 
was analysed using one-sided, independent samples t-tests, comparing each group 
to the vaccine group. A value of p< 0.05 was considered significant. 
 
4.4 Results 
4.4.1 Antigen specific antibody responses in mice treated 
with APE and AND for 14 days 
4.4.1.1 Analysis of serum antibody responses by ELISA 
 
Mice immunized with one dose of whole-cell killed S. typhimurium (mentioned in 
Section 4.2.10) were treated with or without APE at doses of 25 and 50mg/kg bw 
or AND at doses of 1 and 4 mg/kg bw for 14 days (see Section 4.2.4). The anti- S. 
typhimurium IgG and IgA titres in sera were determined and calculated (described 
in Materials and Methods in Section 4.2.13). The anti- S. typhimurium IgG levels 
of APE or AND treated mice were found to increase when compared with the 
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titres of untreated mice but the enhancement in the titres was not statistically 
significant (Figure 4-1 and Appendix E.1.2). IgA was also determined in pooled 
sera (n=5) for each group, but no IgA was detectable in all the groups tested. 
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Figure 4-1 Anti-S typhimurium serum IgG titres of treated with APE or AND, and 
untreated mice immunized with one dose of killed S. typhimurium vaccine.  
All values are means ± standard errors (SE) around the means. PBS: mice treated 
with PBS. 1vaccine: mice vaccinated with inactivated S. typhimurium. 
25APE+1vac: mice treated with 25 mg/kg bw of APE and immunized with killed 
S. typhimurium. 50APE+1vac: mice treated with 50 mg/kg bw of APE and 
immunized with killed S. typhimurium. 1AND+1vac: mice treated with 1 mg/kg 
bw of AND and immunized with killed S. typhimurium. 4AND+1vac: mice 
treated with 4 mg/kg bw of AND and immunized with killed S. typhimurium. 
 
4.4.1.2 Analysis of antibody responses in pooled small intestinal 
washes by ELISA 
 
No antibodies (IgG and IgA) against S. typhimurium were detected in pooled 
small intestinal washes of any of the groups (data not shown). 
 4.4.2 Antigen specific antibody responses in mice treated with APE 
and AND for 28 days 
 
4.4.2.1 Analysis of serum antibody responses by ELISA 
 
Mice immunized with 2 doses of whole-cell killed S. typhimurium (mentioned in 
Section 4.2.10) were treated with or without APE at doses of 25 and 50 mg/kg bw 
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or AND at doses of 1 and 4 mg/kg bw in 250 μl for 28 days (see section 4.2.4). 
The IgG and IgA titres in sera were determined and calculated (described in 
Materials and Methods in Section 4.2.13). APE or AND treatment of vaccinated 
mice, at all given doses elicited significantly higher levels of anti- S. typhimurium 
Ig G than the levels elicited in untreated mice (Figure 4-2 and appendix E.3.2). 
However no serum IgA was detectable in either the treated or untreated 
vaccinated mice. 
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 Figure 4-2 Anti- S. typhimurium serum IgG titres of treated with APE or AND, 
and untreated mice immunized with 2 doses of killed S. typhimurium vaccine.  
Sera were taken from groups of five mice after vaccination with killed S. 
typhimurium by i/p route or treated orally with APE or AND at two different 
doses for 28 days. All values are means ± standard errors of the means. PBS: mice 
treated with PBS. 2vaccine: mice vaccinated with 2 doses of inactivated S. 
typhimurium. 25APE+2vac: mice treated with 25 mg/kg bw of APE and 
immunized with 2 doses of killed S. typhimurium. 50APE+2vac: mice treated with 
50 mg/kg bw of APE and immunized with 2 doses of killed S. typhimurium. 
1AND+2vac: mice treated with 1 mg/kg bw of AND and immunized with 2 doses 
of killed S. typhimurium. 4AND+2vac: mice treated with 4 mg/kg bw of AND and 
immunized with 2 doses of killed S. typhimurium. The asterisk *  indicates 
significant difference of IgG titre (P<0.05) compared to 2vaccine group. 
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4.4.2.2 Analysis of antibody responses in pooled small intestinal 
washes by ELISA 
 
Anti- S. typhimurium IgG was weakly detected in pooled small intestinal washes 
of mice vaccinated with S. typhimurium (Figure 4-3). No anti- S. typhimurium IgA 
was detected in pooled small intestinal washes of mice vaccinated with S. 
typhimurium (data not shown). 
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Figure 4-3 IgG response against S. typhimurium in pooled small intestinal 
washings of treated with APE or AND, and untreated mice immunized with 2 
doses of killed S. typhimurium vaccine.  
Pooled small intestinal washes were taken from groups of five mice after 
vaccination with killed S. typhimurium by i/p route or treated orally with APE or 
AND at two different doses for 28 days. 
 
4.4.3 Antigen specific antibody responses in mice treated 
with APE for 14 and 28 days 
 
An alternately represented histogram to compare the Salmonella-specific antibody 
response data from mice immunized with one or 2 doses of inactivated S. 
typhimurium vaccine and orally gavaged with APE for 14 or 28 days is shown in 
Figure 4-4.  
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Figure 4-4 Comparison of the anti-S. typhimurium serum IgG titres of mice 
immunized with inactivated S. typhimurium and fed APE for 14 or 28 days. 
Comparison of the anti-S. typhimurium serum IgG titres of mice immunized with 
one dose (marked as 1 in parenthesis on the X-axis) and 2 doses (marked as 2 in 
parenthesis on the X-axis) of the inactivated S. typhimurium and fed APE for 14 
or 28 days respectively. All values are means ± standard errors (SE) around the 
means. The asterisk *  indicates significant difference of IgG titre (P<0.05) 
compared to groups of 25APE (1) or 50 APE (1). 
 
 
 
It can be seen that the anti-S. typhimurium serum IgG titres in the group of mice 
immunised with 2 doses of  the inactivated S. typhimurium (SL3261) vaccine and 
treated with the APE for 28 days were significantly higher (p< 0.05) than in mice 
immunised with one dose of the inactivated S. typhimurium (SL3261) vaccine and 
orally gavaged with the APE for 14 days (Figure 4-4). However, the serum IgG 
antibody titres of untreated mice vaccinated with one dose of SL3261 were lower 
than that of mice vaccinated with 2 doses of the inactivated S. typhimurium 
vaccine although the difference was not statistically significant (p=0.108). 
 
4.4.4 Antigen specific antibody responses in mice treated 
with AND for 14 and 28 days 
 
A differently represented histogram to compare the Salmonella-specific antibody 
response data from mice immunised with one or 2 doses of inactivated S. 
typhimurium vaccine and orally gavaged with AND for 14 or 28 days is shown in 
Figure 4-5.  
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Figure 4-5 Comparison of the anti-S. typhimurium serum Ig G titres of mice 
immunized with inactivated S. typhimurium and fed APE for 14 or 28 days. 
Comparison of the anti-S. typhimurium serum Ig G titres of mice immunized with 
one dose (marked as 1 in parenthesis on the X-axis) and 2 doses (marked as 2 in 
parenthesis on the X-axis) of the inactivated S. typhimurium and fed AND for 14 
or 28 days respectively. All values are means ± standard errors (SE) around the 
means. The asterisk *  indicates significant difference of IgG titre (P<0.05) 
compared to groups of 1AND (1) or 4AND (1). 
 
 
  
It can be seen that the S. typhimurium-specific serum IgG titre of mice treated 
with AND for 28 days and immunised with 2 doses of the inactivated Salmonella 
vaccine was significantly higher than that of mice treated with AND for 14 days 
and immunised with one dose of the inactivated Salmonella vaccine (p<0.05).  As 
observed with the groups of mice treated with the APE (Figure 4-4), the anti-S. 
typhimurium serum IgG levels of mice immunised with one dose of SL3261 was 
lower than that of 2 doses of the inactivated Salmonella vaccine although the 
difference was not statistically significant (p=0.108).  
 
4.4.5 Effects of 14 days APE or AND treatment on cytokine 
production in mice immunized with the inactivated 
Salmonella vaccine  
 
The cultured splenocytes of immunized and APE or AND treated groups at all 
given doses secreted both IFN-γ and IL-4 type cytokines during 72 hour 
incubation in the presence of sonicated SL3261 (2μg/ml) (Figure 4-6). No IL-2 
type cytokine was determined. The cultured splenocytes of immunization control 
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group (1vaccine) also secreted IFN-γ type cytokine, but IL-4 type cytokine was 
not detected (Figure 4-6). 
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Figure 4-6 IFN-γ and IL-4 production by whole spleen cells after 72 hr 
stimulation with sonicated SL3261 antigen.  
Spleens were removed 14 days after mice had been treated with APE or AND. 
Pooled spleens from groups of 5 mice were used. The plotted values represent 
mean values of duplicate wells. The asterisk *  indicates significant difference of 
IFN-γ production (P<0.05) compared to 1vaccine group. 
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4.4.6 Effect of 28 days APE or AND treatment on cytokine 
production in mice immunized with the inactivated 
Salmonella vaccine 
 
0
200
400
600
800
1000
1200
PB
S
2v
ac
cin
e
25
AP
E+
2v
ac
50
AP
E+
2v
ac
1A
ND
+2
va
c
4A
ND
+2
va
c
IF
N
-y
 (p
g/
m
l)
*
*
*
*
 
 
 
0
10
20
30
40
50
60
70
80
PB
S
2v
ac
cin
e
25
AP
E+
2v
ac
50
AP
E+
2v
ac
1A
ND
+2
va
c
4A
ND
+2
va
c
IL
-4
 (p
g/
m
l)
 
 
Figure 4-7 IFN-γ and IL-4 production by whole spleen cells after 72 hr 
stimulation with sonicated SL3261 antigen.  
Spleens were removed 28 days after mice had been treated with APE or AND. 
Pooled spleens from groups of 5 mice were used. The plotted values represent 
mean values of duplicate wells. The asterisk *  indicates significant difference of 
IFN-γ production (P<0.05) compared to 2vaccine group. 
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The cultured splenocytes with the exception of the PBS control group, secreted 
both IFN-γ and IL-4 type cytokines upon stimulation with sonicated SL3261 
(2μg/ml) (Figure 4-7). All APE or AND treatment of vaccinated mice elicited 
significantly higher IFN-γ levels than the level elicited in 2vaccine group. No IL-2 
was detectable.  
 
4.5 Discussion 
 
Results obtained in this investigation revealed that oral administration of either 
APE or AND to mice vaccinated with inactivated S. typhimurium for 28 days not 
only significantly enhanced anti- S. typhimurium serum IgG titres, but also 
induced high IFN-γ levels indicating induction of a CMI response. The serum 
anti-S. typhimurium IgG levels of mice vaccinated with 2 doses of the inactivated 
Salmonella vaccine and gavaged with either APE or AND for 28 days were 
significantly greater than the group of mice immunised with one dose of the 
inactivated Salmonella vaccine by the i/p route and gavaged with APE or AND 
for 14 days. The serum anti-S typhimurium IgG level of mice immunised with 2 
doses vaccine was substantially higher than the group of mice receiving only one 
dose of the inactivated salmonella vaccine although the difference was not 
statistically significant (p=0.108). These results suggested that the APE or AND 
treatment period may potentially be an important factor influencing the magnitude 
of enhancement of antibody levels of immunised animals. However, no serum 
anti-S. typhimurium IgA was detected in any of the treated or untreated groups in 
this investigation.  
 
Puri et al (1993) reported that feeding mice for 7 days with the ethanol extract of 
A. paniculata or injecting mice with andrographolide at 7 and 3 days prior to 
immunisation with sheep red blood cells resulted in a significant enhancement of 
haemagglutinating antibody and delayed type hypersensitivity as compared to 
untreated animals. These authors also reported that there was a significant 
enhancement [not induction] of non-specific or innate immune response as 
measured by an increase in macrophage migration indices, phagocytosis of 14C 
labelled E coli, and increased incorporation of 3 H-thymidine in PHA 
(phytohaemagglutinin) - stimulated splenocyte supernatants. Furthermore it was 
also reported that administration of pure AND or neoandrographolide by the 
intraperitoneal route enhanced the haemagglutinating antibody levels and 
macrophage migration index significantly higher than when these compounds 
were administered by the oral route. In contrast, Iruretagoyena et al (2005) 
recently reported that AND administered by the intraperitoneal route down-
modulated the antibody response to a thymus-dependent antigen and delayed-type 
hypersensitivity were drastically diminished in mice by AND treatment. These 
authors further reported that this molecule was able to interfere with T cell 
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proliferation and IFN-γ or IL-2 release in vitro in response to allogenic stimulation 
with MOG (mouse myelin oligodendrocyte glycoprotein). Whether the 
discrepancies observed in the effect of AND on the immune response to different 
antigens are due to the difference in the route of administration, viz., oral versus 
intraperitoneal, is not understood and clearly warrants further investigation. 
  
However, results obtained in this investigation showed that both the APE or AND 
not only increased anti-S. typhimurium IgG titres, but also induced CMI to the 
inactivated salmonella vaccine. Except in the 14 day-1 mg/kg bw-AND treatment 
group, the IFN-γ levels of all other APE or AND treatment groups viz., 14 day or 
28 day treatment groups, increased remarkably compared to the untreated vaccine 
controls (P<0.05)  . Therefore, it was concluded that oral administration of APE or 
AND to vaccinated mice enhanced production of IFN-γ, indicating induction of 
CMI response potentially via Th1 cells. 
 
The IL-4 levels in the APE or AND treatment groups ranged from 15 pg/ml to 62 
pg/ml with the level in the 2 dose vaccine control group being higher than that in 
the one dose vaccine control group. Essentially no IL-2 was detectable in the 
splenocyte supernatants prepared from treated or untreated groups after 72 hr 
stimulation with Salmonella antigen. 
 
This investigation differed from that of Puri et al. (1993) in the following respects:  
i. Whereas the particulate antigen used in our investigation was an 
intracellular pathogen (S. typhimurium, used as a model for human 
typhoid for the last nearly 4 decades and that is also responsible for 
serious economic losses in food-producing animals), Puri et al. (1993) 
used a non-invasive particulate antigen viz., sheep RBCs in their study, 
that still required validation in an infectious disease model. 
ii. The intracellular pathogen selected for this study did not induce CMI 
when used as an inactivated or killed vaccine, providing an 
opportunity to differentiate between induction and enhancement of an 
immune response to the intracellular pathogen. In the study by Puri et 
al. (1993), there was at least a basal, but not negative level, of DTH 
response to  SRBCs, and hence their conclusion implying enhancement 
and not induction of DTH, not necessarily equating to potential 
protection (Tsukada et al., 1991). 
iii. CMI response in our investigation was determined using the indicator 
cytokine, INF-γ, rather than DTH in order to avoid potential problem 
associated with the dissociated development of T-cell mediated DTH 
(IL-2+, IL-3+) versus protective T-cells (IL-2+, IL-3+, INF-γ) as 
reported for another intracellular pathogen, Listeria monocytogenes 
(Tsukada et al., 1991).  
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The investigation differed from that of Kumar et al. (2004) by the following facts: 
i. This study investigated the antigen-specific induction of the CMI-
indicator cytokine, IFN-γ, rather than an enhancement of IL-2 
secretion by splenocytes stimulated with a T-cell mitogen viz., PHA. 
ii. This study investigated enhancement or induction of antigen-specific 
antibodies or CMI respectively in vaccinated mice treated with 
andrographolide, rather than an enhancement of innate immune 
responses (unvaccinated mice). 
 
 The protective efficacy of live attenuated Salmonella vaccines in the mouse 
model has been well demonstrated to be due to both CMI and antibody responses 
(Viret et al., 1999; Harrison et al., 1997; Mastroeni et al., 1993; Mukkur et al., 
1987; Mukkur et al., 1991a, 1991b). Killed vaccines were also observed to 
generally produce a less broad immune response than live attenuated vaccines in 
chicken (Babu et al., 2004; Babu et al., 2003; Thatte et al., 1993). Although 
Okamura et al. (2004; 2003) reported that killed S. enteritidis vaccine induced 
CMI response in chicken; the CMI response is mainly limited to an age-dependent 
manner. Our results showed that both APE and AND not only enhance the 
humoral (anti-S. typhimurium IgG), but also induced cellular (IFN-γ) immune 
responses, which are considered to be important for protection against 
salmonellosis. Whether the enhancement of antibody and cell-mediated immune 
responses induced by APE or AND in mice vaccinated with inactivated 
Salmonella vaccine is significant enough to protect mice against challenge 
infection with virulent S. typhimurium, the model intracellular pathogen used in 
this investigation, was further evaluated in work reported in the next chapter. 
 
Rajgopal et al. (2003) reported that AND exerted direct anti-cancer activity on 
different types of cancer cell lines by cell cycle arrest at G 0 / G1  phase through the 
induction of inhibitory protein p27 and decreased expression of cyclin-dependent 
kinase 4 (CDK4), whereas other groups have suggested AND-induced cell death 
either through the apoptotic pathway, via activation of the caspase cascade (Kim 
et al., 2005) or regulation of expression of pre-apoptotic markers (Cheung et al., 
2005 and Zhou et al., 2006). Rajgopal et al. (2003) and Kumar et al. (2004) also 
reported immunomodulatory activity of AND in vitro and suggested that the latter 
may indirectly contribute to its anti-cancer activity. On the other hand, other 
groups have reported immunosuppressant activity of AND in vitro (Burgos et al., 
2005 and Quin et al., 2006). This study demonstrated that feeding mice with APE 
or AND and immunizing with the inactivated Salmonella vaccine resulted in 
stimulation of both humoral (anti-S. typhimurium IgG) and cellular (IFN-γ) 
immune responses of acquired immunity. 
 
In conclusion, our results have provided evidence that both the Andrographis 
extract and AND significantly enhance serum anti-S. typhimurium Ig G levels and 
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induce CMI against Salmonella antigens as judged by the production of the 
indicator cytokine IFN-γ in antigen-stimulated splenocyte supernatants, the latter 
being a correlate of protection against salmonellosis (VanCott et al., 1998; 
Harrison et al., 1997; Nauciel et al., 1992). 
 
74                     Chapter 4 Evaluations of immunmodulatory properties of APE or AND 
 
Y Xu  75 
Chapter 5 Protection against 
experimental salmonellosis of ethanol 
extract of Andrographis paniculata or 
andrographolide in mice vaccinated with 
inactive S. typhimurium 
 
5.1 Introduction 
 
Protection against infection with an intracellular pathogen involves both humoral 
and CMI. CMI plays a significant role in protection against salmonellosis (Gupta, 
1998; Harrison et al., 1997; Mastroeni et al., 1993; Hahn and Kaufman, 1981; 
Matsui and Arai, 1992; Collins, 1973). Previous studies (see Chapter 4) carried 
out revealed that Salmonella-specific antibody response was enhanced and CMI 
against S. typhimurium was induced in mice vaccinated with a killed Salmonella 
vaccine if the vaccinated mice were orally dosed with an ethanol extract of AP or 
purified AND. The focus of this study was functionally validate the immune 
response-modifying potential of AP extract or AND against intracellular 
microbial infections using mouse salmonellosis as a model system. In this study, 
mice were orally administered with the optimal doses of APE or AND for 28 days 
and immunized with 2 doses of killed S. typhimurium by i/p route. This was 
followed by oral challenge with virulent microorganisms to evaluate if APE or 
AND, that were found to enhance humoral immunity and to induce CMI also 
provided protection against infection with the intracellular pathogen used in this 
investigation viz., S. typhimurium. 
  
5.2 Materials and Methods 
 
The experimental design for this study partly repeated the previous methods used. 
This time, mice were orally administered with 25mg/kg bw of APE or 4mg/kg bw 
of AND for 28 days and immunized with 2 doses of killed S. typhimurium by i/p 
route. The other main difference from the previous experiments was that most 
mice were followed by oral challenge with virulent microorganisms (S. 
typhimurium, ovine strain 12313) and after 28 days treatment with APE or AND. 
In order to ensure that the stimulation of both humoral (anti-S. typhimurium IgG) 
and cellular (IFN-γ) immune responses of acquired immunity reported in the 
previous chapter was due to treatment with APE or AND, and not simply to an 
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additional vaccine booster dose, age-matched female mice administrated with 
either APE or AND, were also used. Mice were sacrificed pre-challenge as well as 
post-challenge at 4 or 8 or 12 or 15 days to collect blood or spleen or liver 
samples for the relevant bio-assay.   
  
5.2.1 Preparation of APE and isolation of andrographolide 
 
The preparation of APE and isolation of AND were described in Chapter 4, 
Section 4.2.1 and Chapter 2, Section 2.2.4. The identification of AND was 
described in Chapter 2, Section 2.3.4. 
 
5.2.2 Animals 
 
The same mouse strain, age and maintenance conditions were used as mentioned 
in Chapter 4, Section 4.2.3, but this time mice were given two doses of the 
vaccine and treated with APE or AND for 28 days. All experiments with 
laboratory animals were carried out to comply with the Animal Care and 
Protection Act 2001 and approved by the Animal Ethics Committee of the 
University of Southern Queensland (approved number: 04REA252). 
 
5.2.3 APE and AND treatment of mice 
 
Treatments were essentially the same as outlined in Chapter 4, Section 4.2.4 
except that only 25mg/kg bw of APE or 4mg/kg bw of AND, single dose/day 
were used for 28 days. Age-matched female mice, which were administrated with 
either APE or AND alone, were also used. 
 
5.2.4 Bacteria 
 
The avirulent S. typhimurium aroA strain SL3261 (obtained from stock in the 
Department of Biological and Physical Sciences, University of Southern 
Queensland) were used for all immunizations, preparation of ELISA antigen and 
preparation of lysate for splenocyte stimulation. The virulent S. typhimurium 
(strain 12313, oral 1.5x10 6 cfu or 1.5×10 5  cfu suspended in 250 µl PBS) was used 
for challenge. 
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5.2.5 Reagents and culture media 
 
Reagents and culture media were the same as outlined in Chapter 4, Section 4.2.5.  
 
5.2.6 Preparation of inactivated whole cell SL3261 vaccines 
for immunization 
 
Avirulent S. typhimurium aroA strain SL3261 was used to prepare the inactivated 
whole-cell vaccine. The preparation was described in Chapter 4, Section 4.2.7.  
 
5.2.7 Preparation of S. typhimurium (strain 12313) for 
challenge 
 
Virulent S. typhimurium (strain 12313) was used. Ten µl of the stock culture of S. 
typhimurium (strain 12313) (stored at -70°C, Biofreezer, Forma Scientific) was 
streaked on LB agar and incubated o/n at 37°C. A single colony was picked up 
from this plate grown with virulent S. typhimurium (strain 12313) and inoculated 
in 10 ml LB broth, then incubated with agitation o/n at 37°C and 200rpm (Bioline 
Shaker Incubator, Edwards Instrument Co, Australia).1 ml o/n culture was 
transferred to 200ml LB broth and incubated with agitation at 37°C and 200rpm 
until an optical density at 600 nm reached 1.2 (OD 600 =1.2). 
 
A series of dilutions (10 4− -10 8− ) prepared in LB broth, were plated out on LB 
agar plates and incubated o/n at 37°C to count the number of colony forming units 
per ml. The broth was centrifuged at 8500xg for 15 minutes at 4°C (Biofuge 
Primo-R, Heraeus, supplied by Radiometer Pacific) and the pellets were washed 
twice with sterile PBS. The final pellets were resuspended in 50ml sterile PBS and 
appropriately diluted in PBS. The preparation was made as fresh as possible. 
 
5.2.8 Preparation of Salmonella antigen for ELISA 
 
Avirulent S. typhimurium aroA strain SL3261 was used to prepare the antigen for 
ELISA of antibody levels as mentioned in Chapter 4, Sections 4.2.7 and 4.2.8.  
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5.2.9 Preparation of S. typhimurium lysate for splenocyte 
stimulation 
 
Avirulent S. typhimurium aroA strain SL3261 was used to prepare lysate for 
splenocyte stimulation. The preparation was described in Chapter 4, Section 4.2.9. 
 
5.2.10 Immunization and challenge 
 
For immunization, two doses (1x10 7 cfu and 5x10 7 cfu) of whole-cell killed S. 
typhimurium (on days 7 and 21) were administered in 250 µl PBS by the i/p route. 
 
Groups of 9 mice were challenged by the oral route with a sublethal dose of 
virulent S. typhimurium (strain 12313, 1.5x10 5 cfu suspended in 250 µl PBS) at 7 
days post-booster vaccination according to Mukkur et al. (1987). At days 4, 8 and 
12 post-challenge, 3 mice from each group were euthanased for collection of 
blood sample, small intestine, spleen (described in Chapter 4, Section 4.2.11, 
except for the spleen from day 12 post-challenge) and liver (described in Section 
5.2.11 below).  For the day 12 post-challenge, the spleen was removed under 
aseptic conditions, placed into 1 ml DMEM and mashed through a sieve with a 1 
ml syringe plunger. After rinsing though a sieve 3 times using 1 ml DMEM 
media, 0.1 ml of suspensions were used for enumeration of bacteria in mouse 
spleen (see in Section 5.2.11). The remaining suspensions were pooled in group 
for T cell assay (see in Section 5.2.16). 
 
Other groups of 4 mice were challenged by the oral route with 1.5x10 6  cfu (10 
fold of sublethal dose) virulent S. typhimurium (strain 12313) suspended in 250 µl 
PBS (Mukkur et al.,1987) at 7 days post-booster vaccination and survival was 
recorded for 15 days. 
 
Groups of 5 mice were euthanased for collection of blood and small intestinal 
wash samples (described in Chapter 4, Sections 4.2.11.1, 4.2.11.3, 4.2.12 and 
4.2.13) for measurement of antibody responses and spleens (described in Chapter 
4, Sections 4.2.11.2, 4.2.14 and 4.2.15) for measurement of cytokine production 
before challenge (recorded as day 0 post-challenge or pre-challenge). 
 
An outline of experiment design is tabled as the following: 
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Group Treatment Immunization No. of mice challenged with 
strain 12313 
0 (pre-
challenge)
1.5×10 5  
cfu 
1.5×10 6  
cfu 
PBS PBS   5 9 4 
2vaccine  2 doses 5 9 4 
AND AND  5 9 4 
AND+2vaccine AND 2 doses 5 9 4 
APE APE  5 9 4 
APE+2vaccine APE 2 doses 5 9 4 
 
5.2.11 Enumeration of bacteria in mouse organs 
 
Around ¼ of liver and a whole spleen (except for the 12 day post-challenge; see in 
Section 5.2.10 above) were removed from each animal and weighed individually 
in aseptic condition. The liver and spleen (of 4 and 8 day post-challenge) were 
placed into a sterile 2.0 ml conical screw cap microtube (Quality Scientific 
Plastics) which contained 0.9 ml LB sterile broth and 1cm depth of 1.0 mm glass 
beads on ice. The tissues were homogenized using a mini bead beater (Biospec 
products) at 4600 rpm for 1 min. Each homogenate or 0.1 ml of suspension from 
Section 5.2.10 was serially diluted (ten-fold) up to 10 5−  for each time point and 
plated on LB agar by spread-plate method, and then incubated at 37°C for 18 
hours for counting. The colonies in the 80 to 200 range were selected to calculate 
the number of colonies for the specimen. The number of colonies counted on the 
selected plate multiplied by the dilution of the specimen contained on that plate 
equals the bacteria, or CFU (colony-forming units), count per gram of the 
specimen. 
 
5.2.12 Measurement of the protection-inducing potential of 
APE or AND 
 
Seven days after post-booster vaccination, groups of 4 mice were challenged 
orally with 1.5x10 6 cfu (10 fold of sublethal dose) virulent S. typhimurium (strain 
12313) suspended in 250 µl PBS (Mukkur et al.,1987 ) and survival was recorded 
for 15 days. Survival of mice was recorded daily and percentage of live animals at 
each chosen interval was calculated. Any mice, which became moribund during 
the experiments, were considered as dead. Mice were euthanased immediately and 
their spleen and liver were weighed, then bacteria in these organs were 
enumerated as described previously (see in Section 5.2.11).  
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5.2.13 Serum collection 
 
Serum was collected as described elsewhere in Chapter 4 (Section 4.2.11.1). 
 
5.2.14 Preparation of small intestinal washes for estimation 
of anti-S. typhimurium IgG and IgA by ELISA 
 
Small intestinal washes were collected and prepared as described in Chapter 4, 
Sections 4.2.11.3 and 4.2.12. 
 
5.2.15 Measurement of antibody responses by ELISA 
 
The measurement of antibody responses in serum and small intestinal washes by 
ELISA were described in Chapter 4, Section 4.2.13. 
 
5.2.16 T-cell assay 
 
The processes were essentially the same as described in Chapter 4, Section 4.2.14, 
except that the remaining suspensions of spleens from Section 5.2.10 were used. 
 
5.2.17 Measurement of production of cytokines in the 
antigen-stimulated splenocyte supernatants 
 
Levels of interleukin-2 (IL-2), IL-4 or interferon-gamma (IFN-γ) in Salmonella 
lysate-stimulated splenocyte supernatants were estimated using mouse cytokine 
ELISA kits (R & D Systems, USA) according to the manufacturer’s instructions. 
Each sample was analyzed in duplicate by ELISA. The absorbances were read at 
450 nm on the Bio-Rad 550 microplate reader. The final concentration of each 
sample was calculated by subtracting the concentration of splenocytes stimulated 
with protein buffer (PBS) from the concentration of splenocytes stimulated with 
the antigen. 
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5.2.18 Measurement of average gain (AG) after APE or AND 
treatment pre-challenge 
 
The initial body weight of 5 mice was recorded per group from the first day of 
APE or AND treatment. Mouse weight was measured in the morning. AG was 
calculated as follows: 
AG = )(g
groupofnumberTotal
weightgroupinitalweightgroupFinal −  
 
5.3 Statistical Analysis 
 
All statistical analysis was conducted using SPSS 12.0 for Windows™. The data 
was analysed using one-side, independent samples t-tests. A value of p< 0.05 was 
considered significant. 
 
5.4 Results 
5.4.1 Antibody isotype titres 
 
Seven week old female Balb/c mice were orally administered with the optimal 
doses of APE or AND for total 28 days and immunized with 2 doses of killed S. 
typhimurium (on days 7 and 21) by i/p route, followed by oral challenge with 
1.5x10 5  cfu S. typhimurium 12313. Antibody isotypes (IgG or IgA) were 
quantified for serum or small intestinal wash of the treatment groups at days 0, 4, 
8 and 12 post-challenge with 1.5x10 5  cfu S. typhimurium 12313. The results are 
presented in Figures 5-1, 5-2 and 5-3. 
 
5.4.1.1 Analysis of serum antibody responses by ELISA 
 
Levels of anti- S. typhimurium IgG for all vaccinated mice increased in 4 days 
post-challenge, and then reduced in 12 days post-challenge. Low or no serum IgG 
was detectable among unvaccinated mice in 12 day post-challenge (Figure 5-1). 
There was no significant change in IgG titres between day 0 and 12 post-
challenge (Figure 5-1). It was discovered that neither APE nor AND induced anti- 
S. typhimurium IgG in the pre-challenge experiment. On the other hand, the serum 
IgA titres were only detectable in vaccinated mice at 4 and 8 days post-challenge 
(Figure 5-2). No serum IgA was detectable in unvaccinated mice at the tested time 
points.  
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Figure 5-1 Serum IgG ELISA antibody titre in vaccinated mice at 0, 4, 8 and 12 
days post-challenge with 1.5x10 5  cfu S. typhimurium 12313.  
Sera were taken from groups of 3 mice except for the pre-challenge groups (day 
0), which were taken from groups of 5 mice. All values are the means ± standard 
error. PBS: mice treated with PBS. 2vaccine: mice vaccinated with 2 doses of 
inactivated S. typhimurium. APE+2vac: mice treated with 25 mg/kg bw of APE 
and immunized with 2 doses of killed S. typhimurium. APE: mice treated with 25 
mg/kg bw of APE. AND+2vac: mice treated with 4 mg/kg bw of AND and 
immunized with 2 doses of killed S. typhimurium. AND: mice treated with 4 
mg/kg bw of AND. 
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Figure 5-2 Serum IgA ELISA antibody titre in vaccinated mice at 0, 4, 8 and 12 
days post-challenge with 1.5x10 5  cfu S. typhimurium 12313.  
Sera were taken from groups of 3 mice except for the pre-challenge groups (day 
0), which were taken from groups of 5 mice. All values are the means ± standard 
error.   
 
5.4.1.2 Determination of antibody responses in small intestinal 
washes by ELISA 
 
No anti-S. typhimurium IgA was detected in all mice groups at 0 and 4 days post-
challenge. Anti-S. typhimurium IgA was detectable in all mice groups at 8 and 12 
days post-challenge (Figure 5-3). Anti-S. typhimurium IgA for all vaccinated mice 
increased in 4 to 8 days post-challenge, and then reduced in 12 days post-
challenge. The vaccinated mice alone elicited higher level of anti- S. typhimurium 
IgA at 8 days post-challenge than the levels elicited in other groups of mice. On 
the other hand, levels of anti-S. typhimurium IgA for two control groups of mice 
(PBS and APE) were increased at 12 days post-challenge.    
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Figure 5-3 Small intestinal washes IgA ELISA antibody titre in vaccinated mice 
at 0, 4, 8 and 12 days post-challenge with 1.5x10 5  cfu S. typhimurium 12313.  
Washes were taken from groups of 3 mice except for the pre-challenge groups, 
which were taken from groups of 5 mice. All values are the means ± standard 
error  
 
5.4.2 Estimation of interferon-γ (IFN-γ), interleukin (IL-2) 
and IL-4 levels in the splenocyte culture supernatant 
 
Mice of 12 day post-challenge were sacrificed on day 12 post-challenge with 
1.5x10 5  cfu S. typhimurium 12313 and their spleens were collected and processed 
as described in Section 5.2.16. IFN-γ, IL-2 and IL-4 were determined using 
pooled splenocyte culture supernatants in duplicate during 72 hour incubation in 
the presence of Sallmonella lysate (2μg/ml).  
 
5.4.2.1 Measurement of IFN- γ levels by ELISA 
 
The IFN-γ results are summarized below in Figure 5-4. The cultured splenocytes 
secreted IFN-γ type cytokine during 72 hour incubation in the presence of SL3261 
lysate (2μg/ml).  
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Figure 5-4 IFN-γ production by splenocytes after 72 hour stimulation with the 
Salmonella lysate antigen.  
Spleens were removed 12 days post-challenge with 1.5x10 5  cfu S. typhimurium 
12313. Pooled spleens from groups of 3 mice were used. The plotted values 
represent mean values of duplicate wells.  
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Figure 5-5 Comparison of IFN-γ levels of mice between 12 days post-challenge 
with 1.5x10 5  cfu S. typhimurium 12313 and pre-challenge respectively.  
IFN-γ was determined using pooled splenocyte culture supernatant in duplicate 
during 72 hour incubation in the presence of killed and sonicated SL3261. The 
plotted values represent mean values of duplicate wells. The asterisk *  indicates 
significant difference of IFN-γ production (p<0.05) compared to groups of pre-
challenge.  
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The splenocytes stimulated for 72 hours with the Salmonella lysate, secreted IFN-
γ in all groups after 12 days post-challenge (Figure 5-4). After 12 days post-
challenge, AND treatment of vaccinated mice (AND+2vaccine) elicited slightly 
higher IFN-γ levels after 72 hour stimulation with the Salmonella lysate than the 
levels elicited in pre-challenge mice (p=0.145), meanwhile, unvaccinated (PBS, 
APE and AND), vaccinated alone (2vaccine) and APE+2vaccine groups of mice 
after 12 days post-challenge elicited significantly higher IFN-γ levels than the 
levels elicited in pre-challenge (p<0.05) (Figure 5-5). In the pre-challenge 
experiment, groups of mice were not vaccinated but were gavaged with either 
APE or AND only. It was discovered that APE or AND induced only low levels 
of IFN-γ. Their IFN-γ levels were similar in magnitude to those in the PBS 
control group of mice. Whereas, the levels in mice immunized with 2 doses of the 
vaccine and fed either APE or AND were 75 to 90 percent higher than the levels 
detected in the PBS, APE or AND control groups of mice. 
 
5.4.2.2 Measurement of IL-2 levels by ELISA 
 
After 12 days post-challenge, IL-2 levels were detectable in all vaccinated mice 
splenocytes after the splenocytes were stimulated for 72 hours (Figure 5-6). On 
the other hand, no or low levels of IL-2 were detectable in PBS, AND and APE 
mice splenocytes. AND+2vaccine and APE+2vaccine groups of mice not only 
appear to elicit significantly higher IL-2 levels (p<0.05) than the AND or APE 
groups after 72 hour stimulation with the lysate, but also elicit significantly higher 
IL-2 levels (p<0.05) than the 2vaccine group (Figure 5-6). No IL-2 was detected 
in all groups of pre-challenge.  
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Figure 5-6 IL-2 production by splenocytes after 72 hour stimulation with the Salmonella 
lysate.  
Spleens were removed 12 days post-challenge with 1.5x10 5  cfu S. typhimurium 
12313. Pooled spleens from groups of 3 mice were used. The plotted values 
represent mean values of duplicate wells. The asterisk *  indicates significant 
difference of IL-2 production (p<0.05) compared to group of 2vaccine. 
 
 
5.4.2.3 Measurement of IL-4 levels by ELISA 
 
After 12 days post-challenge, no IL-4 was detected in all groups after 72 hour 
stimulation with the Salmonella lysate. 
5.4.3 Survival of mice after challenge with strain 12313, 
1.5x10 6 cfu suspensions  
 
Seven days after booster vaccination, groups of 4 mice were challenged orally 
with 1.5x10 6 cfu S. typhimurium 12313 and survival was recorded for 15 days. 
Survival of mice was recorded daily and is shown as percentage of animal’s 
survival at each interval (Figure 5-7). No protection against strain 12313 was 
observed in both PBS and 2vaccine groups, as all eight mice died within 5-10 
days of post-challenge. In contrast, a proportion of mice from groups of APE or 
AND treatment survived challenge infection and at least 50% mice were protected 
against challenge with strain 12313, no matter whether the mice were vaccinated 
with the killed Salmonella vaccine or not. 
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Figure 5-7 Percentage survival of mice in different groups, following challenge 
with 1.5x10 6 cfu virulent S. typhimurium.  
Survival was recorded daily and is shown as percentage of mouse survival at each 
interval. Groups consisted of 4 mice. 
 
 
 
The enumeration of bacteria in individual mouse liver or spleen showed that the 
average numbers of viable bacteria in spleens or livers of dying mice were much 
higher (1.1×10 4  times) than those of surviving mice (data are shown in 
Appendices F and G). All mice with high enumeration of bacteria in spleens were 
accompanied by splenomegaly (spleen weights up to 2 to 4 times normal) (data 
are shown in Appendix H), whereas all spleen weights of surviving mice fell 
within the normal range. 
 
5.4.4 Numbers of viable bacteria in the spleens and livers 
of mice post-challenge with 1.5x10 5  cfu Salmonella, strain 
12313 
 
As shown in figures 5-8, numbers of viable bacteria from three control groups 
viz., 2vaccine, APE or AND increased significantly, particularly in liver. In 
contrast, the CFU in the APE+2vac and AND+2vac groups cleared the pathogen 
by 8 or 12 days post-challenge. A few viable bacteria from PBS group were 
counted only on days 4 post-challenge (data are shown in Appendices I, I.1, I.2 
and I.3).   
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Figure 5-8 Determination of the CFU in mice challenged with Salmonella, 12313.  
Balb/c female mice were orally infected with 1.5x10 5  cfu Salmonella, 12313. 
Groups of 3 mice per time point were killed on days 4, 8 and 12 post-challenge. 
The spleen and liver were removed, homogenized and the CFU per gram of tissue 
determined. Values are shown the mean of CFU from three mice. 
 
5.4.5 Average mouse weight and average weight gain  
 
Five mice were weighed (g) in each group before challenge. The average weight 
gain (g) and average weight in the group (g) were calculated (Table 5-1 and 
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Figure 5-9) to evaluate if APE or AND at given doses affected mice adversely. 
None of the mice in any group lost weight indicating absence of apparent toxicity.  
 
Table 5-1 The average gain (AG) (unit: g) 
 
Groups AG 
PBS 1.6 
APE+2vaccine 1.4 
AND+2vaccine 1.5 
APE  2.1 
AND  1.6 
2vaccine 1.2 
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Figure 5-9 Average weight gains of mice in different group post-treatment with 
APE or AND. Each group consisted of 5 mice. 
 
5.5 Discussion 
 
The experimental mouse model was used to study the protective effect of APE or 
AND on mice vaccinated with killed S. typhimurium vaccine which had 
previously been reported to induce an antibody response (Mukkur et al., 1987; 
1991a; 1991b). Results obtained in this investigation revealed that oral 
administration of either APE or AND to mice for 28 days substantially increased 
the protective efficacy on mice vaccinated with inactivated S. typhimurium. Fifty 
percent of mice from groups representing treatment with APE, AND or 
AND+2vac and 75% from APE+ 2vac group survived after being challenged by 
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the oral route with 1.5x10 6  (10 fold of sublethal dose) cfu virulent S. typhimurium 
(strain 12313) for 15 days (Figure 5-7). Furthermore, clearance of S. typhimurium 
12313 from mice challenged by the oral route with the sublethal dose of virulent 
S. typhimurium (strain 12313, 1.5x10 5 cfu) showed that treatment of vaccinated 
mice with APE or AND promoted clearance of S. typhimurium on days 8 or 12 
post-challenge respectively. In contrast, numbers of viable bacteria from three 
control groups of 2vaccine, APE or AND increased significantly (Figure 5-8).  
 
In the pre-challenge investigation, mice were immunized with two doses of 
inactivated Salmonella vaccine and were treated with APE or AND for 28 days. 
Neither APE or AND alone induced an anti- S. typhimurium IgG antibody 
response. APE or AND control groups induced only low levels of IFN- γ, similar 
in magnitude to those in the PBS control group of mice. These discoveries 
suggested that the stimulation of both humoral (anti-S. typhimurium IgG) and 
cellular (IFN-γ) immune responses of acquired immunity, described in the 
previous chapter, were due to treatment with APE or AND, and not simply to an 
additional vaccine booster dose. APE and AND were confirmed to significantly 
increase IgG titres and IFN- γ production (Figure 5-10 and 5-11). 
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Figure 5-10 Anti-S typhimurium serum IgG titres of pre-challenge mice 
 
Mice were treated with or without APE or AND for 28 days, and immunised with 
2 doses of killed S. typhimurium vaccine. All values are means ± standard errors. 
The asterisk *  indicates significant difference of IgG titre (p<0.05) compared to 
group of 2vaccine.  
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Figure 5-11 IFN-γ production of pre-challenge mice spleen cells 
 
IFN-γ production by splenocytes after 72 hr stimulation with Salmonella antigen. 
Spleens were removed 28 days after mice had been treated with APE or AND. 
Pooled spleens from groups of 5 mice were used. The plotted values represent 
mean values of duplicate wells. The asterisk *  indicates significant difference of 
IFN-γ production (p<0.05) compared to control groups of 2vaccine, PBS, AND 
and APE.  
 
 
 
At 15 day post-challenge, fifty percent of unimmunized mice treated with APE 
and AND alone were found to be protected against oral challenge with virulent S. 
typhimurium. Given that no anti- S. typhimurium IgA or IgG antibody response 
was detected in mice pre-challenge with only basal level of IFN- γ (Figures 5-10 
and 5-11), the protection observed could be contributed at least in part to innate 
immunity. This is an observation that clearly warrants further investigation.   
 
Vaccinated mice responded with highest sera IgG titres against S. typhimurium on 
day 4 post-challenge, whereas, all control (unvaccinated) mice did not respond or 
responded with low sera IgG titres on days 8 and 12 post-challenge (Figure 5-1). 
These results confirmed that secondary response was rapid onset and greater 
production of IgG than the primary response.  
 
IgA is thought to be important in the primary immunological defence against local 
gastrointestinal infection (Neutra, et al., 1996; Kraehenbuhl and Neutra, 1992). 
IgA of small intestinal washes was detectable on days 8 and 12 post-challenge for 
all tested groups, although IgA antibody isotype was low. The mechanism of 
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action of IgA might prevent the invading organism from attaching to and 
penetrating the epithelial surface (Coico et al., 2003), but this is yet to be proved.   
 
Measurement of cytokine production from mouse splenocytes on day 12 post-
challenge with a sublethal dose (1.5x10 5 cfu) of virulent S. typhimurium showed 
that IFN-γ was produced in all groups. This is because all groups were infected 
with live virulent S. typhimurium. As numbers of viable S. typhimurium in spleens 
of three control mice groups (2vaccine, APE and AND) were still high at 12 days 
post-challenge with virulent S. typhimurium, bacteria may still be present in 
splenocytes prepared from these mice, potentially increasing stimulant 
concentration resulting in higher cytokine production in these three groups. 
However, the results of cytokine production in AND+2vaccine and 
APE+2vaccine groups are not affected as no viable S. typhimurium was found in 
the spleens in these two groups of mice. High levels of IL-2 were only produced 
in vaccinated mice, but AND+2vaccine and APE+2vaccine groups of mice 
elicited substantially higher IL-2 levels (p<0.05) than the 2vaccine group (Figure 
5-6). No IL-4 was detected in all groups after 72 hour stimulation with the 
Salmonella lysate. 
  
Our results confirmed that inactivated S. typhimurium could not provide good 
protection against S. typhimurium (Mukkur et al., 1987; 1991a and 1991b), as all 
vaccinated control mice died within 5-10 days post-challenge with 1.5x10 6 cfu 
virulent S. typhimurium. Although the serum IgG and IgA were produced within 
12 days post-challenge with 1.5x10 5 cfu virulent S. typhimurium and IFN-γ or IL-
2 were detected at 12 days post-challenge, significantly large numbers of viable 
bacteria in spleens and livers were presented within 12 days post-challenge. The 
production of IL-2 may be one of the reasons leading to a failure to protect against 
S. typhimurium in this case as IL-2 levels in groups of APE+2vaccine and 
AND+2vaccine were significantly higher than group 2vaccine (p<0.05) (Figure 5-
6). IL-2 is also involved in the induction of CMI (Gupta, 1998; Tsukada et al., 
1991) suggesting that this may be the reason for such a response.   
 
APE and AND did protect vaccinated mice against 1.5x10 6 cfu virulent S. 
typhimurium, as 75% or 50% vaccinated mice survived from the challenge after 
28 days APE or AND treatment. Furthermore, clearance of S. typhimurium 12313 
in spleens or livers after mice were challenged by the oral route with a sublethal 
dose of virulent S. typhimurium (strain 12313, 1.5x10 5 cfu) showed that APE or 
AND helped vaccinated mice eliminate S. typhimurium on days 8 or 12 post-
challenge respectively, whereas, numbers of viable bacteria from three control 
groups of 2 vaccine, APE or AND increased significantly. This is despite the fact 
that the serum IgG and IgA antibody titres against S. typhimurium were increased 
within 8 days post-challenge with 1.5x10 5 cfu virulent S. typhimurium and IFN-γ 
or IL-2 produced. 
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It was interesting to note that APE or AND alone also provided a degree of 
protection against 1.5x10 6 cfu virulent S. typhimurium, as 50% mice survived 
from the challenge infection after 28 days APE or AND treatment. However, no 
serum IgG and IgA were detected and significantly large numbers of viable 
bacteria in the spleens and livers of mice were presented within 12 days post-
challenge with 1.5x10 5 cfu virulent S. typhimurium. Also either no or low IL-2 
was detected at 12 days post-challenge, although IFN-γ was detected. No or low 
IL-2 determination may due to the splenocyte collection time. It may be too long 
for IL-2 determination after 72 hour stimulation with the Salmonella lysate, 
although it was good time for IFN-γ determination. Although the reason for the 
survival of mice could not be due to the direct anti-bacterial activity of APE or 
AND, because no direct anti-bacterial activity of APE or AND was detected in 
our previous study (see Chapter 3), it may be potentially due to innate immunity 
(Panossian et al., 2002; Rajagopal et al., 2003; Kumar et al., 2004). Another 
possible reason is some metabolites of APE or AND that are being generated in 
vivo. The metabolites could lead to their antibacterial activity. A further anti-
bacterial activity study on metabolite of AND by LC MS/MS from mouse serum 
should be warranted.  
 
Unvaccinated mice without APE or AND treatment (PBS group) were not 
protected following challenge with 1.5x10 6 cfu virulent S. typhimurium, as all 
PBS mice died within 5-10 days post-challenge.  
 
In conclusion, our results showed that both the Andrographis extract and 
andrographolide substantially enhance the protective efficacy against Salmonella 
on mice vaccinated with inactivated S. typhimurium. Consequently 
andrographolide might be a useful potential immunomodulator in the 
development of nonviable vaccines. 
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Live attenuated vaccines elicit both humoral and cellular immunity similar to that 
elicited by the natural infection (Viret et al., 1999; Harrison et al., 1997; 
Mastroeni et al., 1993; Mukkur et al., 1991a, 1991b; Mukkur et al., 1987), but 
they may pose some risk such as reversion to pathogenicity within an immunized 
individual. On the other hand, inactivated vaccines may be safer than live 
vaccines, but their antigens elicit only antibody responses and essentially no CMI. 
The new type of DNA (or nucleic acid) vaccines are composed of a bacterial 
plasmid encoding foreign antigens cloned in eukaryotic expression vectors (Wolff 
et al., 1990; Dubensky et al., 1984; Will et al., 1982). This new type of vaccines is 
being developed because of the potential to induce both the humoral and the 
cellular arms of the immune response (Zinkernagel, 2003; Ulmer et al., 1993; 
Tang et al., 1992). If one could tailor the immune response towards CMI, the 
potential to develop safe inactivated vaccines capable of generating CMI that 
provide protection against intracellular infectious diseases would become 
possible.  
 
Traditional herbal medicines are widely used for the treatment of many kinds of 
acute and chronic diseases in Asia. Some herbs, such as Echinacea, Astragalus, 
Picrorrhiza, Phytolacca and Andrographis has been claimed to be immune-
enhancing herbs (Mills and Bone, 2000). However, herbal extracts are a mixture 
of bioactive and inactive chemical ingredients. Also, the chemical composition of 
extracts varies depending on geographical distribution, climate condition of 
cultivation and the method used for preparation of the extracts. Hence, it is 
desirable to validate these bioactive chemical ingredients responsible for the 
claimed therapeutic properties. 
 
 Extracts of whole plants of Andrographis paniculata have been reported to have 
anti-cancer, anti-inflammatory, anti-allergic, immunostimulatory, antithrombotic, 
hypoglycaemic and hepatoprotective activities (Kumar, 2004; ; Zhang & Tan, 
1996 & 2000; Gupta et al., 1998; Habtemariam, 1998; Trivedi & Rawal, 1998; 
Matsuda et al., 1994; Puri et al., 1993; Kapil et al., 1993; Zhao & Fang, 1991; 
Handa & Sharma, 1990; Sawasdimongkol et al., 1990; Chantasutra & 
Limpapanichkul, 1989; Dutta & Sukul, 1982). Andrographolide has been reported 
to be anti-inflammatory, stimulate or suppress innate immunity as assessed by 
cytokine induction/deduction and anti-carcinogenic activity (Qin et al., 2006; 
Zhou et al., 2006; Burgos et al., 2005; Kumar et al., 2004; Rajagopal et al., 2003; 
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Panossian et al., 2002; Shen. et al., 2002; Madav et al., 1996) and either 
stimulated (Puri et al., 1993) or suppressed adaptive immunity (Iruretagoyena et 
al, 2006; 2005). However, the potential of this medicinal plant and AND in the 
induction or enhancement of immune response particularly, against infectious 
diseases had not been evaluated.  
 
The first phase in this project involved purification and confirmation of 
andrographolide, the active principle from Andrographis paniculata. The second 
phase was to investigate the direct antimicrobial activity of AP extracts and AND 
in vitro. The third phase was to investigate if oral administration of an AP extract 
or AND was capable of inducing or promoting one or both effector arms of the 
immune response viz., the humoral and/or CMI on mice immunized with an 
inactivated vaccine. This inactivated vaccine was previously demonstrated to 
induce only an antibody response (Mukkur et al., 1991a; 1991b; 1987; Harrison et 
al., 1997) and unable to protect mice against challenge with virulent S. 
typhimurium. The final phase of this investigation was to extend the third phase 
and to validate the potential of the induced CMI in protecting mice against 
challenge with the intracellular pathogen, S. typhimurium. 
 
A modification of the method reported by Rajani et al (2000) was used to isolate 
AND from AP in the first process. Before AND was purified from AP, 
preliminary and confirmatory tests were conducted to make sure the plant sample 
contained active diterpene lactones and AND was contained in AP. The purified 
AND was further confirmed by melting point, color test, UV λmax, TLC, ESI-MS 
and 1 H-NMR compared with commercial AND and the published data 
(http://www.plantpharm.net/new_page_25.htm; Cui et al., 2005; Medforth et al., 
1990) to ensure the compound quality. All data from the experiments indicated 
that the plant sample and purified AND were qualified to be used. An aqueous 
and two ethanolic extracts of Andrographis paniculata, and AND, an active 
principle of Andrographis paniculata, were investigated for their antimicrobial 
activity against nine bacterial species including Salmonella typhimurium, 
Escherichia coli, Shigella sonnei, Staphylococcus aureus, Pseudomonas 
aeruginosa, Streptococcus pneumoniae, Streptococcus pyogenes, Legionella 
pneumophila, and Bordetella pertussis, using the disc diffusion method in the 
second investigation. Of all tested concentrations, direct antimicrobial activity of 
the two ethanolic Andrographis paniculata extracts was observed for only two 
human pathogens, Legionella pneumophila and Bordetella pertussis. However, no 
antibacterial activity of AND against any of the pathogens tested in this 
investigation was observed. Given that the TLC of Andrographis paniculata 
extracts showed that AND was present in all the three Andrographis paniculata 
extracts, it was concluded that the observed antimicrobial activity was due to 
other active principle(s) present in the extracts used in this investigation. This 
study was important because without this information, it would not be possible to 
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determine whether any protection observed was due to the direct antimicrobial 
activity or modulatory effect of APE or AND. In the third investigation, the 
immunomodulatory activities of an ethanolic extract of Andrographis paniculata 
and AND, administered by the oral route in mice vaccinated with inactivated 
Salmonella typhimurium, that by itself has been previously shown to induce only 
humoral and no CMI response (Harrison et al., 1997; Mukkur et al., 1987; 
Mukkur et al., 1991a, 1991b) were investigated. The results demonstrated that 
both the Andrographis extract and andrographolide enhanced not only anti-S. 
typhimurium IgG antibody levels in sera of vaccinated mice but also induced CMI 
as judged by production of the CMI indicator cytokine IFN-γ in antigen 
stimulated splenocyte supernatants. When these mice were challenged with the 
pathogen by the oral route, it was discovered that oral administration of either 
APE or AND to mice for 28 days substantially increased the protective efficacy in 
the mice, as fifty to 75 percent of mice from AND or APE treatment survived 
after challenge with the virulent organism (1.5x10 6  cfu S. typhimurium, strain 
12313). Furthermore, clearance of S. typhimurium 12313 in spleens or livers from 
mice which were challenged by the oral route with a sublethal dose of virulent S. 
typhimurium suggested that treatment of vaccinated mice with APE or AND 
promoted clearance of S. typhimurium from challenged mice by days 8 or 12 post-
challenge respectively, whereas, numbers of viable bacteria in the control groups 
(2vaccine, APE or AND) increased significantly. Meanwhile, the sera IgG, IgA 
and IFN-γ or IL-2 of the splenocytes were detected after the mice were challenged 
by the oral route with a sublethal dose of virulent S. typhimurium for 12 days. The 
investigations presented in this thesis warrant extension of these studies to other 
intracellular pathogens, particularly Mycobacterium tuberculosis and viral 
infectious agents such as acquired immunodeficiency syndrome virus because of 
(a) the clear demonstration that adaptive immune responses can be modified to 
induce CMI and enhance antibody responses as shown in this investigation, and 
(b) an increase in the CD4 +  T-cells in HIV-postive patients (Calabrese et al., 
2000).  
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Chapter 8 APPENDICES 
 
Appendix A: White cell counting 
 
White cell counting was performed using a haemocytometer with conversion 
factor of 10.000 for a counting chamber of depth 0.1 mm (Life technologies). 
Briefly, 10 µl cell suspension was added to 90µl CDMEM and then 10 µl was 
taken out and mixed with 10 µl of 0.14% trypan blue (Life technologies). The 
mixture was added to the haemocytometer to fill the chamber. The chamber 
consists of 4 large squares at the corners and each large square has 16 small 
squares. The unstained cells were counted in 4 small squares in each of the large 
square. The total number for each large square was calculated by multiplying the 
number of the cells from each 4 small squares by 4. The equation for viable cells 
per ml is: average cell count per large square × the dilution factor × 
haemocytometer conversion factor. And then, the remaining cell suspension was 
adjusted to 1×10 7 cells/ml. 
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Appendix B: Determination of protein concentration 
 
The protein concentration was determined using “Coomassie® Plus TM -the Better 
Bradford Assay kit” (Pierce, Rockford, USA). Briefly, a series of diluted bovine 
serum albumin (BSA) standards were prepared in the same diluent as the samples 
to 25, 125, 250, 500 and 750 µg/ml. 10 µl of each standard or unknown sample 
were pipetted into the appropriate 96 microplate wells. 300 µl of the Coomassie® 
Plus TM  reagent was added to each well and mixed with plate shaker for 30 
seconds. The plate was then incubated for 10 minutes at RT. The absorbance was 
measured at 595 nm (Bio-Rad 550, microplate reader, Hercules, CA), minus the 
reagent blank. A standard curve was plotted, from which the unknown protein 
concentration was determined. A standard curve is shown in the following figure.     
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Figure A 1: a standard curve of BSA protein (unit: μg/ml) 
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Appendix C: Tissue culture media 
 
(a) Without Fetal Bovine Serum (FBS) (used for washing cells) 
To 500ml Dulbecco’s Modified Eagle Media (Gibco, Invitrogen Corporation, 
Auckland, NZ) added 25mM HEPES, 200 units/ml penicillin-steptomycin, 
50µM 2-Mecaptoethanol and 10µg/ml Polymyxin B (all final concentration). 
 
(b) With 10% FBS ( CDMEM media, used for culturing cells) 
To the tissue culture media (a), add 10% fetal bovine serum (Gibco, 
Invitrogen Corporation, Auckland, NZ). 
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Appendix D: Borate saline coating Buffer 
 
(a) Stock buffer 
1.5 M NaCl (Sodium chloride) 
0.5 M H 3 BO 4  (Boric acid) 
1.0 M NaOH (Sodium hydroxide) 
 
(b) Working buffer (120mM NaCl, 50mM H 3 BO 4  and 24 mM NaOH, pH 
9.0) 
To 80 ml of 1.5 M NaCl, 100 ml of 0.5 M H 3 BO 4 , 24 ml of 1.0 M NaOH, 
add  distilled water to about 1 litre and adjust pH to 9. And then adjust to 1 
litre by distilled water. Make the buffer as fresh as possible. 
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Appendix E: Antigen-specific immune responses for S. 
typhimurium 
E.1: Antigen specific antibody responses in mice treated 
with APE and AND for 14 days 
E.1.1: Serum IgG titers against Salmonella typhimurium aroA 
SL3261 whole-cell lysate 
 
Groups (5 mice/group) Serum IgG titers 
PBS-1 0 
PBS-2 0 
PBS-3 0 
PBS-4 0 
PBS-5 0 
  
1vaccine-1 1100 
1vaccine-2 1150 
1vaccine-3 600 
1vaccine-4 1550 
1vaccine-5 1550 
  
25APE+1vaccine-1 1050 
25APE+1vaccine-2 2000 
25APE+1vaccine-3 1050 
25APE+1vaccine-4 900 
25APE+1vaccine-5 1550 
  
50APE+1vaccine-1 2000 
50APE+1vaccine-2 2250 
50APE+1vaccine-3 700 
50APE+1vaccine-4 3000 
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50APE+1vaccine-5 1500 
  
1AND+1vaccine-1 1500 
1AND+1vaccine-2 1500 
1AND+1vaccine-3 1500 
1AND+1vaccine-4 1500 
1AND+1vaccine-5 1550 
  
4AND+1vaccine-1 2700, 
4AND+1vaccine-2 1700 
4AND+1vaccine-3 2000 
4AND+1vaccine-4 1650 
4AND+1vaccine-5 1100 
 
E.1.2: Statistical analysis of serum antibody (IgG) titre for 1 dose 
S. typhimurium-vaccinated mice given oral doses of either APE or 
AND  
 
Groups Mean IgG 
titre ± 1SE 
Standard 
Deviation 
Independent-sample t-tests for 
equality means 
t-statistic P value df 
PBS 0     
1vaccine 1190±175 392 n/a n/a n/a 
25APE+1vaccine 1310±204 457 -0.445 0.668 7 
50APE+1vaccine 1890±383 857 -1.659 0.152 5 
1AND+1vaccine 1510±10 22 -1.819 0.143 4 
4AND+1vaccine 1830±261 584 -2.031 0.082 7 
 
Note: SE=standard error, df=degrees of freedom, n/a=not applicable since 
comparison of means is made to this group, p value two tailed (equal variance not 
assumed) 
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E.2: Effects of 14 days APE and AND treatment on cytokine 
production in mice immunized with the inactivated 
Salmonella vaccine 
E.2.1: S. typhimurium-specific IFN-γ production  
 
 
 
 
(Duplicate culture wells were pooled from 5 mice) 
Groups (5 mice/group) IFN-γ production (pg/ml) 
PBS 22.2 
 23.8 
1vaccine 245.2 
 311.8 
25APE+1vaccine 541.6 
 647.6 
50APE+1vaccine 395.8 
 441.2 
1AND+1vaccine 240.8 
 332.8 
4AND+1vaccine 870.4 
 883.2 
  
E.2.2: S. typhimurium-specific IL-4 production  
 
(Duplicate culture wells were pooled from 5 mice) 
Groups (5 mice/group) IL-4 production (pg/ml) 
PBS 0 
 0 
1vaccine 0 
 0 
25APE+1vaccine 22.0 
 23.0 
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50APE+1vaccine 14.8 
 14.8 
1AND+1vaccine 40.2 
 48.4 
4AND+1vaccine 29.8 
 28.4 
 
 
E.3: Antigen specific antibody responses in mice treated 
with APE and AND for 28 days 
E.3.1: Serum IgG titers against Salmonella typhimurium aroA 
SL3261 whole-cell lysate 
Groups (5 mice/group) Serum IgG titers 
PBS-1 0 
PBS-2 0 
PBS-3 0 
PBS-4 0 
PBS-5 0 
  
2vaccine-1 1800 
2vaccine-2 2300 
2vaccine-3 2350 
2vaccine-4 15000 
2vaccine-5 3100 
  
25 APE+2vaccine-1 26000 
25APE+2vaccine-2 1700 
25APE+2vaccine-3 26000 
25APE+2vaccine-4 26000 
25APE+2vaccine-5 26000 
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50APE+2vaccine-1 26000 
50APE+2vaccine-2 26000 
50APE+2vaccine-3 26000 
50APE+2vaccine-4 26000 
50APE+2vaccine-5 1600 
  
1AND+2vaccine-1 26000 
1AND+2vaccine-2 26000 
1AND+2vaccine-3 6400 
1AND+2vaccine-4 12800 
1AND+2vaccine-5 26000 
  
4AND+2vaccine-1 25600 
4AND+2vaccine-2 18000 
4AND+2vaccine-3 13000 
4AND+2vaccine-4 13000 
4AND+2vaccine-5 27000 
 
E.3.2: Statistical analysis of serum antibody (IgG) titre for 2 dose 
S. typhimurium-vaccinated mice given oral doses of either APE or 
AND  
 
Groups Mean IgG 
titre ± 1SE 
Standard 
Deviation 
Independent-sample t-tests for 
equality means 
t-statistic P value df 
PBS 0     
2vaccine 4910±2531 5659 n/a n/a n/a 
25APE+2vaccine 21140±4859 10867 -2.962 0.025 6 
50APE+2vaccine 21120±4879 10912 -2.949 0.026 6 
1AND+2vaccine 19440±4142 9263 -2.993 0.022 6 
4AND+2vaccine 19320±3000 6709 -3.671 0.007 7 
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Note: SE=standard error, df=degrees of freedom, n/a=not applicable since 
comparison of means is made to this group, p value two tailed (equal variance not 
assumed) 
 
E.4: Effects of 28 days APE or AND treatment on cytokine 
production in mice immunized with the inactivated 
Salmonella vaccine  
E.4.1: S. typhimurium-specific IFN-γ production  
 
(Duplicate culture wells were pooled from 5 mice) 
Groups (5 mice/group) IFN-γ production (pg/ml) 
PBS 6.8 
 9.4 
2vaccine 124.0 
 152.4 
25APE+2vaccine 573.6 
 622.6 
50APE+2vaccine 230.8 
 258.8 
1AND+2vaccine 882.0 
 959.6 
4AND+2vaccine 768.2 
 799.2 
 
E.4.2: S. typhimurium-specific IL-4 production  
 
(Duplicate culture wells were pooled from 5 mice) 
Groups (5 mice/group) IL-4 production (pg/ml) 
PBS 0 
 0 
2vaccine 70.6 
 65.2 
25APE+2vaccine 31.2 
Y Xu  141 
 26.2 
50APE+2vaccine 40.2 
 34.2 
1AND+2vaccine 22.0 
 18.4 
4AND+2vaccine 60.4 
 65.6 
 
 
E.5: Antigen specific antibody responses in mice post-
challenge with 1. 5x10 5 cfu of S. typhimurium 12313 
E.5.1: Serum IgG titers against Salmonella typhimurium aroA 
SL3261 whole-cell lysate on four time points  
 
Groups 
 Serum IgG 
titers     
 0 day 4 days 8 days 12 days 
        
PBS-1 0 1700 600 0 
PBS-2 0 0 0 0 
PBS-3 0 0 0 0 
PBS-4 0    
PBS-5 0       
     
2vaccine-1 1800 102500 102400 3200 
2vaccine-2 2300 51200 51200 12800 
2vaccine-3 2350 51200 25600 25600 
2vaccine-4 15000    
2vaccine-5 3100       
     
AND-1 0 0 0 0 
AND-2 0 0 0 0 
AND-3 0 0 0 0 
AND-4 0    
AND-5 0       
     
AND+2vaccine-1 25600 102600 25600 51200 
AND+2vaccine-2 18000 51300 102400 12800 
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AND+2vaccine-3 28000 51200 51200 6400 
AND+2vaccine-4 14000    
AND+2vaccine-5 6700       
     
APE-1 0 0 0 0 
APE-2 0 0 0 0 
APE-3 0 0 0 0 
APE-4 0    
APE-5 0       
     
APE+2vaccine-1 13800 204800 25400 25600 
APE+2vaccine-2 26000 204900 25600 12800 
APE+2vaccine-3 26000 51200 51200 6400 
APE+2vaccine-4 26000    
APE+2vaccine-5 11800    
 
E.5.2: Serum IgA titers against Salmonella typhimurium aroA 
SL3261 whole-cell lysate on four time points  
 
Groups 
  Serum IgA 
titers    
 0 day 4 days 8 days 12 days 
PBS-1 0 0 0 0 
PBS-2 0 0 0 0 
PBS-3 0 0 0 0 
PBS-4 0    
PBS-5 0       
     
2vaccine-1 0 160 380 0 
2vaccine-2 0 170 260 0 
2vaccine-3 0 190 115 0 
2vaccine-4 0    
2vaccine-5 0       
     
AND-1 0 0 0 0 
AND-2 0 0 0 0 
AND-3 0 0 0 0 
AND-4 0    
AND-5 0       
     
AND+2vaccine-1 0 180 170 0 
AND+2vaccine-2 0 210 420 0 
Y Xu  143 
AND+2vaccine-3 0 200 50 0 
AND+2vaccine-4 0    
AND+2vaccine-5 0       
     
APE-1 0 0 0 0 
APE-2 0 0 0 0 
APE-3 0 0 0 0 
APE-4 0    
APE-5 0       
     
APE+2vac 0 250 10 0 
APE+2vaccine-2 0 170 85 0 
APE+2vaccine-3 0 260 35 0 
APE+2vaccine-4 0    
APE+2vaccine-5 0    
 
 
E.5.3: Small intestinal washes (SIW) IgA titers against Salmonella 
typhimurium aroA SL3261 whole-cell lysate on four time points  
 
Groups 
  SIW IgA 
titers    
 0 day 4 days 8 days 12 days 
PBS-1 0 0 0 10 
PBS-2 0 0 30 20 
PBS-3 0 0 0 20 
PBS-4 0    
PBS-5 0      
     
2vaccine-1 0 0 80 40 
2vaccine-2 0 0 90 0 
2vaccine-3 0 0 320 40 
2vaccine-4 0    
2vaccine-5 0      
     
AND-1 0 0 40 60 
AND-2 0 0 80 17 
AND-3 0 0 20 15 
AND-4 0    
AND-5 0      
     
AND+2vaccine-1 0 0 80 20 
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AND+2vaccine-2 0 0 90 50 
AND+2vaccine-3 0 0 40 80 
AND+2vaccine-4 0    
AND+2vaccine-5 0      
     
APE-1 0 0 40 20 
APE-2 0 0 20 10 
APE-3 0 0 0 55 
APE-4 0    
APE-5 0      
     
APE+2vaccine-1 0 0 50 30 
APE+2vaccine-2 0 0 30 30 
APE+2vaccine-3 0 0 25 35 
APE+2vaccine-4 0    
APE+2vaccine-5 0    
 
E.5.4: S. typhimurium-specific IL-2, IFN-γ and IL-4 production on 
day 12 post-challenge with 1. 5x10 5 cfu of S. typhimurium 12313 
 
(Duplicate culture wells were pooled from 3 mice) 
 
Groups (3 
mice/group) 
IL-2 level 
(pg/ml) 
IFN-y level 
(pg/ml) 
IL-4 level 
(pg/ml) 
PBS 1.7 846.0 0 
  3.7 765.4 0 
2vaccine 28.4 1093.8 0 
  32.4 1030.6 0 
AND 0 1635.5 0 
  0 1628.4 0 
AND+2vaccine 58.5 1071.2 0 
  59.9 1065.8 0 
APE 9.5 500.6 0 
  21.2 742.6 0 
APE+2vaccine 63.4 1072.8 0 
  59.9 1114.4 0 
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E.5.5: S. typhimurium-specific IFN-γ production of pre-challenge 
mice spleen cells 
(Duplicate culture wells were pooled from 5 mice, 72 hours stimulated with 
antigen) 
 
 
Groups (5 mice/group) IFN-γ production (pg/ml) 
PBS 94.1 
 112.3 
2vaccine 124.0 
 155.2 
APE 129.3 
 210.1 
APE+2vaccine 715.8 
 738.6 
AND 61.9 
 91.0 
AND+2vaccine 764.4 
 879.6 
 
 
 
146                                                                                                                                                                                                   
Appendices 
 
Appendix F: The colony number (cfu)/gram liver sample, after challenge with 1.5× 10 6  cfu S. 
typhimurium (strain 12313) 
 
Groups 5 days 6 days 7 days 8 days 9 days 10 days 11 days 15 days 
PBS-1 1.8x10 6               
PBS-2   5. 2x10 5             
PBS-3           1. 0x10 8     
PBS-4           2.8x10 5     
         
2vaccine-1   1.3x10 8             
2vaccine-2     3. 1x10 7           
2vaccine-3         1. 0x10 8       
2vaccine-4           7. 5x10 7     
         
AND-1         dead      
AND-2           6. 1x10 7     
AND-3               0 
AND-4               6. 2x10 3  
         
AND+2vaccine-1       dead        
AND+2vaccine-2             5.1x10 8   
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AND+2vaccine-3               6. 0x10 3  
AND+2vaccine-4               0 
         
APE-1       dead        
APE-2         1. 4x10 8       
APE-3               7. 2x10 4  
APE-4               0 
         
APE+2vaccine-1           dead    
APE+2vaccine-2               0 
APE+2vaccine-3               0 
APE+2vaccine-4               0 
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Appendix G: The colony number (cfu) / gram spleen sample, after challenge with 1.5x 10 6  cfu S. 
typhimurium (strain 12313) 
                    
Groups 5 days 6 days 7 days 8 days 9 days 10 days 11 days 15 days   
PBS-1 7.4x10 6           
PBS-2  3.5x10 5          
PBS-3      1.1x 10 8      
PBS-4      4.7x10 5      
           
2vaccine-1  1.3x10 8          
2vaccine-2   9.5x10 7         
2vaccine-3     1.7x10 8       
2vaccine-4      3. 0x10 7      
           
AND-1     dead      
AND-2      1.9x 10 8      
AND-3        0   
AND-4        5.8x10 3    
           
AND+2vacine-1    dead       
AND+2vaccine-2       6.0x10 8     
AND+2vaccine-3        1.3x10 4    
Y Xu  149 
AND+2vaccine-4        0   
           
APE-1    dead       
APE-2     1.6x10 8       
APE-3        1. 2x10 5    
APE-4        0   
           
APE+2vaccine-1      dead     
APE+2vaccine-2        0   
APE+2vaccine-3        0   
APE+2vaccine-4        0   
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Appendix H: Mouse spleen weight (gram), after challenge with 1.5x 10 6  cfu S. typhimurium (strain 
12313) 
           
Spleen weight (g)                   
Groups 5 days 6 days 7 days 8 days 9 days 10 days 11 days 15 days   
PBS-1 0.22          
PBS-2  0.40         
PBS-3      0.46     
PBS-4      0.27     
           
2vaccine-1  0.49         
2vaccine-2   0.25        
2vaccine-3     0.51      
2vaccine-4      0.59     
           
AND-1     0.36      
AND-2      0.47     
AND-3        0.11   
AND-4        0.11   
           
AND+2 vaccine-1    0.42       
AND+2vaccine-2       0.39    
AND+2vaccine-3        0.12   
AND+2vaccine-4        0.12   
Y Xu  151 
           
APE-1    0.44       
APE-2     0.41      
APE-3        0.15   
APE-4        0.17   
           
APE+2vaccine-1      0.51     
APE+2vaccine-2        0.17   
APE+2vaccine-3        0.17   
APE+2vaccine-4        0.17   
 
 
152                                                                                                                                                                                                   
Appendices 
 
Appendix I: The colony number (cfu)/ gram sample, after challenge with 1.5x 10 5  S. typhimurium 
(strain 12313) 
       
I.1: On day 4 post-challenge     
       
Groups 
whole spleen 
weight (g) 
the colony number (cfu)/g 
spleen 
liver sample weight 
(g) 
the colony number (cfu)/ 
g liver 
PBS-1 0.11  0 0.51  0 
PBS-2 0.12  7.6×10³ 0.64  4.5x10² 
PBS-3 0.11  0 0.50  0 
          
2vaccine-1 0.12  0 0.45  0 
2vaccine-2 0.11  0 0.49  0 
2vaccine-3 0.19  6.4×10 4  0.41  2.5x10² 
          
AND-1 0.14  3.0x10³ 0.42  3.1x10³ 
AND-2 0.15  1.1x10 4  0.40  5.2x10³ 
AND-3 0.09  0 0.38  0 
       
AND+2vaccine-1 0.14  4.6x10² 0.43  1.4x10² 
AND+2vaccine-2 0.11  8.3x10³ 0.32  7.5x10 4  
Y Xu  153 
AND+2vaccine-3 0.12  0 0.32  0 
          
APE-1 0.09  8.0×10 4  0.35  4.4×10 4  
APE-2 0.08  4.2x10³ 0.29  6.2x10³ 
APE-3 0.14  0 0.39  1.0x10³ 
      
APE+2vaccine-1 0.17  5.3x10 5  0.42  1.7x10 5  
APE+2vaccine-2 0.13  0 0.41  0 
APE+2vaccine-3 0.06  0 0.43  0 
 
I.2: On day 8 post-challenge     
       
Groups 
whole spleen 
weight (g) 
the colony number (cfu)/g 
spleen 
liver sample weight 
(g) 
the colony number (cfu)/ 
g liver 
PBS-1 0.11  0 0.50  0 
PBS-2 0.11  0 0.41  0 
PBS-3 0.10  0 0.65  0 
          
2vaccine-1 0.29  1.5x10 7  0.46  4.3x10 7  
2vaccine-2 0.25  6.0x10 6  0.36  2.4x10 6  
2vaccine-3 0.16  1.3x10 7  0.53  1.3x10 6  
          
AND-1 0.34  3.7x10 6  0.52  1.7x10 6  
154                                                                                                                                                                                                   
Appendices 
AND-2 0.10  0 0.43  0 
AND-3 0.33  1.5x10 7  0.58  3.9x10 6  
          
AND+2vaccine-1 0.28  8.2x10 7  0.48  3.1x10 7  
AND+2vaccine-2 0.43  8.9x10 6  0.44  1.6x10 7  
AND+2vaccine-3 0.12  0 0.35  0 
          
APE-1 0.49  1.2x10 6  0.46  5.2x10 5  
APE-2 0.39  1.6x10 6  0.38  2.6x10 5  
APE-3 0.39  1.9x10 6  0.38  2.8x10 5  
          
APE+2vaccine-1 0.14  0 0.43  0 
APE+2vaccine-2 0.13  0 0.45  0 
APE+2vaccine-3 0.14   0 0.48   0 
       
I.3: On day 12 post-challenge     
       
Groups 
whole spleen weight 
(g) 
the colony number (cfu)/g 
spleen liver sample weight (g) 
the colony number (cfu)/ g 
liver 
PBS-1 0.11  0 0.46  0 
PBS-2 0.11  0 0.44  1.0x10² 
PBS-3 0.11  0 0.47  0 
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2vaccine-1 dead  1.7x10 8  dead  1.0x10 8  
2vaccine-2 0.23 (close to die) 4. 4x10 7  0.52 (close to die) 4.6x10 7  
2vaccine-3 0.16  0 0.35  0 
          
AND-1 0.51 (close to die) 3.1x10 7  0.44 (close to die) 1.3x10 8  
AND-2 0.25  4.1×10 4  0.48  2.5×10 4  
AND-3 0.11  0 0.45  0 
          
AND+2vaccine-1 0.12  0 0.39  3.4x10² 
AND+2vaccine-2 0.12  0 0.39  0 
AND+2vaccine-3 0.13  0  0.31 0 
          
APE-1 0.48 (close to die) 1.8x10 8  0.60 (close to die) 1.1x10 8  
APE-2 0.13  0 0.30  0 
APE-3 0.12  0 0.37  0 
          
APE+2vaccine-1 0.11  0 0.37  0 
APE+2vaccine-2 0.11  0 0.36  0 
APE+2vaccine-3 0.12   0 0.33   0 
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Appendix J: Mouse weight post-treatment with APE or AND (gram) 
 
Groups 1day 4 days 7 days 10 days 13 days 16 days 19 days 22 days 25 days 
PBS-1 18.1 18.1 18.4 18.5 18.7 18.7 19 19 19.4 
PBS-2 17.8 17.9 18 18.4 18.5 18.9 18.9 19.2 19.5 
PBS-3 17.9 18.1 18.5 18.6 18.8 18.7 19.1 19.2 19.6 
PBS-4 17.7 17.7 18.2 18.3 18.5 18.6 18.7 18.9 19.2 
PBS-5 18 18.1 18.3 18.5 18.8 18.5 18.6 19 19.7 
          
APE+2vaccine-1 18.2 18.8 17.4 18.3 19 19.4 19.8 18.7 19.7 
APE+2vaccine-2 18 18.4 17.1 17.8 18.2 18.6 18.9 18.2 19.4 
APE+2vaccine-3 18.7 18.9 18.1 18.7 19.1 19.3 19.9 18.6 19.6 
APE+2vaccine-4 18.1 18.7 17.3 17.9 18.8 18.8 19.2 18.6 19.3 
APE+2vaccine-5 17.9 18.5 17.5 18.2 18.9 19.3 19.7 19.1 19.8 
          
AND+2vaccine-1 18.1 18.9 17.4 17.9 18.8 19.1 19.7 18.5 19.5 
AND+2vaccine-2 18 18.7 17.1 17.7 18.6 18.6 19.2 18.4 19.1 
AND+2vaccine-3 18.3 18.9 17.8 18.1 18.9 19.3 19.8 18.7 19.7 
AND+2vaccine-4 17.9 18.3 17.2 17.6 18.5 18.9 19.2 18.5 19.4 
AND+2vaccine-5 17.8 18.4 17.7 18.2 18.9 19.4 20 19.2 19.8 
          
APE-1 17.8 18.4 18.8 18.8 18.9 19 19.4 19.5 19.9 
APE-2 17.7 18.2 18.3 18.5 18.7 18.8 19.1 19.3 19.5 
APE-3 18.5 18.9 19.2 19.3 19.4 19.3 19.5 20 20.1 
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APE-4 17.1 17.6 18.1 18.4 18.4 18.7 19 19.3 19.6 
APE-5 17.6 18.1 18.6 19.1 19.3 19.5 19.7 19.8 20 
          
AND-1 18.4 18.8 19 19.1 19.1 19.1 19.4 19.4 20.1 
AND-2 18 18.3 18.7 19 18.9 19.2 19.2 19.3 19.6 
AND-3 18.5 18.5 18.9 18.9 19 19 19.2 19.5 19.5 
AND-4 18.6 18.9 19.2 19.4 19.4 19.7 19.9 20 20.2 
AND-5 17.7 18.4 18.7 18.8 19 18.9 19.1 19.3 19.6 
          
2vaccine-1 17.5 17.9 16.6 17.4 17.8 18.2 18.6 17.6 18.7 
2vaccine-2 17.5 18 17.1 17.2 18.2 18.7 18.9 18 19.3 
2vaccine-3 18.1 18.5 17.6 17.8 17.9 18.1 18.5 18.5 18.8 
2vaccine-4 18.1 18.3 17.2 17.7 18 18.2 18.7 18.6 18.7 
2vaccine-5 17.1 17.7 16.3 16.9 17.5 17.8 18.1 18.4 18.6 
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Appendix K: Chemicals 
 
The companies and relevant chemicals used in this research project are listed in 
the followings: 
Sigma-Aldrich: Standard andrographolide (98%); ethyl alcohol (food grade); 
charcoal activated; 3,5-dinitrobenzoic acid; potassium hydroxide; methanol; ethyl 
acetate; glycerol; ethylenediamine tetraacetic acid (EDTA); 
polyoxyethylenesorbitan monolaurate (Tween 20); phenylmethylsulfonyl fluoride 
(PMSF); polymyxin B; sodium chloride; formaldehyde (37 wt. %) solution in 
water 
AnalaR: Dichloromethane 
Ajax: Toluene; boric acid 
Gibco: HEPES buffer solution (1M); phosphate buffered saline (PBS, pH 7.2)  
BDH: 2-mercaptoethanol       
ICN: Sodium hydroxide 
Merck: A precoated plate of silica gel 60F254  
Baxter: 0.9% sodium chloride (0.9% saline) 
BBL®/ Becton Dickinson: Commercial antibiotic-impregnated disks as follows: 
ST: streptomycin (100µg); P10: penicillin G (10IU); VA30: vancomycin (30µg); 
E15: erythromycin (15µg); FOX30: cefoxitin (30µg); SXT: 
sulfamethoxazole/trimethoprim (23.75:1.25µg); AM10: ampicillin (10µg); GM10: 
gentamicin (10µg) 
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Appendix L: Publications 
